Proxy Statement (definitive) (def 14a)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

(Amendment No. )


Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐			Preliminary Proxy Statement
☐			Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒			Definitive Proxy Statement
☐			Definitive Additional Materials
☐			Soliciting Material under §240.14a-12


CRONOS GROUP INC.
(Name of Registrant as Specified in Its Charter)
N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
☒	No fee required.
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:

	(2)	Aggregate number of securities to which transaction applies:

	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	(4)	Proposed maximum aggregate value of transaction:

	(5)	Total fee paid:

☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:

	(2)	Form, Schedule or Registration Statement No.:

	(3)	Filing Party:

	(4)	Date Filed:

Table of Contents

April 27, 2021

Dear Shareholder:

On behalf of the Board of Directors and management of Cronos Group Inc., I am pleased to invite you to the 2021 Annual Meeting of shareholders which will be held on June 25, 2021 at 11:00 a.m., Toronto time.

This year, given the continued public health impact of the coronavirus disease 2019 (COVID-19), and to mitigate risks to the health and safety of our communities, shareholders, employees and other stakeholders, we will hold our 2021 Annual Meeting in a virtual only format, which will be conducted via live audio webcast.

The attached Notice of 2021 Annual Meeting and Proxy Statement describe the formal business to be conducted at the 2021 Annual Meeting. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2021 Annual Meeting online regardless of their geographic location, including having the opportunity to ask questions and vote on a number of important matters. The attached Proxy Statement contains detailed instructions about how to participate in the virtual 2021 Annual Meeting.

Your vote is important. Whether or not you plan to attend the virtual 2021 Annual Meeting, please vote your shares at your earliest convenience by using the facsimile and Internet voting procedures described on the proxy card or voting instruction form or, if you received a paper copy of a proxy card or voting instruction form by mail, by completing, signing, dating and returning your proxy card or voting instruction form in the envelope provided.

Thank you for your continued support of Cronos.


			Sincerely,

			Michael Gorenstein
			Executive Chairman

Table of Contents

CRONOS GROUP INC.

NOTICE OF 2021 ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD FRIDAY, JUNE 25, 2021

NOTICE HEREBY IS GIVEN that the 2021 Annual Meeting (the “Annual Meeting”) of the holders (the “Shareholders”) of common shares (“Shares”) of Cronos Group Inc. (the “Company”) will be held on Friday, June 25, 2021 at 11:00 a.m., Toronto time, via live audio webcast online at https://web.lumiagm.com/226761154. The Annual Meeting will be held for the following purposes:

1. the receipt of the audited consolidated financial statements of the Company as at and for the fiscal year ended December 31, 2020 and the auditors’ reports thereon;

2. the election to the board of directors of the Company (the “Board of Directors”) of the seven directors named in the attached Proxy Statement;

3. the adoption of an advisory (non-binding) resolution on the compensation of the Company’s named executive officers as disclosed in the attached Proxy Statement;

4. the appointment of KPMG LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 and to authorize the Board of Directors to fix KPMG LLP’s remuneration; and

5. such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

The Board of Directors is not aware of any other business to be presented to a vote of the Shareholders at the Annual Meeting.

The items of business are described more fully in the accompanying Proxy Statement. In order to reduce printing and mailing costs and as a matter of good environmental stewardship, we will this year be providing access to our proxy materials over the Internet under the U.S. Securities and Exchange Commission’s “notice and access” rules. As a result, on or about May 14, 2021, we are mailing to most of the Company’s Shareholders a notice of availability of proxy materials instead of a paper copy of the Proxy Statement and our Annual Report for the fiscal year ended December 31, 2020. Shareholders that would like to receive a paper copy may do so by following the instructions in the Proxy Statement.

This year, given the continued public health impact of the coronavirus disease 2019 (COVID-19), and to mitigate risks to the health and safety of our communities, Shareholders, employees and other stakeholders, we will hold our Annual Meeting in a virtual only format, which will be conducted via live audio webcast. Registered Shareholders and duly appointed proxyholders, including non-registered Shareholders who have duly appointed themselves as proxyholder, will have an equal opportunity to participate in the Annual Meeting online regardless of their geographic location, including asking questions and voting, all in real time, provided they are connected to the Internet and comply with all of the requirements set out in the attached Proxy Statement.

The Board of Directors has fixed 5:00 p.m., Toronto time, on April 26, 2021 as the record date for determining the Shareholders entitled to notice of, and to vote at, the Annual Meeting and any adjournments or postponements thereof.

Non-registered Shareholders who have not duly appointed themselves as proxyholder will be able to listen to the Annual Meeting as guests, but guests will not be able to ask questions or vote at the Annual Meeting. A registered

Table of Contents

Shareholder who wishes to appoint a person, other than the Board nominees identified on the proxy card, as a proxy must carefully follow the instructions in the attached Proxy Statement and on such registered Shareholder’s proxy card. These instructions include the additional step of registering such proxyholder with the Company’s transfer agent and registrar, TSX Trust Company, after submitting such registered Shareholder’s proxy card. Failure to register the proxyholder with TSX Trust Company will result in such proxyholder not receiving a control number to participate in the Annual Meeting and only being able to listen to the Annual Meeting as a guest.

Registered Shareholders as of 5:00 p.m., Toronto time, on the record date of April 26, 2021 may exercise their right to vote by completing and submitting the proxy card provided to them. To be effective, the proxy must be received by the Company’s transfer agent and registrar, TSX Trust Company, prior to 11:59 p.m., Toronto time, on June 23, 2021 or, in the case of any adjournment or postponement of the Annual Meeting, prior to 11:59 p.m., Toronto time, on the date that is two business days before the date of the adjourned or postponed meeting. Registered Shareholders may also vote their Shares by participating in the Annual Meeting. Detailed instructions on how to complete and return proxies or vote by facsimile or electronically using the facsimile and Internet voting procedures are provided in the attached Proxy Statement.

Non-registered Shareholders, including those who hold Shares in the name of a bank, trust company, securities dealer or broker, or other intermediary, will receive a voting instruction form. The voting instruction form contains instructions on how to complete the form, where to return it to and the deadline for returning it, which may be earlier than the deadline for registered Shareholders, and whether facsimile or Internet voting options are available. If you do not receive such voting instructions or are unsure about anything in such voting instructions, contact your bank, trust company, securities dealer or broker, or other intermediary through which you hold your Shares.

WHETHER OR NOT YOU EXPECT TO ATTEND THE VIRTUAL ANNUAL MEETING, PLEASE SUBMIT YOUR PROXY WITH YOUR VOTING INSTRUCTIONS. YOU MAY VOTE BY FACSIMILE OR INTERNET (BY FOLLOWING THE INSTRUCTIONS ON THE PROXY CARD OR VOTING INSTRUCTION FORM) OR BY MAIL.


By order of the Board of Directors,

Michael Gorenstein
Executive Chairman

Toronto, Ontario

April 27, 2021

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be Held on June 25, 2021.

Our Notice of Annual Meeting, Proxy Statement and Annual Report for the fiscal year ended December 31, 2020 are available at https://ir.thecronosgroup.com/financial-information/annual-meeting.

We are making the Proxy Statement and the form of proxy first available on or about May 14, 2021.

Table of Contents

TABLE OF CONTENTS


			Page
About the Meeting			1
Proposal No. 1—Election of Directors			1 1
Directors and Executive Officers			14
Board of Directors, Committees and Governance			19
Security Ownership of Certain Beneficial Owners, Directors and Management			30
Compensation Discussion and Analysis			35
Compensation Committee Report			56
Executive Compensation			57
CEO Pay Ratio			70
Director Compensation			71
Audit Committee Report			73
Principal Accountant Fees			75
Proposal No. 2—Advisory Vote on the Compensation of Our Named Executive Officers			76
Proposal No. 3—Appointment of KPMG LLP			78
Section 16(a) Beneficial Ownership Reporting Compliance			79
Other Business			79
Shareholder Proposals for the 2022 Annual Meeting			79
Householding of Annual Meeting Materials			80
Distribution of Certain Documents			80
Appendix A —Board Mandate			A-1

When used in this Proxy Statement, the terms “Cronos,” “we,” “our,” “us” and the “Company” refer to Cronos Group Inc., its consolidated subsidiaries and, if applicable, its joint ventures and investments accounted for by the equity method; the term “fiscal year” refers to our fiscal year, which is based on a 12-month period ending December 31 of each year (e.g., fiscal year 2020 refers to the 12-month period ended December 31, 2020); the term “Intermediary” means any bank, trust company, securities dealer or broker, or other intermediary; the term “cannabis” means the plant of any species or subspecies of genus Cannabis and any part of that plant, including all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, and the term “U.S. hemp” has the meaning given to term “hemp” in the U.S. Agricultural Improvement Act of 2018, including hemp-derived cannabidiol (“CBD”).

Unless otherwise specified, the information contained in this Proxy Statement is given as of April 27, 2021, the date of this Proxy Statement. Unless otherwise specified, all references to “dollars” or “$” in this Proxy Statement are to United States dollars and all references to “C$” are to Canadian dollars.

In addition, this Proxy Statement includes several website addresses. These website addresses are intended to provide inactive, textual references only. The information on or referred to on these websites is not part of this Proxy Statement.

iii

Table of Contents


This Proxy Statement includes forward-looking statements. These statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. For a discussion of some of the risks and important factors that could affect the Company’s business, prospects, operations, future results and financial condition, see “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Table of Contents

CRONOS GROUP INC.

111 Peter Street, Suite 300

Toronto, Ontario, M5V 2H1

PROXY STATEMENT

FOR THE 2021 ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD FRIDAY, JUNE 25, 2021

These proxy materials are furnished in connection with the solicitation by the board of directors (the “Board” or our “Board”) of Cronos Group Inc. (“Cronos” or the “Company”), a corporation incorporated under the Business Corporations Act (British Columbia) (“BCBCA”), of proxies to be voted at the 2021 Annual Meeting of the holders (the “Shareholders”) of common shares (“Shares”) of the Company and at any adjournment or postponement of such meeting (the “Annual Meeting”). This proxy statement (this “Proxy Statement”), together with the Notice of Annual Meeting and proxy card or voting instruction form, is first being made available to Shareholders on or about May 14, 2021.

ABOUT THE MEETING

Why am I receiving these materials?

We have made these proxy materials available to you on the Internet or have delivered printed versions of these materials to you by mail in connection with the solicitation, by the Board, of proxies to be voted at the Annual Meeting. You are receiving this Proxy Statement because you were a Shareholder as of 5:00 p.m., Toronto time, on April 26, 2021, the record date for the Annual Meeting. The Notice of Annual Meeting provides notice of the Annual Meeting, and this Proxy Statement describes the proposals presented for Shareholder action and includes information required to be disclosed to Shareholders.

What is included in these proxy materials?

These proxy materials include:

•this Proxy Statement for the Annual Meeting; and

•our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

If you received printed versions of these materials by mail, these materials also include the proxy card or voting instruction form for the Annual Meeting.

Why did I receive a Notice of Internet Availability of Proxy Materials in the mail instead of proxy materials?

In accordance with the “notice and access” rules of the U.S. Securities and Exchange Commission (“SEC”), instead of mailing a printed copy of our proxy materials to all Shareholders, we have elected to furnish such materials to selected Shareholders by providing access to these documents over the Internet. Accordingly, on or about May 14, 2021, we sent a Notice of Internet Availability of Proxy Materials (“Notice of Internet Availability”) to most of our Shareholders.

These Shareholders have the ability to access the proxy materials on a website referred to in the Notice of Internet Availability or request to receive a printed set of the proxy materials by calling the toll-free number found on the Notice of Internet Availability. We encourage you to take advantage of the availability of the proxy materials on the Internet in order to help save natural resources and reduce the cost to print and distribute the proxy materials.

Table of Contents

How can I get electronic access to the proxy materials?

For those shareholders who receive a Notice of Internet Availability, the Notice of Internet Availability provides instructions regarding how to:

•view our proxy materials for the Annual Meeting on the Internet;

•vote your Shares after you have viewed our proxy materials;

•request a printed copy of the proxy materials; and

•instruct us to send our future proxy materials to you electronically by email.

Copies of the proxy materials are available for viewing at https://docs.tsxtrust.com/2221.

You may elect to receive proxy materials by email. Even if you received a printed copy of our proxy materials, you may choose to receive future proxy materials by email. If you do so, you will receive an email next year with instructions containing a link to view those proxy materials and a link to the proxy voting site. Your election to receive proxy materials by email will remain in effect until you terminate it or for so long as the email address provided by you is valid.

When and where is the Annual Meeting?

The Annual Meeting will be held on Friday, June 25, 2021 at 11:00 a.m., Toronto time, via live audio webcast online at https://web.lumiagm.com/226761154. We are not holding an in-person meeting.

What matters will be submitted to Shareholders at the Annual Meeting?

At the Annual Meeting, you will be asked to vote on each of the following matters:

Proposal 1: To elect the seven nominees named in this Proxy Statement to the Board;

Proposal 2: To adopt an advisory (non-binding) resolution approving the compensation of our named executive officers (“NEOs”) as disclosed in this Proxy Statement; and

Proposal 3: To appoint KPMG LLP (“KPMG”) to serve as the Company’s independent registered public accounting firm for fiscal year 2021 and to authorize the Board to fix KPMG’s remuneration.

We will conduct such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. The Board is not aware of any other business to be presented to a vote of the Shareholders at the Annual Meeting.

In addition, the audited consolidated financial statements of the Company as of and for the fiscal year ended December 31, 2020 and the auditors’ reports thereon will be placed before the Shareholders at the Annual Meeting.

Who may vote at the Annual Meeting?

Only record holders of our Shares as of 5:00 p.m., Toronto time, on April 26, 2021 (the “Record Date”) will be entitled to vote at the Annual Meeting. On the Record Date, the Company had 371,656,590 Shares outstanding. Each outstanding Share entitles the holder to one vote on each matter to be voted upon at the Annual Meeting.

How are votes counted and what is the required vote for each proposal?

Table of Contents

As of April 26, 2021, the Record Date, there were 371,656,590 Shares outstanding, each of which entitles the holder to one vote on each matter to be voted upon at the Annual Meeting.

Proposal 1: Election of Directors

You may select “For” or “Withhold” with respect to each nominee for director under Proposal 1. Directors will be elected by a plurality of the votes cast at the Annual Meeting. However, the Board’s majority voting policy (the “Majority Voting Policy”) requires that any nominee for director who does not receive a greater number of votes “for” his or her election as a director than votes “withheld” from voting tender his or her resignation to the Board for consideration by the independent directors of the Company promptly following the meeting. The independent directors of the Company will consider the resignation and will provide a recommendation to the Board within 45 days following the meeting. The Board will consider the recommendation of the independent directors of the Company and determine whether to accept such recommendation within 90 days of the meeting. Absent exceptional circumstances, the Board will accept the resignation which will be effective upon such acceptance. A news release will be issued promptly by the Company announcing the Board’s determination, including, if applicable, the reasons for rejecting the resignation. A director who tenders his or her resignation will not participate in any meetings to consider whether the resignation shall be accepted. Shares held by brokers who are prohibited from exercising discretionary authority for beneficial owners who have not given voting instructions (“broker non-votes”) will not be counted as votes cast and will have no effect on the outcome of the voting on this proposal.

Proposal 2: Advisory Vote on the Compensation of Our Named Executive Officers

You may select “For”, “Against” or “Abstain” with respect to Proposal 2. The affirmative vote of a majority of the votes cast at the Annual Meeting is required for the approval, on an advisory (non-binding) basis, of the compensation of our NEOs as disclosed in this Proxy Statement. The results of the vote on the proposal are not binding on the Board or the Compensation Committee. Abstentions and broker non-votes will not be included in the total votes cast and will not affect the results.

Proposal 3: Appointment of KPMG LLP

You may select “For” or “Withhold” your vote with respect to Proposal 3. The affirmative vote of a majority of the votes cast at the Annual Meeting is required in order to appoint our independent registered public accounting firm for fiscal year 2021. U.S. (but not Canadian) brokers may exercise discretion and vote on this matter and these will be counted as votes cast. Broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting on this proposal.

What are the Board’s recommendations as to how I should vote on each proposal?

The Board recommends a vote:

•“FOR” the election of each of the seven director nominees named in this Proxy Statement;

•“FOR” the advisory (non-binding) resolution approving the compensation of the NEOs as disclosed in this Proxy Statement; and

•“FOR” the appointment of KPMG to serve as the Company’s independent registered public accounting firm for fiscal year 2021 and the authorization of the Board to fix KPMG’s remuneration.

Table of Contents

How do I participate in the Annual Meeting?

The Company is holding the Annual Meeting in a virtual only format, which will be conducted via live audio webcast. Shareholders will not be able to attend the Annual Meeting in person. Participating in the Annual Meeting online enables registered Shareholders and duly appointed proxyholders, including non-registered Shareholders who have duly appointed themselves as proxyholder, to ask questions and vote, all in real time. Registered Shareholders and duly appointed proxyholders can vote at the appropriate times during the Annual Meeting. Guests, including non-registered Shareholders who have not duly appointed themselves as proxyholder, can log in to the Annual Meeting as set out below. Guests can listen to the Annual Meeting but are not able to ask questions or vote at the Annual Meeting.

To log in to the Annual Meeting online, visit https://web.lumiagm.com/226761154 on your smart phone, tablet or computer. You will need the latest versions of Chrome, Safari, Edge, Firefox or Internet Explorer 11. Please ensure your browser is compatible. For example, some operating systems may experience difficulty accessing the Annual Meeting using Internet Explorer. We recommend that you log in at least 15 minutes before the Annual Meeting starts. To log in, either click:

After logging in, if you are a registered Shareholder or duly appointed proxyholder:

1. Click on “I Have a Control Number”.

2. Enter your 12-digit Control Number located on your proxy card.

3. Enter the password “cronos2021” (case sensitive).

If you are a guest, including non-registered Shareholders who have not duly appointed themselves as proxy holder, click on “I Am A Guest” and then complete the online form.

When successfully authenticated, the information screen will be displayed. You can view company information, ask questions, vote (where applicable) and listen to the webcast.

Duly appointed proxyholders must contact TSX Trust Company (“TSX Trust”), the Company’s transfer agent, in advance of the Annual Meeting to obtain a new Control Number as described under “If I have appointed a proxyholder, how can they participate in and vote at the Annual Meeting?”. Without the Control Number, proxyholders will not be able to participate at the meeting.

If you are a registered Shareholder or duly appointed proxyholder that would like to vote in the Annual Meeting, it is important that you are connected to the Internet at all times during the Annual Meeting in order to vote when balloting commences. It is your responsibility to ensure connectivity for the duration of the Annual Meeting. You should allow ample time to check into the Annual Meeting online and complete the related procedures.

How can I submit questions during the Annual Meeting?

Registered Shareholders and duly appointed proxyholders, including non-registered Shareholders who have duly appointed themselves as proxyholder, will be able to submit questions online by clicking on the submit questions button. Questions can be submitted only during the meeting and using the means specified during the Annual Meeting.

We intend to answer properly submitted questions that are pertinent to the Company and Annual Meeting matters, as time permits. Questions sent will be moderated before being sent to the Chairman of the Meeting. The Company reserves the right to edit profanity or other inappropriate language, or to exclude questions that are not pertinent to Annual Meeting matters or that are otherwise inappropriate.

Table of Contents

What if I need technical assistance?

If you encounter any technical difficulties accessing the virtual Annual Meeting during the check-in or the Annual Meeting, please access the frequently asked questions portal online at https://go.lumiglobal.com/faq.

How do I submit my vote?

Voting by Proxy before the Annual Meeting

If you are a Shareholder of record as of 5:00 p.m., Toronto time, on the Record Date, April 26, 2021, you can vote via the Internet, by telephone or, for those Shareholders who receive a paper proxy card in the mail, by completing, dating and signing your proxy card and returning it to TSX Trust by facsimile at (416) 595-9593 or by mail or courier to 100 Adelaide Street West, Suite 301, Toronto, Ontario, M5H 4H1.

For those Shareholders who receive a Notice of Internet Availability, the Notice of Internet Availability provides information on how to access their proxy on the Internet, which contains instructions on how to vote via the Internet or by telephone. If you received a Notice of Internet Availability, you can request a printed copy of your proxy materials by following the instructions contained in the notice.

If you are voting by proxy, you must ensure that the proxy is received not later than 11:59 p.m. (Toronto time) on June 23, 2021, or, in the case of any adjournment or postponement of the Annual Meeting, prior to 11:59 p.m. (Toronto time) on the date that is two business days before the date of the adjourned or postponed meeting. The time limit for the delivery of proxies may also be waived or extended by the Chair of the Annual Meeting at his or her discretion, without notice.

Voting at the Meeting

Registered Shareholders and duly appointed proxy holders can vote at the appropriate times by completing a ballot online during the Annual Meeting. We anticipate that once voting has opened during the Annual Meeting, the resolutions and voting choices will be displayed and you will be able to vote by selecting your voting direction from the options shown on the screen. Confirmation that your vote has been received should then appear. We anticipate that while voting remains open during the Annual Meeting you will be able to change your vote by selecting another voting direction or cancel your vote by pressing the cancel button.

What do I do if I hold my Shares through an Intermediary?

If you hold your Shares through an Intermediary, you can vote by following the instructions in the voting instruction form or in accordance with any other instructions provided by that Intermediary.

Non-registered Shareholders who have not duly appointed themselves as proxyholder will be able to listen to the Annual Meeting but will not be able to ask questions or vote at the Annual Meeting. This is because the Company and TSX Trust do not have a record of the non-registered Shareholders and, as a result, have no knowledge of your shareholdings or entitlement to vote unless you appoint yourself as proxyholder.

The Company has distributed copies of the Notice of Internet Availability to the Intermediaries for onward distribution to non-registered Shareholders. Intermediaries are required to forward the Notice of Internet Availability to non-registered Shareholders unless a non-registered Shareholder has waived the right to receive it. Typically, Intermediaries will use a service company (such as Broadridge Financial Solutions, Inc. (“Broadridge”)) to forward the Notice of Internet Availability to non-registered Shareholders. The Company is a “Participating Issuer” under Broadridge’s Electronic Delivery

Table of Contents

Procedures. Non-registered Shareholders who have enrolled in Broadridge’s Electronic Delivery Procedures (at www.investordelivery.com) will have received an email notification from Broadridge that the Notice of Meeting, this Proxy Statement and a proxy card or voting instruction form are available electronically, which notification includes a hyperlink to the page on the Internet where the proxy materials can be viewed. Generally, non-registered Shareholders who have not waived the right to receive proxy materials will be given a voting instruction form which must be completed and signed by the non-registered Shareholders in accordance with the directions on the voting instruction form; voting instruction forms sent by the Company and Broadridge permit the completion of the voting instruction form by facsimile or through the Internet at www.proxyvote.com.

The Company will pay for an Intermediary to deliver proxy materials to non-objecting beneficial owners of Shares (“NOBOs”) and objecting beneficial owners of Shares (“OBOs”). Any proxy materials sent to NOBOs and OBOs will be accompanied by a voting instruction form. By returning the voting instruction form in accordance with the instructions noted thereon, a NOBO or OBO is able to instruct the voting of the Shares owned by it. Voting instruction forms, whether provided by the Company or by an Intermediary, should be completed and returned in accordance with the specific instructions noted thereon. The purpose of this procedure is to permit non-registered Shareholders to direct the voting of the Shares which they beneficially own.

If you are a non-registered Shareholder and wish to vote at the Annual Meeting, you should follow the instructions in the voting instruction form or contact your Intermediary for instructions and must follow all of the applicable instructions, including the deadline, provided by your Intermediary.

Can I appoint a proxyholder not named in the proxy card or voting instruction form?

The persons named in the proxy card or voting instruction form are directors or officers of the Company designated by the Board. A registered Shareholder has the right to appoint as proxyholder a person or company (who need not be a Shareholder) other than the persons already named by the Board in the proxy card to attend and act on such registered Shareholder’s behalf at the Annual Meeting. Such right may be exercised by crossing out the names of the Board’s nominees and inserting the name of the person or company in the blank space provided in the proxy card or by completing another proxy card. The proxyholder does not need to be a Shareholder, but the proxyholder does need to understand that the registered Shareholder’s vote will not be counted unless the proxyholder attends the Annual Meeting and votes the registered Shareholder’s Shares.

If you are a non-registered Shareholder and wish to appoint someone else as your proxyholder, including yourself, to participate in the Annual Meeting, including asking questions and voting, please follow the instructions in the voting instruction form or contact your Intermediary for instructions.

If I have appointed a proxyholder, how can they participate in and vote at the Annual Meeting?

If you have appointed someone other than the Board’s nominees as your proxyholder, the person you have appointed as your proxyholder must contact TSX Trust at tsxtrustproxyvoting@tmx.com to request a Control Number to participate in the Annual Meeting as your proxy and vote your Shares. It is the responsibility of the Shareholder to advise his or her proxy holder to contact TSX Trust to request a Control Number. Without the Control Number, proxyholders will not be able to participate at the Annual Meeting, including asking questions and voting.

Requests for a Control Number must be made by 11:59 p.m. (Toronto time) on June 23, 2021.

Table of Contents

What do I do if I am located in the United States and hold my Shares through an Intermediary?

If you are a non-registered Shareholder located in the United States and wish to vote at the Annual Meeting or, if permitted, appoint a third party as your proxyholder, in addition to the steps described herein, you must obtain a valid legal proxy from your Intermediary. Follow the instructions from your Intermediary or contact your Intermediary to request an image of your valid legal proxy. After obtaining a valid legal proxy from your Intermediary, you must then submit a copy of such legal proxy to TSX Trust at tsxtrustproxyvoting@tmx.com. Requests for registration from non-registered Shareholders located in the United States that wish to participate in and vote at the Annual Meeting or, if permitted, appoint a third party as their proxyholder must be sent by facsimile or by courier to: 416-595-9593 (if by facsimile), or TSX Trust Company, 100 Adelaide Street West, Suite 301, Toronto, Ontario, M5H 4H1, Canada (if by courier). In both cases, the request for registration must be labeled “Legal Proxy” and received no later than the voting deadline of 11:59 p.m. (Toronto time) on June 23, 2021. You will receive a confirmation of your registration by email after TSX Trust receives your registration materials.

What constitutes a quorum?

The Annual Meeting will be held only if a quorum is present. A quorum will be present if the holders of 33 1/3% of the Shares outstanding as of 5:00 p.m., Toronto time, on the Record Date and entitled to vote on a matter at the Annual Meeting are represented, directly or by proxy, at the Annual Meeting. Shares represented by properly completed proxy cards or voting instruction forms either marked “abstain” or “withhold,” or returned without voting instructions, are counted as present and entitled to vote for the purpose of determining whether a quorum is present at the Annual Meeting. If Shares are held by brokers who are prohibited from exercising discretionary authority for beneficial owners who have not given voting instructions, those Shares will be counted as represented at the Annual Meeting for the purpose of determining whether a quorum is present at the Annual Meeting.

Can I change or revoke my vote after I return my proxy card or voting instruction form?

Yes. In addition to revocation in any manner permitted by law, a registered Shareholder as of 5:00 p.m., Toronto time, on the Record Date who has returned a proxy card may revoke it at any time before it is voted at the Annual Meeting by:

•completing and signing a proxy card bearing a later date, and delivering it to TSX Trust in accordance with the instructions (including the submissions deadlines) set out above;

•delivering a written statement expressly revoking such proxy, signed by the registered Shareholder or by the registered Shareholders’ attorney, who is authorized in writing, to:

◦the Corporate Secretary of the Company at 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1, at any time up to and including two business days prior to the Annual Meeting, or two business days preceding the day to which the Annual Meeting is adjourned or postponed; or

◦the Chair of the Annual Meeting prior to the start of the Annual Meeting.

If a registered Shareholder has followed the process for participating in and voting at the Annual Meeting online, voting at the Annual Meeting online will revoke all previously submitted proxies.

A non-registered Shareholder who wishes to revoke their voting instructions must complete, sign and submit a voting instruction form bearing a later date or contact their Intermediary in respect of such instructions and comply with any

Table of Contents

applicable requirements imposed by such Intermediary. An Intermediary may not be able to revoke such instructions if it receives insufficient notice of revocation.

Who will count the votes?

A representative of our transfer agent and registrar, TSX Trust, will act as scrutineer at the Annual Meeting and will count the votes.

Will my vote be kept confidential?

Yes. As a matter of policy, Shareholder proxies, ballots and tabulations that identify individual Shareholders are kept confidential.

Who pays to prepare, mail and solicit the proxies?

The Company pays all of the costs of preparing, mailing and soliciting proxies in connection with this Proxy Statement. We may solicit proxies by advertisement, telephone, online or personally by directors or officers or other employees of the Company without additional compensation. Intermediaries may request and forward proxy materials to beneficial owners and seek authority to execute proxies. The Company will reimburse the Intermediaries for their expenses in forwarding the proxy materials to and seeking authority from such beneficial owners. In addition to solicitation by advertisement, telephone, facsimile, email or personal contact by its directors, officers and employees, the Company has retained the services of Innisfree M&A Incorporated to assist in the solicitation of proxies for a fee of approximately $15,000 plus reasonable out of pocket expenses. The costs of solicitation will be borne by the Company.

How will my Shares be voted if I sign, date and return my proxy card or voting instruction form?

If you sign, date and return your proxy card or voting instruction form and indicate how you would like your Shares voted, your Shares will be voted or withheld from voting as you have instructed. If you sign, date and return your proxy card or voting instruction form but do not indicate how you would like your Shares voted, your proxy will be voted:

•“FOR” the election of each of the seven director nominees named in this Proxy Statement;

•“FOR” the advisory (non-binding) resolution approving the compensation of the NEOs as disclosed in this Proxy Statement; and

•“FOR” the appointment of KPMG to serve as the Company’s independent registered public accounting firm for fiscal year 2021 and the authorization of the Board to fix KPMG’s remuneration.

How will broker non-votes be treated?

A “broker non-vote” occurs when a broker who holds its customer’s Shares in street name submits proxies for such Shares but indicates that it does not have authority to vote on a particular matter. Generally, this occurs when brokers have not received any instructions from their customers. Without specific instructions, Canadian brokers are prohibited from voting their customers’ Shares.

Table of Contents

Without specific instructions, U.S. brokers, as the holders of record, are permitted to vote their customers’ Shares on “routine” matters only, but not on other matters. Shares for which U.S. brokers have not received instructions from their customers will only be permitted to vote on the following proposal:

•To appoint KPMG to serve as the Company’s independent registered public accounting firm for fiscal year 2021 and to authorize the Board to fix KPMG’s remuneration.

Shares for which U.S. brokers have not received instructions from their customers will not be permitted to vote on the following proposals:

•to elect the seven director nominees named in this Proxy Statement to the Board; or

•to approve, on an advisory (non-binding) basis, the compensation of the NEOs as disclosed in this Proxy Statement.

Does the Company have cumulative voting?

Shareholders have no cumulative voting rights with respect to the election of directors.

What if other matters come up during the Annual Meeting?

If any matters other than those referred to in the Notice of Annual Meeting properly come before the Annual Meeting, the individuals named in the proxy card or voting instruction form will vote the proxies held by them in accordance with their best judgment. As of the date of this Proxy Statement, Cronos is not aware of any business other than the items referred to in the Notice of Annual Meeting that will be considered at the Annual Meeting.

How do I contact the Corporate Secretary of the Company?

In several sections of this Proxy Statement, we suggest that you should contact the Corporate Secretary of the Company to follow up on various items. You can reach our Corporate Secretary by writing to 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1 or by email at corporate.secretary@thecronosgroup.com.

Principal Holders of Voting Securities.

As of the date of this Proxy Statement, to the knowledge of the directors and executive officers of the Company, no person or entity beneficially owns, or controls or directs, directly or indirectly, voting securities of the Company carrying 5% or more of the voting rights attached to any class of outstanding voting securities of the Company entitled to vote at the Annual Meeting, other than Altria Group, Inc. (“Altria”), as indirect beneficial owner of 156,573,537 Shares or approximately 42% of the issued and outstanding Shares as of March 22, 2021 (calculated on a non-diluted basis).

Your vote is important.

Because many Shareholders cannot participate in the Annual Meeting, it is necessary that a large number be represented by proxy in order to satisfy that a quorum be present to conduct business at the Annual Meeting. Whether or not you plan to participate in the Annual Meeting, prompt voting will be appreciated. Shareholders can vote their Shares via the Internet or by facsimile. Instructions for using this convenient service are provided on the proxy card or voting instruction form. Of course, you may still vote your Shares on the proxy card or voting instruction form. Shareholders who received a

Table of Contents

paper copy of a proxy card or voting instruction form may complete, sign, date and return the proxy card or voting instruction form promptly in the postage-paid envelope.

Important Notice Regarding the Availability of Proxy Materials

for the Annual Meeting of Shareholders to Be Held on Friday, June 25, 2021:

The Notice and Proxy Statement and Our Annual Report on Form 10-K for the Year Ended December 31, 2020 Are Available Free of Charge at:

https://ir.thecronosgroup.com/financial-information/annual-meeting.

Table of Contents

PROPOSAL NO. 1—ELECTION OF DIRECTORS

Board of Directors

The Company’s articles provide that the size of the Board shall be set at seven directors. Each director will hold office from the date of the Annual Meeting until the close of the next annual meeting of Shareholders or until the successor of such director has been duly elected and/or appointed in accordance with the articles of the Company, the Investor Rights Agreement dated as of March 8, 2019 between the Company and Altria (the “Investor Rights Agreement”), and applicable law.

The Investor Rights Agreement provides that, for so long as Altria, Maple Acquireco (Canada) ULC, Altria Summit LLC and each of their respective controlled affiliates (the “Altria Group”) continues to beneficially own at least 40% of the issued and outstanding Shares, and the size of the Board is seven directors, the Company will nominate for election as directors to the Board four individuals designated by Altria (each, an “Altria Nominee”). In addition, for so long as Altria Group continues to beneficially own greater than 10% but less than 40% of the issued and outstanding Shares, Altria is entitled to designate a number of Altria Nominees that represents Altria Group’s proportionate share of the number of directors comprising the Board (rounded up to the next whole number) based on the percentage of the issued and outstanding Shares beneficially owned by the Altria Group at the relevant time. At least one Altria Nominee must be “independent” as defined in the Investor Rights Agreement (“Investor Rights Agreement Independent”) as long as Altria has the right to designate at least three individuals to be nominated for election as directors to the Board and the Altria Group’s beneficial ownership of the issued and outstanding Shares does not exceed 50%. The meaning of Investor Rights Agreement Independent differs from the meaning of the term “independent” as defined under applicable NASDAQ listing standards and the NASDAQ marketplace rules (the “NASDAQ Rules”) and as defined in National Instrument 58-101 Disclosure of Corporate Governance Practices (“NI 58-101”). Directors who are not Investor Rights Agreement Independent may still be independent under the applicable NASDAQ Rules and/or NI 58-101. Kendrick Ashton, Jr., Jody Begley, Murray Garnick and Heather Newman are the Altria Nominees. Other than the Altria Nominees, the nominees for election as directors of the Company were selected by a majority of the Board’s independent directors within the meaning of such term under the applicable NASDAQ Rules.

Nominees for Election as Directors at the Annual Meeting

The Board has not established a formal nominating committee. Rather, the Board has determined that compliance with the NASDAQ Rules, which require that director nominees (other than the Altria Nominees) are recommended for the Board’s selection by independent directors within the meaning of such term under applicable NASDAQ Rules constituting a majority of the Board’s independent directors in a vote in which only independent directors participate, with the independence requirements applicable to such directors to be confirmed at such time, adequately encourages an objective nomination process. Individuals are selected with the desired experience and qualifications, taking into account the needs of the Board at the time. In making its recommendations, the Board’s independent directors consider:

•the attributes and skills that the Board considers to be necessary for the Board, as a whole, to possess;

•the attributes and skills that the Board considers each existing director to possess;

•the attributes and skills each new nominee will bring to the boardroom;

Table of Contents

•whether or not each new nominee can devote sufficient time and resources to his or her duties as a Board member; and

•diversity criteria, pursuant to the Company’s Diversity Policy as further described below under “– Diversity.”

The following table sets forth certain information regarding the director nominees. Additional biographical information on each of the nominees is included below under the section entitled “Directors and Executive Officers.”

Director Name

Age

Director Since

Residency

Principal Occupation

Michael Gorenstein

2015

Miami, FL

United States

Executive Chairman of Cronos

Jason Adler(1)(2)(3)

2016

Pacific Palisades, CA

United States

Co-founder and Managing Member of Gotham Green Partners

Kendrick Ashton, Jr. (1)(2)(3)

—

McLean, VA

United States

Co-founder and Co-Chief Executive Officer of The St. James

Jody Begley(1)

2019

Midlothian, VA

United States

Executive Vice President and Chief Operating Officer of Altria

Murray Garnick(1)

2019

Manakin Sabot, VA

United States

Executive Vice President and General Counsel of Altria

Heather Newman(1)

2019

Midlothian, VA

United States

Senior Vice President, Corporate Strategy of Altria

James Rudyk(1)(2)(3)

2018

Oakville, ON

Canada

Chief Financial Officer of Ag Growth International Inc.

(1) “Independent” within the meaning of such term under the applicable NASDAQ Rules.

(2) “Independent” within the meaning of such term under NI 58-101.

(3) Investor Rights Agreement Independent.

In considering the nominees’ individual experience, qualifications, attributes, skills and past Board participation, the Board’s independent directors have concluded that when considered all together, the appropriate experience, qualifications, attributes, skills and participation are represented for the Board as a whole and for each of the Board’s committees.

There are no family relationships among any directors and executive officers. Each nominee has indicated a willingness to serve and has consented to being named in this Proxy Statement, and the Board has no reason to believe that any of the nominees will not be available for election. However, if any of the nominees is not available for election, proxies may be voted for the election of other persons selected by the Board unless the proxy specifies the Shares are to be withheld from voting in the election of the directors. Proxies cannot, however, be voted for a greater number of persons than the number of nominees named. Shareholders have no cumulative voting rights with respect to the election of directors.

Required Vote

With regard to the election of the director nominees you may select “For” or “Withhold”. A plurality of the votes cast at the Annual Meeting is necessary to elect each director nominee.

Table of Contents

However, under the Majority Voting Policy any nominee for director who does not receive a greater number of votes “for” his or her election as a director than votes “withheld” from voting is required to tender his or her resignation to the Board for consideration by the independent directors of the Company promptly following the Annual Meeting. The independent directors of the Company will consider the resignation and will provide a recommendation to the Board within 45 days following the Annual Meeting. The Board will consider the recommendation of the independent directors of the Company and determine whether to accept such recommendation within 90 days of the Annual Meeting. Absent exceptional circumstances, the Board shall accept the resignation which will be effective upon such acceptance. A news release will be issued promptly by the Company announcing the Board’s determination, including, if applicable, the reasons for rejecting the resignation. A director who tenders his or her resignation will not participate in any meetings to consider whether the resignation shall be accepted.

A copy of the Majority Voting Policy is available on the Company’s website at https://ir.thecronosgroup.com/governance/documents-charters.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE ELECTION OF EACH OF THE NOMINEES FOR DIRECTOR NAMED ABOVE.

Table of Contents

DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth information regarding each director, director nominee and executive officer of the Company.


Name	Age	Position
Michael Gorenstein	34	Executive Chairman
Jason Adler	49	Director
Jody Begley	49	Director
Bronwen Evans	51	Director
Murray Garnick	61	Director
Heather Newman	44	Director
James Rudyk	54	Director
Kendrick Ashton, Jr.	45	Director nominee
Todd Abraham	66	Chief Innovation Officer
Jerry Barbato	45	Chief Financial Officer
Shannon Buggy	51	Senior Vice President, Global Head of People
Summer Frein	37	General Manager, USA
Jeff Jacobson	35	General Manager, Canada and Europe
Kurt Schmidt	64	President and Chief Executive Officer
Anna Shlimak	35	Senior Vice President, Corporate Affairs
Xiuming Shum	35	Executive Vice President, Legal and Regulatory Affairs

A brief biography of each director, director nominee and executive officer of Cronos is set forth below:

Michael Gorenstein is the Executive Chairman of Cronos. Mr. Gorenstein is also a Co-founder and passive Member of Gotham Green Partners. Before joining the Company, Mr. Gorenstein was the Vice President and General Counsel at Alphabet Partners, LP, a New York City based multi-strategy investment management firm, focused on identifying mispriced assets across various industries, asset classes and geographies. Prior to Alphabet Partners, LP, he was a corporate attorney at Sullivan & Cromwell LLP where he focused on mergers and acquisitions and capital markets transactions. Mr. Gorenstein graduated from the University of Pennsylvania Law School with a Juris Doctor, the Wharton School at University of Pennsylvania with a certificate in Business Economics and Public Policy and the Kelley School of Business at Indiana University with a Bachelor of Science Business in Finance. The combination of Mr. Gorenstein’s leadership capabilities and business and legal background, as well as his deep knowledge of the cannabis and U.S. hemp business, make him an ideal director and Chairman of the Board.

Jason Adler is the Co-founder and Managing Member of Gotham Green Partners, a private equity firm focused primarily on early-stage investing in companies in the cannabis industry. Prior to co-founding Gotham Green, Mr. Adler was the cofounder and Chief Executive Officer of Alphabet Partners, LP, a New York City based multi-strategy investment management firm, focused on identifying mispriced assets across various industries, asset classes and geographies. Prior to Alphabet Partners, LP, Mr. Adler also founded Geronimo, LLC, a broker dealer and member of the American Stock Exchange, that made markets in equity options, and he began his career as a

Table of Contents

market maker at G&D Trading. Mr. Adler graduated with a Bachelor of Arts from the University of Rhode Island. Mr. Adler’s extensive experience in the cannabis industry as well as in assisting startup companies to grow into successful, mature companies make Mr. Adler a valuable director.

Kendrick Ashton, Jr. is the Co-Founder and Co-Chief Executive Officer of The St. James, a leading developer and operator of performance, wellness and lifestyle brands, experiences and destinations. Prior to founding The St. James in 2014, Mr. Ashton was a founding member and Managing Director of Perella Weinberg Partners, a boutique financial services firm founded in 2006 by Joseph Perella and Peter Weinberg. From 2009 to 2011, he served as Chief Operating Officer of the Firm’s Corporate Advisory Business. Prior to joining Perella Weinberg, Mr. Ashton was an investment banker at Goldman, Sachs & Co. and gained legal experience at Cravath, Swaine & Moore and Wachtell, Lipton, Rosen & Katz. Mr. Ashton received a Juris Doctorate from the University of Chicago Law School, where he was a Merit Scholar and the Earl Dickerson Public Service Scholar, and a Master of Business Administration from the University of Chicago Graduate School of Business, where he was also a Merit Scholar. He earned his A.B. from the College of William and Mary. Mr. Ashton is a member of the Board of Trustees of the Colonial Williamsburg Foundation, the Board of Trustees of the National Urban League, the Board of Directors of Archbishop John Carroll High School and the Board of Directors of Bellwether Education Partners and is an emeritus member of the Board of Visitors and Foundation Board of the College of William & Mary. Mr. Ashton has been selected to be a director nominee by Altria.

Jody Begley currently serves as Executive Vice President and Chief Operating Officer for Altria, overseeing the manufacturing, marketing and distribution of Altria’s companies’ tobacco products and various functions supporting those operations. Prior to Mr. Begley’s current role, he served as Senior Vice President, Tobacco Products for Altria, overseeing Altria’s core tobacco businesses as well as Engineering, Quality and Product Development support and Consumer & Marketplace Insights. Mr. Begley also served as President and General Manager of Nu Mark from July 2015 until May 2018, leading the company’s development and marketing of innovative tobacco products for adult smokers and vapers. He joined Philip Morris USA in 1995 and has held various leadership positions at several Altria companies, including Vice President, Brand Management, PM USA; Vice President, Strategy & Business Development; Vice President, Marketing & Promotion Services; Vice President, Brand Management, Smokeless; and Vice President, Customer & Marketing Services. Mr. Begley is a graduate of the University of Tennessee-Knoxville where he received a Bachelor of Science in Industrial Engineering in 1993, and a Master of Business Administration in 1995. He also serves on the Board for the Boys & Girls Clubs in the metro Richmond area. Mr. Begley was appointed a director by Altria.

Bronwen Evans is the Chief Talent Officer at Medcan with executive oversight on talent-related functions, including recruitment, development and retention. Ms. Evans was a Founding Director of the True Patriot Love Foundation, where she served as its first CEO from 2012 to 2019 and raised record funds to support 25,000 Canadian military and veteran families. Before that, Ms. Evans was the Vice President of Marketing and Corporate Affairs at Medcan Health Management, and became the company’s first Chief Privacy Officer. She is a recipient of The Queen’s Diamond Jubilee Medal (2012) and currently serves as Director, Secretary and Chair of the Governance Committee of Kingsway College School. Ms. Evans holds a Bachelor of Arts in Philosophy with Honors from McGill University, and a Master of Arts in Philosophy with a concentration in Biomedical Ethics from Carleton University. Ms. Evans was appointed a director by Altria.

Murray Garnick serves as Executive Vice President and General Counsel of Altria. In his role since 2017, he leads the company’s Law Department, Regulatory Affairs and Regulatory Sciences. Mr. Garnick previously served as Deputy General Counsel for Altria Client Services, a subsidiary of Altria, which provides professional services and support to Altria and its operating companies. At Altria, Mr. Garnick has led the legal support for sales,

Table of Contents

marketing, regulation, and product development and intellectual property matters. He has also supervised the management of tobacco, health and all other litigation brought against Altria and its operating companies. Prior to joining Altria in 2008 as Senior Vice President, Litigation and Associate General Counsel, Mr. Garnick served for more than two decades as a senior litigation partner at the law firm of Arnold & Porter in Washington, D.C. Mr. Garnick received his Bachelor of Arts from the University of Georgia and his Juris Doctor from the University of Georgia School of Law. Mr. Garnick was appointed a director by Altria.

Heather Newman serves as Senior Vice President, Corporate Strategy for Altria. In her role, she oversees Altria’s Strategy & Business Development, Consumer & Marketplace Insights, Digital & Technology, Investor Relations, Corporate Communications and Ste. Michelle Wine Estates. Previously, Ms. Newman served as President and Chief Executive Officer for Philip Morris USA, where she led the company’s efforts to responsibly manufacture and market its brands, including Marlboro, the leading cigarette brand in all 50 U.S. states, and IQOS, to adult tobacco consumers in a financially disciplined way. Since 1999, Ms. Newman held numerous leadership roles in Sales and Brand Management including Vice President & General Manager, Marlboro. Ms. Newman received her undergraduate business degree from Saint Joseph’s University’s Erivan K Haub School of Business and completed her Master of Business Administration at Saint Joseph’s University with a concentration in Marketing in 2005. She serves on the Board of Directors for MENTOR Virginia, The Executive Advisory Council for the University of Richmond Robins School of Business, as well as on the Board of Visitors for Saint Joseph’s University. Ms. Newman was appointed a director by Altria.

James Rudyk is currently the Chief Financial Officer at Ag Growth International Inc., a leading global food infrastructure company providing products, systems and solutions to the agriculture and food processing industries, where he is responsible for finance, accounting, business intelligence and information technology. Mr. Rudyk is a seasoned executive with more than 25 years of financial and operational experience, and a track record of supporting ambitious growth plans. Prior to joining Ag Growth International in September 2020, he was the Chief Financial Officer of Sofina Foods Inc. from September 2019 until May 2020, and was the Chief Financial Officer of Roots Corporation from January 2016 until August 2019, where he helped the company grow and transition from a family-led organization to a Canadian public company. Prior to joining Roots Corporation, Mr. Rudyk served as the Chief Financial Officer of Shred-It International Inc. from 2009 to 2015, where he was instrumental in helping the company grow from approximately $200 million to over $700 million in revenue and expand to more than 17 countries around the world. He also served as Chief Financial Officer and Chief Operating Officer of Canada Cartage Systems Limited from 2004 to 2009. He received his Bachelor of Arts and Master of Accounting degree from the University of Waterloo. Mr. Rudyk is also a Chartered Professional Accountant and holds an ICD.D designation from the Institute of Corporate Directors and the University of Toronto’s Rotman School of Management. Mr. Rudyk’s financial and accounting experience, together with his experience with growth companies, make him a valuable director.

Todd Abraham is Cronos’s Chief Innovation Officer. Prior to joining the Company in August 2019, Dr. Abraham was Senior Vice President of Research and Nutrition for Mondelēz International (formally Kraft Foods), and was responsible for worldwide technology development and strategy, scientific screening, nutritional science and communication, consumer guidance testing, analytical programs, research and development training and intellectual property strategy for a $35 billion multi-national business. Prior to Mondelēz, Dr. Abraham served in various research and development, technology, marketing and product development roles for The Pillsbury Company and Procter & Gamble. Dr. Abraham received his Bachelor of Science degree in Chemistry at Brown University and his Doctor of Philosophy in Chemistry from the University of Pennsylvania and his Master of Business Administration in Strategic Planning from the Wharton School at University of Pennsylvania.

Table of Contents

Jerry Barbato is the Chief Financial Officer of Cronos. Mr. Barbato joined Cronos with 20 years of experience in strategic planning, corporate financial analysis and services, and brand management. Prior to joining Cronos, he held various roles within the Altria family of companies. Mr. Barbato joined Altria in 2003 and served in leadership roles within the Finance, Strategy & Business Development and Marketing functions, and most recently held the role of Senior Director of Corporate Strategy. He has broad experience in both finance and operating roles, as well as managing operations in regulated international markets. Mr. Barbato supported the Marlboro brand and provided analysis that shaped brand strategies for Altria’s smokeable segment. He also served as Assistant General Manager for a joint venture, Richmark GmbH, in Zurich, Switzerland. Mr. Barbato holds a Bachelor of Science in Accounting from Marquette University and a Master of Business Administration from the University of Maryland, University College.

Shannon Buggy is Cronos’ Senior Vice President, Global Head of People for Cronos Group since November 2020. Ms. Buggy is responsible for leading the Company’s human resources strategy across its global operations. Prior to Cronos, Ms. Buggy was the Senior Vice President of Global Human Resources for Nielsen from February 2018 until August 2020, where she led the human resources strategy for Nielsen Media, and the Executive Director, Head of Talent Strategy and HR Business Partners for Purdue Pharma L.P. from December 2014 until November 2017. With over 25 years of experience, Ms. Buggy has a proven track record of leading and managing global human resources teams and driving excellence in talent acquisition, development, retention, employee relations, compensation, benefits, talent management and labor relations. Ms. Buggy holds a certification as a Senior Professional in Human Resources from the HR Certification Institute. Ms. Buggy graduated magna cum laude with a Bachelor of Science degree in Human Resources Management from the Pace University, Lubin School of Business.

Summer Frein is Cronos’ General Manager, USA since July 2020. As the General Manager, USA, Ms. Frein is responsible for implementing and defining the strategy and execution across all areas of the U.S. hemp-derived CBD business including sales strategy, marketing and operations. Ms. Frein joined Cronos in January 2020 as the Vice President, U.S. Head of Sales of Redwood. Prior to joining Cronos, Ms. Frein held a variety of senior leadership roles at Altria, which she joined in 2006, including as Senior Director of Corporate Strategy, Senior Director of Brand Management and Digital Marketing Strategy Director. In 2018, Ms. Frein led the cannabis research investment strategy in the Strategy and Business Development Group at Altria. Since joining the Company, Ms. Frein has been responsible for leading Cronos’ U.S. brand sales operations, including building and managing brand and retail partnerships for the Lord Jones™ and Happy Dance™ brands. Ms. Frein has a Bachelor of Business Administration from the McCombs School of Business at the University of Texas at Austin.

Jeff Jacobson is the General Manager of Canada and Europe for Cronos. As General Manager of Canada and Europe, Mr. Jacobson is responsible for implementing and defining the strategy and execution across all areas of the Canadian and European business including sales, marketing and manufacturing operations. Prior to joining Cronos in December 2016, Mr. Jacobson founded a Toronto based marketing agency and successfully launched and licensed several innovative software products in the mobile industry. As a co-founder of Peace Naturals, Mr. Jacobson’s expertise and experience in licensing and compliance, new business development, project management and resource management help Cronos lead in domestic and international markets.

Kurt Schmidt serves as Cronos’ President and Chief Executive Officer since September 2020. Before joining the Company, Mr. Schmidt served as director and Chief Executive Officer of Blue Buffalo Company, Ltd. from 2012 through 2016 and a senior advisor to Blue Buffalo from January 2017 until December 2017. Prior to joining Blue Buffalo, Mr. Schmidt was Deputy Executive Vice President at Nestlé S.A., where he was responsible for the Nestlé Nutrition, including several science-oriented and heavily regulated businesses. He also served as a member of the company’s Executive Committee. Mr. Schmidt joined Nestlé in 2007 as part of its acquisition of

Table of Contents

Gerber Products from Novartis, where he was the President and Chief Executive Officer of Gerber Products Company from 2004 to 2007. Prior to Gerber, Mr. Schmidt held a variety of leadership roles at Kraft Foods, Inc. Mr. Schmidt currently serves on the Board of Directors of Campbell Soup Company. He received a Bachelor of Science in Chemistry from the United States Naval Academy and a Master of Business Administration from the University of Chicago. Mr. Schmidt brings deep experience in consumer products with decades of leadership experience in the U.S. and overseas.

Anna Shlimak is the Company’s Senior Vice President of Corporate Affairs and responsible for managing and directing the organization’s internal and external communications, government affairs and investor relations. Prior to joining the Company, Ms. Shlimak was the Head of Investor Relations at Quest Partners LLC, a research driven alternative investment firm. Ms. Shlimak was responsible for business development, investor reporting, marketing and communication initiatives for the fund. Previously, Ms. Shlimak held a range of diverse roles at the New York Stock Exchange in both the New York and London offices. Most recently, Ms. Shlimak was on the Investor Relations Team within the Corporate Finance Group, where she was responsible for developing relationships with investors and sell side analysts, as well as all creating investor communication and reporting. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.

Xiuming Shum is the Executive Vice President, Legal and Regulatory Affairs of Cronos. Ms. Shum manages the legal and regulatory affairs functions at Cronos, which informs the Company’s strategy and execution. Ms. Shum has a decade of transactional and in-house experience in mergers and acquisitions and regulatory change management. Prior to joining Cronos, Ms. Shum served as in-house counsel at BNP Paribas’ Corporate and Institutional Banking division in New York and London, where she provided advice to senior management on disruptive and transformative legislative changes, such as the BASEL banking reforms, the United Kingdom’s expected withdrawal from the European Union, and the Dodd-Frank Wall Street Reform and Consumer Protection Act. Previously, she was a corporate attorney at Sullivan & Cromwell LLP in New York, where she focused on mergers and acquisitions in large, complex cross-border transactions in diverse industries, including alcohol and spirits, insurance, banking, private equity, and hedge funds. Ms. Shum is a New York-qualified attorney, holding a Juris Doctor from Columbia Law School where she was a Harlan Fiske Stone Scholar and a first-class Bachelor of Laws degree from University College London in the United Kingdom.

Table of Contents

BOARD OF DIRECTORS, COMMITTEES AND GOVERNANCE

Overview

The Board considers good corporate governance practices to be an important factor in the overall success of the Company. Under NI 58-101 and National Policy 58-201 Corporate Governance Guidelines, the Company is required to disclose information relating to its corporate governance practices, which disclosure is set out herein. With respect to the United States, the Company is required to comply with the provisions of the Sarbanes-Oxley Act of 2002 (the “Act”) and the applicable rules adopted by the SEC pursuant to the Act, as well as the NASDAQ Rules.

The Board is responsible for the oversight of the business and affairs of the Company. The Board oversees the development of the Company’s strategic plan and the ability of the executive officers to continue to deliver on the corporate objectives. The Board Mandate is attached as Appendix A to this Proxy Statement.

The independent judgment of the Board in carrying out its responsibilities is the responsibility of all directors. The Board facilitates independent supervision of the executive officers through meetings of the Board and through frequent informal discussions among independent members of the Board and executive officers. In addition, the Board has unrestricted access to the Company’s external auditors, external legal counsel and to the Company’s executive officers and employees.

Meetings

The Board held 16 meetings in 2020. Five Board members attended 100% of these meetings, and one Board member, Ms. Newman, attended 100% of the meetings from the time of her appointment in March 2020. Two Board meetings had been convened to consider employment terms for Mr. Gorenstein in connection with his transition from his role as the Company’s President and Chief Executive Officer to Executive Chairman of the Board. As a result, Mr. Gorenstein recused himself from all discussions and considerations of, and voting upon, any such matters. Other than these Board meetings, Mr. Gorenstein attended all of the Board meetings in 2020.

Our current Board members who served on the Compensation Committee attended 100% of its ten meetings held in 2020.

The Audit Committee held 19 meetings in 2020. Mr. Rudyk, the Chair of the Audit Committee, attended 100% of the meetings and the other members of the Audit Committee attended at least 95% of the meetings.

Director Independence

The Board is currently comprised of seven directors: Michael Gorenstein (“Chair”), Jason Adler, Jody Begley, Murray Garnick, Heather Newman, Bronwen Evans and James Rudyk. Ms. Evans’ term will end immediately prior to the Annual Meeting. Please see the biographies of individual directors and director nominee under “Directors and Executive Officers”.

The Board has determined that three of the seven directors of the Company (or approximately 43% of the nominees), namely Mr. Adler, Ms. Evans and Mr. Rudyk, and Mr. Ashton, a director nominee, have no material relationship with the Company, either directly or indirectly, which could, in the view of the Board, be reasonably expected to interfere with the exercise of such individual’s independent judgment, and are “independent” within the meaning of such term under the applicable NASDAQ Rules and NI 58-101. As Altria is the parent company of Maple Acquireco (Canada) ULC, the beneficial owner of approximately 42% of the issued and outstanding Shares

Table of Contents

as of March 22, 2021 (calculated on a non-diluted basis), for the purposes of NI 58-101, the Company is considered to be “controlled” by Altria. As such, Messrs. Begley and Garnick and Ms. Newman are not “independent” within the meaning of such term under NI 58-101 (but are considered to be “independent” within the meaning of such term under the applicable NASDAQ Rules) as they are the Executive Vice President and Chief Operating Officer, the Executive Vice President and General Counsel and the Senior Vice President, Corporate Strategy, respectively, of Altria. Messrs. Begley and Garnick and Ms. Newman are considered to be “independent” within the meaning of such term under applicable NASDAQ Rules, other than for Audit Committee purposes. Mr. Gorenstein is not “independent” within the meaning of such term under the applicable NASDAQ Rules and NI 58-101 as he is the Executive Chairman of the Board.

While the majority of the directors of the Company are not independent within the meaning of such term under NI 58-101, only Mr. Gorenstein is an executive officer of the Company, and thus the Board believes that it is able to exercise independent judgment in carrying out its responsibilities. In addition, to facilitate the exercise of independent supervision over executive officers, the Board has provided for the role of an independent lead director (the “Independent Lead Director”) as described further under “Board Leadership Structure and Qualifications” below. This role is currently held by Mr. Rudyk.

The directors who are independent within the meaning of such term under NI 58-101 meet in executive session, without the presence of non-independent directors and executive officers, in conjunction with each regularly scheduled meeting of the Board and at other meetings as appropriate. During 2020, seven executive sessions were held. These executive sessions are led by the Independent Lead Director. The Board encourages its independent directors to meet formally or informally without any non-independent directors, including executive officers, being present on an as-needed basis. In addition, the small size of the Board helps to create an atmosphere conducive to candid and open discussion among all directors.

Board Leadership Structure and Qualifications

Each director must have an understanding of the Company’s principal operational and financial objectives, plans and strategies, and financial position and performance. Directors must have sufficient time to carry out their duties and not assume responsibilities that would materially interfere with, or be incompatible with, Board membership. Directors must advise the Executive Chairman of the Board in advance of accepting an invitation to serve on the board of another public corporation.

Currently, Michael Gorenstein serves as the Executive Chairman of our Board, and James Rudyk serves as the Independent Lead Director of our Board. The primary focus of the Independent Lead Director is to provide leadership to ensure that the Board functions independently of the executive officers of the Company and non-independent directors and to foster the effectiveness of the Board. The Independent Lead Director acts as a liaison between the independent directors and the Executive Chairman and:

•chairs all Board meetings when the Executive Chairman is not in attendance;

•seeks to stimulate debate;

•seeks to provide adequate time for discussion of issues, facilitate consensus, encourage full participation and discussion by individual directors and confirm that decision-making is reached and accurately recorded;

Table of Contents

•works with the Executive Chairman to ensure that the appropriate committee structure is in place and makes recommendations for appointment to such committees; and

•together with the Executive Chairman, ensures that the responsibilities of the Board are effectively carried out in compliance with the Board’s mandate and that the functions of the Board delegated to the committees of the Board are effectively carried out and reported to the Board.

Position Descriptions

The Board has written position descriptions for the Executive Chairman of the Board, Independent Lead Director, chairs of the Board committees and the CEO. The Board Mandate and the charters for the committees set out in writing the responsibilities of the Board and the committees for supervising executive officers of the Company.

Orientation and Continuing Education

All new directors are provided with an initial orientation regarding the nature and operation of the Company’s business and its strategy and as to the role of the Board and its committees, as well as the legal obligations of a director of the Company. Directors are periodically updated on these matters.

In order to orient new directors as to the nature and operation of the Company’s business, they are given an opportunity to meet with executive officers to discuss the Company’s business and activities. In addition, new directors receive copies of Board materials, corporate policies and procedures, and other information regarding the business and operations of the Company.

Board members are expected to keep themselves current with industry trends and developments and are encouraged to communicate with executive officers and, where applicable, auditors and advisors of the Company. Board members have access to the Company’s external and in-house legal counsel in the event of any questions or matters relating to their corporate and director responsibilities and to keep themselves current with changes in legislation. Board members have full access to the Company’s records. In addition, external counsel and other external advisors of the Company will be regularly invited to present to the Board at Board meetings on topics and trends facing public companies and private companies in the cannabis industry.

The orientation and continuing education process are reviewed on an annual basis by the Board and revised as necessary.

Board Oversight of Risk Management

The role of our Board in our risk oversight is consistent with our leadership structure, with our President and Chief Executive Officer and other executive officers having day-to-day responsibility for assessing and managing our risk exposure and control processes, and our Board and its committees providing oversight of risk management and control processes.

The Company’s executive officers are responsible for reporting to the Board on the principal risks associated with the Company’s business and operations, implementing appropriate systems to manage these risks and reporting to the Board on the operation of, and any material deficiencies in, these systems. Such reports are provided by executive officers to the Board at each regularly scheduled Board meeting.

Table of Contents

The Audit Committee is responsible for monitoring procedures relating to financial reporting risk management and reviewing the adequacy of the Company’s internal control over financial reporting. The Compensation Committee has primary responsibility for the Company’s compensation policies, plans and practices regarding both executive compensation and the compensation structure generally and in particular, reviews the Company’s incentive compensation arrangements to ensure these programs do not encourage inappropriate or unintended risk-taking by the Company’s employees.

Committees of Our Board of Directors

The standing committees of our Board consist of the Audit Committee and the Compensation Committee. The responsibilities of these committees are described below. Our Board may also establish various other committees to assist it in its responsibilities. The following table summarizes the current membership of the Board and each of its committees:


Director Name	Audit Committee	Compensation Committee
Michael Gorenstein
Jason Adler(1) (2)	Member	Member
Jody Begley(1)		Chair
Bronwen Evans(1) (2)	Member
Murray Garnick(1)
Heather Newman
James Rudyk(1) (2)	Chair	Member

(1) “Independent” within the meaning of such term under the applicable NASDAQ Rules.

(2) “Independent” within the meaning of such term under NI 58-101.

Our Board has adopted a charter for each of the two standing committees that addresses the composition and function of each committee. Copies of such materials are available on our website at https://ir.thecronosgroup.com/governance/documents-charters.

The Investor Rights Agreement also provides that, subject to certain exceptions, for so long as Altria is entitled to designate one or more Altria Nominees, Altria may appoint to each committee established by the Board such number of Altria Nominees that represents Altria’s proportionate share of the number of directors comprising the applicable Board committee based on the percentage of our issued and outstanding Shares beneficially owned by the Altria Group at the relevant time.

Audit Committee.

The Company has a separately designated standing Audit Committee established in accordance with the NASDAQ Rules. The Audit Committee is currently comprised of three directors of the Company: James Rudyk (Chair), Jason Adler and Bronwen Evans, all of whom are considered to be “independent” within the meaning of such term under applicable NASDAQ Rules.

The Board has determined that James Rudyk, the Chair of the Audit Committee, qualifies as an “audit committee financial expert” for purposes of the SEC’s rules. The SEC has indicated that the designation of Mr. Rudyk as an audit committee financial expert does not make him an “expert” for any purpose, impose any duties,

Table of Contents

obligations or liabilities on him that are greater than those imposed on other members of the Audit Committee and the Board who do not carry this designation or affect the duties, obligations or liabilities of any other member of the Audit Committee or the Board.

The members of the Audit Committee are appointed by the Board, and each member of the Audit Committee serves at the pleasure of the Board until the member resigns, is removed or ceases to be a member of the Board.

The responsibilities and operation of the Audit Committee are set out in the Audit Committee Charter, a copy of which is available on the Company’s website at https://ir.thecronosgroup.com/governance/documents-charters.

Compensation Committee.

The Compensation Committee is currently comprised of three directors of the Company: Jody Begley (Chair), Jason Adler, and James Rudyk. Messrs. Rudyk and Adler are considered to be “independent” within the meaning of such term under applicable NASDAQ Rules and NI 58-101. Mr. Begley is not considered to be “independent” within the meaning of such term under NI 58-101 but is considered to be “independent” within the meaning of such term under applicable NASDAQ Rules. In order to ensure that the compensation process remains objective:

•the Board is required to review and evaluate all recommendations and decisions put forward by the Compensation Committee regarding the design of the Company’s compensation plans, including any equity-based compensation and executive compensation; and

•both the Board and the Compensation Committee hold meetings at which non-independent directors of the Company are not present.

The Compensation Committee is responsible for approval of, or making recommendations to the Board with respect to, the compensation of the executive officers of the Company and making recommendations to the Board with respect to the compensation of the directors of the Company.

Compensation Committee Interlocks and Insider Participation

No member of our Compensation Committee is or has been one of our officers or employees, and none have any relationships with us of the type that is required to be disclosed under Item 404 of Regulation S-K. None of our executive officers serves or has served as a member of the Board, Compensation Committee or other Board committee performing equivalent functions of any entity that has one or more executive officers serving as one of our directors or on our Compensation Committee.

Nomination of Directors

The Board has not established a formal nominating committee. Rather, a majority of the Board’s independent directors recommends director nominees for the Board’s selection in a vote in which only independent directors participate, with the independence requirements applicable to such directors confirmed at such time. The Board adopted a resolution to adopt this director nominee selection process upon determining that compliance with the NASDAQ Rules, which require that director nominees (other than the Altria Nominees) are recommended for the Board’s selection by independent directors within the meaning of such term under applicable NASDAQ Rules

Table of Contents

constituting a majority of the Board’s independent directors in a vote in which only independent directors participate, with the independence requirements applicable to such directors to be confirmed at such time, adequately encourages an objective nomination process.

Individuals are selected with the desired background and qualifications, taking into account the needs of the Board at the time. In making recommendations, the Board’s independent directors consider:

•the competencies and skills that the Board considers to be necessary for the Board, as a whole, to possess;

•the competencies and skills that the Board considers each existing director to possess;

•the competencies and skills each new nominee will bring to the boardroom;

•whether or not each new nominee can devote sufficient time and resources to his or her duties as a Board member; and

•diversity criteria, pursuant to the Diversity Policy (as defined herein) as further described below under “– Diversity”.

See “Proposal No. 1–Election of Directors” above for a discussion of Altria’s right to designate director nominees under the Investor Rights Agreement. The Board’s independent directors will consider director candidates recommended by Shareholders and the Company’s articles contain advance notice provisions setting out advance notice requirements for the nomination of directors of the Company by a Shareholder, as further described below.

Shareholder Recommendations for Director Nominations

The Company’s articles contain advance notice provisions setting out advance notice requirements for the nomination of directors of the Company by a Shareholder (who must also meet certain qualifications outlined in the articles) (the “Nominating Shareholder”) at any annual meeting of Shareholders, or for any special meeting of Shareholders if one of the purposes for which the special meeting was called was the election of directors (the “Advance Notice Requirements”). The following description is a summary only and is qualified in its entirety by the full text of the applicable provisions of the Company’s articles which are available on the Company’s website at https://ir.thecronosgroup.com/governance/documents-charters.

In addition to any other applicable requirements, for a nomination to be made by a Nominating Shareholder, the Nominating Shareholder must give timely notice of such nomination in proper written form to the Corporate Secretary of the Company at the principal executive offices of the Company. To be timely, a Nominating Shareholder’s notice to the Corporate Secretary must be made: (i) in the case of an annual meeting of Shareholders, not less than 30 nor more than 65 days prior to the date of the annual meeting of Shareholders; provided, however, that in the event that the annual meeting of Shareholders is to be held on a date that is less than 50 days after the date (the “Notice Date”) on which the first public announcement of the date of the annual meeting was made, notice by the Nominating Shareholder may be made not later than the close of business on the 10th day following the Notice Date; and (ii) in the case of a special meeting (which is not also an annual meeting) of Shareholders called for the purpose of electing directors (whether or not called for other purposes as well), not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting of Shareholders was made. The Company’s articles also prescribe the proper written form for a Nominating Shareholder’s notice.

Table of Contents

The chairperson of the meeting has the power and duty to determine whether a nomination was made in accordance with the notice procedures set forth in the articles and, if any proposed nomination is not in compliance with such provisions, the discretion to declare that such defective nomination will be disregarded.

Notwithstanding the foregoing, the Board may, in its sole discretion, waive any requirement in the Advance Notice Requirements.

Diversity

The Board has adopted a written policy concerning diversity on the Board and with respect to executive officers (the “Diversity Policy”). The Board believes that diversity is important to ensure that Board members and executive officers possess the necessary range of perspectives, experience and expertise required to achieve the Company’s objectives and deliver for its stakeholders. The Company believes that diversity mitigates the risk of group think, ensures that the Company has the opportunity to benefit from all available talent and enhances, among other things, its organizational strength, problem-solving ability and opportunity for innovation. The Diversity Policy states, among other things, that the Board should consider diversity criteria including, but not limited to, any characteristic that can be used to differentiate groups and people from one another such as gender, geographical representation, education, religion, ethnicity, race, nationality, culture, language, aboriginal or indigenous status and other ethnic distinctions, sexual orientation and disability, when determining the composition of the Board. It is an objective of the Company that diversity be considered when hiring executive officers and in connection with succession planning. There are currently two women on the Board (representing 29% of the directors of the Company) and four women in executive officer positions (representing 50% of the executive officers of the Company).

The Company has not adopted numerical targets regarding the representation of women or persons with other self-identified diversity characteristics, such as race, ethnicity, religion, nationality, disability, sexual orientation or cultural background, on the Board or in executive officer positions. However, the Company monitors the level of representation of women and persons with other self-identified diversity characteristics on the Board and in senior management positions.

Code of Business Conduct and Ethics

The Board has adopted a Code of Business Conduct and Ethics (the “Code”), a written code of business conduct and ethics for the Company’s directors, officers and employees. The Code sets out the Board’s expectations for the conduct of such persons in their dealings on behalf of the Company.

The Board has delegated responsibility for monitoring compliance with the Code and for investigating and enforcing matters related to the Code to the Company’s executive officers, who will report breaches of the Code to the Company’s Legal Department or for matters regarding accounting, internal accounting controls and other auditing matters to the Audit Committee or for matters involving the Chief Executive Officer or any other senior executive or financial officer of the Company to any member of the Board. The Company’s Legal Department or Audit Committee, as applicable, will promptly address all allegations of non-compliance with the Code and recommend corrective actions to local or head office management, as appropriate. The Company’s Executive Vice President, Legal and Regulatory Affairs is responsible for allegations relating to the most serious violations of the Code. The Company’s Executive Vice President, Legal and Regulatory Affairs reports regularly to the Board and the Audit Committee regarding serious suspected and confirmed Code violations. Any waivers of the Code can only be granted by the Company’s Executive Vice President, Legal and Regulatory Affairs or the Chief Executive Officer

Table of Contents

and any such waivers are reported to the Audit Committee. Waivers of the Code for executive officers may only be granted by the Board or the Audit Committee and will be disclosed to Shareholders as required under applicable law.

Directors and executive officers are required by the Code to promptly disclose any potential conflict of interest that may arise. If a director or executive officer has a material interest in an agreement or transaction, the Code requires them to declare the interest in writing or request to have such interest entered in the minutes of meetings of directors and, where required by applicable law, abstain from voting with respect to the agreement or transaction. The Code requires the prior approval of the other members of the Board prior to any director accepting an appointment as a director or officer of a competitor or competing business, or becoming otherwise professionally engaged with a competitor or competing business. If we make any amendments to the Code or grant any waiver, including any implicit waiver, we will disclose the nature of such amendment or waiver on our website within four days of such amendment or waiver.

A copy of the Code is available on the Company’s website at https://ir.thecronosgroup.com/governance/documents-charters.

Conflicts of Interest Policy

The Board has adopted a Conflicts of Interest Policy (the “Conflicts Policy”) that applies to the Company’s directors, officers and employees. The Conflicts Policy also applies to employees of affiliates and/or joint ventures controlled by or under common control of the Company (other than the Altria Group). The Conflicts Policy establishes the ethical standards and accountability expected of such persons in situations where there may be a conflict of interest. The Conflicts Policy is in addition to any requirements imposed by the Code, the Related Party Transactions Policy (described under “Related Party Transactions” below) and the requirements of the Investor Rights Agreement, which, among other things, requires the prior approval of an Independent Committee (as such term is defined in the Investor Rights Agreement) for any transaction between any member of Altria Group and the Company or any of its subsidiaries, subject to certain exceptions.

The Conflicts Policy sets out the Company’s commitment to avoiding actual or perceived conflicts of interest and the obligation of the Company’s directors, officers and employees to disclose such situations. In addition to the requirements of the Conflicts Policy, directors are required to complete an annual questionnaire (the “Director Questionnaire”) with respect to any material interests or relationships that are, or could be perceived to be, an actual or potential conflict of interest with their obligation to act in the best interests of the Company, including details of the extent and nature of the actual, potential or perceived conflict of interest. Directors are also required to disclose any new actual, potential or perceived conflicts of interest if they become aware of them following the completion of the Director Questionnaire.

Insider Trading Policy; Anti-Hedging; and Anti-Pledging

In addition to the Code, the Company has an insider trading policy (the “Insider Trading Policy”) relating to the trading in securities of the Company by directors, officers and employees of the Company and its subsidiaries, and certain persons related to any such persons.

Among other things, the following transactions by directors and employees of the Company are prohibited by the Insider Trading Policy:

•speculating in securities of the Company;

Table of Contents

•pledging securities of the Company as collateral for a loan;

•buying the Company’s securities on margin;

•short sales of the Company’s securities;

•transactions in puts or calls relating to the Company’s securities; and

•purchasing financial instruments, including prepaid variable forward contracts, equity swaps, collars, or units of exchange funds, that are designed to hedge or offset a decrease in market value of securities of the Company held, directly or indirectly by the director or employees, including equity securities granted as compensation.

Related Party Transactions and Related Party Transaction Policy

We or one of our subsidiaries may occasionally enter into transactions with certain “related persons.” Related persons include our executive officers, directors, nominees for director, 5% or more beneficial owners of our Shares, immediate family members of these persons and entities in which one of these persons has a direct or indirect material interest. We generally refer to transactions with these related persons as “related party transactions.”

Our Board has adopted a written policy governing the review and approval of transactions between us and related parties (the “Related Party Transactions Policy”). Our Related Party Transactions Policy is designed to assist with the proper identification, review and disclosure of related party transactions. Under the Related Party Transactions Policy, the following types of transactions must be approved or ratified by a committee of the Board comprised of at least three independent directors (determined in accordance with NASDAQ rules and subject, in certain circumstances, to additional limitations) (the “Independent Committee”):

•any transaction that exceeds $120,000 in which a related party has or will have a direct or indirect material interest;

•any transaction that would require shareholder approval, a formal valuation or disclosure under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions;

•any transaction pursuant to which a director or officer has a disclosable interest pursuant to Section 147 of the BCBCA or under any similar provision of any other corporate statute applicable to the Company;

•any material amendment, modification, extension or termination of the Investor Rights Agreement;

•any transaction that requires TSX approval under Part V of the TSX Company Manual; and

•any other transaction for which disclosure would be required pursuant to Item 404 of Regulation S-K.

In determining whether or not to approve a related party transaction, the Independent Committee will take into account, among other relevant factors:

•the terms of the transaction including the related party’s interest and the purpose and timing of the transaction;

Table of Contents

•whether the Company has demonstrable business reasons to enter into the transaction;

•whether the transaction would impair the independence of a director; and

•any potential reputational or other risk issues.

Certain transactions, including employment relationships, ordinary course sales of products, entering into any of the Commercial Arrangements (as defined below under “Altria Strategic Investment – Commercial Arrangements”) and certain other ordinary course non-preferential transactions, are considered preapproved transactions, and thus do not require specific approval under the Related Party Transactions Policy. The Related Party Transactions Policy is in addition to any requirements imposed by the Code, the Conflicts Policy and the requirements of the Investor Rights Agreement, which, among other things, requires the prior approval of an “Independent Committee” (as such term is defined in the Investor Rights Agreement) for any transaction between any member of Altria Group and the Company or any of its subsidiaries, subject to certain exceptions.

Relationship with Altria

See “Altria Strategic Investment” below for a discussion of the Company’s relationship with Altria.

Share Ownership Guidelines

The Company’s share ownership guidelines establish levels of ownership of Shares at five times the chief executive officer’s salary and two times the salary for other executive officers, which includes each of the named executive officers. Shares held for purposes of the guidelines may include Shares owned outright by the executive officer or his or her spouse and earned but unvested share-based awards, and an executive officer has five years from his or her appointment as an executive officer to achieve the level of Share ownership applicable to such executive officer.

Board and Committee Assessment

The Board is responsible for assessing annually the effectiveness of the Board as a whole, the Board committees and the contribution of individual directors. Assessments of the Board and its committees will consider the Board mandate and the relevant committee charter, as the case may be. Assessments of individual directors will consider the position description and skills and competencies applicable to that individual. The full Board will discuss the collective assessment to determine what, if any, actions should be taken to improve effectiveness.

Director Term Limits

The Board has not adopted a term limit for directors. In light of the tenures of the nominees for election to the Board at the Annual Meeting and the nature of the industry in which the Company operates, the Board does not believe that adopting a term limit for directors is necessary or appropriate at this time.

Shareholder Communications with the Board of Directors

Shareholders and other interested parties who wish to communicate with our Board may do so by writing to the Corporate Secretary of the Company by email at corporate.secretary@thecronosgroup.com. The non-management directors have established procedures for the handling of communications from Shareholders and other interested parties and have directed our Corporate Secretary to act as their agent in processing any communications

Table of Contents

received. Communications that relate to matters that are within the scope of the responsibilities of our Board and its committees are to be forwarded to the Independent Lead Director.

Communications that relate to matters that are within the responsibility of one of the committees are also to be forwarded to the Chair of the appropriate committee. Communications that relate to ordinary business matters that are not within the scope of our Board’s responsibilities, such as customer complaints, are to be sent to the appropriate Company personnel.

Table of Contents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS,

DIRECTORS AND MANAGEMENT

The following table sets forth information, based on data provided to us or filed with the SEC, with respect to beneficial ownership of our Shares as of March 22, 2021 for (i) all persons known by us to own beneficially more than 5% of our outstanding Shares, (ii) each of our NEOs named in the Summary Compensation Table included under “Executive Compensation” herein, (iii) each of our directors, (iv) our director nominee and (v) all of our directors, director nominee, NEOs and other current executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to such securities. Except as otherwise indicated, all persons listed below have sole voting power and dispositive power with respect to the Shares beneficially owned by them, subject to applicable community property laws. Except as otherwise indicated, the address for each Shareholder listed below is c/o Cronos Group Inc., 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1.


Name and Address of Beneficial Owner	Number of Shares Beneficially Owned (1)	Percent of Class
Greater than 5% Shareholders
Altria Group, Inc.(2)	236,629,833	51.96%

Directors, Director Nominee and NEOs
Michael Gorenstein(3)	10,046,699	2.21%
Jason Adler(4)	13,788,734	3.03%
Jody Begley	—	—
Bronwen Evans	—	—
Murray Garnick	—	—
Heather Newman	—	*
Kendrick Ashton Jr.	—	*
James Rudyk	207,221	*
Kurt Schmidt	—	*
Jerry Barbato	15,044	*
Xiuming Shum	443,627	*
Todd Abraham	38,008	*
Anna Shlimak	188,287	*
All directors, director nominee, NEOs and other current executive officers of the Company as a group (16 persons)	25,136,124	5.52%

* Less than 1%.

(1) Amount of Shares shown includes (i) Shares subject to options which may be exercised within 60 days as follows: Gorenstein – 606,187 Shares, Adler – 1,879,317 Shares, Rudyk – 170,984 Shares, Barbato – 15,044 Shares, Shum – 443,627 Shares, Abraham – 10,031 Shares, Shlimak – 150,000 Shares, and all directors, director nominee, NEOs and other current executive officers of Cronos as a group – 3,674,888 Shares; and (ii) Restricted Share Units that vest within 60 days as follows: Abraham – 12,977 Shares, Shlimak – 28,287 Shares, and all directors, director nominee, NEOs and other current executive officers of Cronos as a group – 50,070 Shares.

Table of Contents

(2) The amount reported represents 156,573,537 Shares directly held by Maple Acquireco (Canada) ULC and beneficially owned by Altria, with respect to which Altria, Altria Summit LLC, Maple Holdco (Bermuda) Ltd, and Maple Acquireco (Canada) ULC have shared dispositive power and voting power and 80,056,296 Shares receivable upon the exercise of the Altria Warrant directly held by Altria Summit LLC, which is beneficially owned by Altria.

(3) Excludes 503,478 Shares beneficially owned by Gotham Green 1, L.P. and 2,014,228 Shares beneficially owned by Gotham Green GP 1, LLC, as Michael Gorenstein is a non-managing member of Gotham Green Partners and therefore does not have beneficial ownership of such Shares.

(4) The amount reported represents 503,478 Shares beneficially owned by Gotham Green Fund 1, L.P., 2,014,228 Shares beneficially owned by Gotham Green Fund 1(Q), L.P. and 11,271,028 Shares beneficially owned by Jason Adler (which includes Shares subject to options which may be exercised within 60 days as set forth in Note 1 above and Shares held by the Rachel Adler 2020 Gift Trust, of which he is the trustee). Gotham Green GP 1, LLC is the general partner of Gotham Green Fund 1, L.P. and Gotham Green Fund 1(Q), L.P., and Mr. Adler is the Managing Member of Gotham Green GP 1, LLC. Mr. Adler may be deemed to have beneficial ownership and shared dispositive and voting power with respect to the Shares beneficially owned by Gotham Green Fund 1, L.P. and Gotham Green Fund 1(Q), L.P. Mr. Adler disclaims that he is the beneficial owner of such Shares.

Equity Compensation Plan Information

The following table sets forth information regarding our equity compensation plans as of December 31, 2020 and does not reflect grants made in 2021 for 2020 performance:


Plan Category	(a) Number of Shares to be issued upon exercise of outstanding options, warrants and rights	(b) Weighted average exercise price of outstanding options, warrants and rights	(c) Number of shares remaining available for future issuance under equity compensation plans (excluding securities reflected in Column (a))
Equity compensation plans approved by Shareholders(1)	10,592,039	$3.75	32,288,748
Equity compensation plans not approved by Shareholders(2)	—	—	—
Total	10,592,039	—	32,288,748

(1) Consists of the 2020 Omnibus Equity Incentive Plan (the “2020 Omnibus Plan”), the 2018 Stock Option Plan (the “2018 Option Plan”) and the Amended and Restated Stock Option Plan (the “2015 Option Plan”). See note 16 of the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 regarding share-based payments.

(2) Excludes the Deferred Share Unit Plan for Non-Executive Directors, pursuant to which non-employee directors receive cash-settled Deferred Share Units.

Altria Strategic Investment

As of March 22, 2021, the Altria Group beneficially held 156,573,537 Shares, held the right to acquire up to an additional 80,056,296 Shares on or prior to March 8, 2023 under a warrant held by the Altria Group, which has not exercised, and the right to acquire additional Shares under its pre-emptive and top-up rights as discussed below.

Table of Contents

Investor Rights Agreement

On March 8, 2019, in connection with the closing of Altria Group’s investment in us (the “Altria Investment”), we entered into the Investor Rights Agreement with Altria pursuant to which Altria received certain governance rights which are summarized below.

Board Representation

See “Proposal No. 1–Election of Directors” above for a discussion of Altria’s right to designate director nominees under the Investor Rights Agreement.

The Investor Rights Agreement also provides that, subject to certain exceptions, for so long as Altria is entitled to designate one or more Altria Nominees, we agree to appoint to each committee established by the Board such number of Altria Nominees that represents Altria’s proportionate share of the number of directors comprising the Board (rounded up to the next whole number) based on the percentage of our issued and outstanding Shares beneficially owned by the Altria Group at the relevant time.

Approval Rights

The Investor Rights Agreement also grants Altria, until the Altria Group beneficially owns less than 10% of our issued and outstanding Shares, approval rights over certain transactions that may be taken by us. We have agreed that we will not (and will use our commercially reasonable efforts to cause our affiliates not to), without the prior written consent of Altria:

•consolidate or merge into or with another person or enter into any similar business combination;

•acquire any shares or similar equity interests, instruments convertible into or exchangeable for shares or similar equity interests, assets, business or operations with an aggregate value of more than C$100,000,000, in a single transaction or a series of related transactions;

•sell, transfer, caused to be transferred, exclusively license, lease, pledge or otherwise dispose of any of our or any of our significant subsidiaries’ assets, business or operations in the aggregate with a value of more than C$60,000,000;

•except as required by applicable law, make any changes to our policy with respect to the declaration and payment of any dividends on our Shares;

•subject to certain exceptions, enter into any contract or other agreement, arrangement, or understanding with respect to, or consummate, any transaction or series of related transactions between us or any of our subsidiaries, on the one hand, and any related parties, on the other hand, involving consideration or any other transfer of value required to be disclosed pursuant to Item 404 of Regulation S-K; or

•engage in the production, cultivation, advertisement, marketing, promotion, sale or distribution of cannabis or any Related Products and Services (as defined below) in any jurisdiction, including the U.S., where such activity is prohibited by applicable law as of the date of the Investor Rights Agreement (subject to certain limitations).

Table of Contents

Pre-Emptive Rights and Top-Up Rights

Pursuant to the terms of the Investor Rights Agreement, Altria, provided the Altria Group continues to beneficially own at least 20% of our issued and outstanding Shares, will have a right to purchase, directly or indirectly by another member of the Altria Group, upon the occurrence of certain issuances of Shares by us (including issuances of Shares to Ginkgo Bioworks Inc. (“Ginkgo”) under the collaboration and license agreement (the “Ginkgo Collaboration Agreement”) dated September 1, 2018 between Gingko and the Company (each, a “Ginkgo Issuance”)) (each, a “Triggering Event”) and subject to obtaining the necessary approvals, up to such number of Shares issuable in connection with the Triggering Event which will, when added to the Shares beneficially owned by the Altria Group immediately prior to the Triggering Event, result in the Altria Group beneficially owning the same percentage of our issued and outstanding Shares that the Altria Group beneficially owned immediately prior to the Triggering Event (in each case, calculated on a non-diluted basis). The price per Share to be paid by Altria pursuant to the exercise of these pre-emptive rights will be, subject to certain limited exceptions, the same price per Share at which the Shares are sold in the relevant Triggering Event; provided that if the consideration paid in connection with any such issuance is non-cash, the price per Share that would have been received had such Shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per Share to be paid by Altria pursuant to the exercise of its pre-emptive rights in connection with a Ginkgo Issuance will be C$16.25 per Share.

In addition to (and without duplication of) the aforementioned pre-emptive rights, the Investor Rights Agreement provides Altria with top-up rights, exercisable on a quarterly basis, whereby, subject to obtaining the necessary approvals and for so long as the Altria Group beneficially owns at least 20% of our issued and outstanding Shares, Altria (or another member of the Altria Group to which it has assigned such right) shall have the right to subscribe for such number of Shares in connection with any Top-Up Securities (as defined herein) that we may, from time to time, issue after the date of the Investor Rights Agreement, as will, when added to the Shares beneficially owned by the Altria Group prior to such issuance, result in the Altria Group beneficially owning the same percentage of our issued and outstanding Shares that the Altria Group beneficially owned immediately prior to such issuance. “Top-Up Securities” means any of our Shares issued:

•on the exercise, conversion or exchange of our convertible securities issued prior to the date of the Investor Rights Agreement or on the exercise, conversion or exchange of our convertible securities issued after the date of the Investor Rights Agreement in compliance with the terms of the Investor Rights Agreement, in each case, excluding any of our convertible securities owned by any member of the Altria Group;

•pursuant to any share incentive plan of the Company;

•on the exercise of any right granted by us pro rata to all Shareholders to purchase additional Shares and/or other securities of the Company (other than a right issued in a rights offering in which Altria had the right to participate);

•in connection with bona fide bank debt, equipment financing or non-equity interim financing transactions with our lenders, in each case, with an equity component; or

•in connection with bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures undertaken and completed by us,

Table of Contents

in each case, other than (A) Shares issued pursuant to Altria’s pre-emptive right and (B) Shares issued pursuant to the Ginkgo Collaboration Agreement.

The price per Share to be paid by Altria pursuant to the exercise of its top-up rights will be, subject to certain limited exceptions, the volume-weighted average price of our Shares on the TSX for the ten full days preceding such exercise by Altria (or another member of the Altria Group to which it has assigned such right); provided that the price per Share to be paid by Altria pursuant to the exercise of its top-up rights in connection with the issuance of Shares pursuant to the exercise of options or warrants that were outstanding on the date of closing of the Altria Investment will be C$16.25 per Share without any setoff, counterclaim, deduction or withholding.

Standstill Covenant

For a period commencing on the date of the Investor Rights Agreement and ending on the earlier of (i) the date on which the Altria Warrant has been exercised in full by Altria, and (ii) the expiry or termination of the Altria Warrant, the Investor Rights Agreement provides that, without the prior approval of an independent committee of the Board, no member of the Altria Group shall, directly or indirectly, acquire our Shares (other than upon settlement of any Shares issued, sold and delivered pursuant to the proper exercise of rights contemplated by the Altria Warrant Certificate or the exercise of pre-emptive rights or top-up rights): (A) on the TSX, the NASDAQ or any other stock exchange, marketplace or trading market on which our Shares are then listed; (B) through private agreement transactions with existing holders of Shares; or (C) in any other manner or take any action which would require any public announcement with respect to any of the foregoing; provided that nothing shall prohibit any member of the Altria Group from making a take-over bid or commencing a tender offer, in each case, to acquire not less than all of our issued and outstanding Shares (other than any such Shares beneficially owned by any member of the Altria Group and its affiliates) in accordance with applicable law.

Registration Rights

The Investor Rights Agreement provides the Altria Group with the right, subject to certain limitations and to the extent permitted by applicable law, to require us to use reasonable commercial efforts to file a prospectus under applicable securities laws and/or a registration statement, qualifying our Shares held by the Altria Group for distribution in Canada and/or the U.S. In addition, the Investor Rights Agreement provides the Altria Group with the right to require us to include our Shares held by the Altria Group in any proposed distribution of Shares in Canada and/or the U.S. by us for our own account.

Commercial Arrangements

In connection with the Altria Investment, we and Altria and/or one or more other members of the Altria Group have entered into certain commercial support arrangements (the “Commercial Arrangements”), pursuant to which Altria provides us with strategic advisory and consulting services on matters which may include research and development, marketing, advertising and brand management, government relations and regulatory affairs, finance, tax planning, logistics and other corporate administrative matters. The services under the Commercial Arrangements are provided on customary terms and for a services fee payable by us that is equal to Altria’s reasonably allocated costs plus 5%.

Table of Contents

COMPENSATION DISCUSSION AND ANALYSIS

Throughout this Compensation Discussion & Analysis (“CD&A”), we describe our executive compensation philosophy, program and decisions made in 2020 for our NEOs. For a complete understanding of the executive compensation program, this disclosure should be read in conjunction with the Summary Compensation Table and other executive compensation-related disclosure included in this Proxy Statement.

For 2020, the Company’s NEOs included our President and Chief Executive Officer (“CEO”), our Chief Financial Officer (“CFO”), our Executive Chairman and former President and CEO, and our next three most highly compensated executive officers. The following individuals are the NEOs for the year ended December 31, 2020:


Name			Position
Kurt Schmidt			President and CEO
Michael Gorenstein			Executive Chairman, formerly President and CEO (until September 9, 2020)
Jerry Barbato			CFO
Xiuming Shum			Executive Vice President, Legal and Regulatory Affairs
Todd Abraham			Chief Innovation Officer
Anna Shlimak			Senior Vice President, Corporate Affairs

Executive Summary

Overview of Executive Compensation Program

The cannabis industry is highly competitive and rapidly evolving due to stringent regulatory frameworks and changes in economic, market and political conditions. As a result, we believe it will take discipline, deliberate strategic growth and flexibility to succeed and create long-term value for our Shareholders.

Our executive compensation program is designed to attract, motivate and retain talented and high-performing executives to lead the Company’s business strategy and objectives, while also effectively aligning the compensation of our executives with the creation of long-term value for our Shareholders. The Compensation Committee is responsible for designing an executive compensation program that ensures an appropriate level of risk-taking by the Company’s executives. The Compensation Committee designs our pay executive compensation program to support our compensation philosophy and goals to:

•position the Company competitively among companies against which we compete for talent;

•align the interests of our executives with those of our Shareholders by tying significant portions of pay to performance, paying a substantial portion of compensation in equity and subjecting equity compensation to multi-year vesting periods and, beginning in March 2021, requiring share ownership; and

•tie executive compensation to performance and achievement of the Company’s short- and long-term business goals and ensuring that compensation varies based on business performance and achievement of individual objectives.

Table of Contents

Our 2020 annual compensation package for our NEOs in 2020 consists of base salary, short-term incentives based on Company and individual performance, and long-term incentives in the form of restricted share units (“Restricted Share Units”), which, with the exception of the Restricted Share Units granted to Mr. Schmidt, vest ratably on an annual basis over three years. In connection with Mr. Schmidt’s appointment as President and CEO of the Company, effective September 9, 2020, Mr. Schmidt received a one-time grant of 2,000,000 options (“Stock Options”) that vest ratably on an annual basis over a five-year period, and 450,000 Restricted Share Units that vest on the third anniversary of the grant date.

In setting target compensation packages for our NEOs, the Compensation Committee reviewed the total compensation opportunity for each executive compared to compensation offered to executives in comparable positions within the Cronos Peer Group (as defined below), along with other comparative factors. The Company’s short-term incentive compensation program (the “STIC Program”) is designed to reward the achievement of the Company’s short-term goals, primarily related to the Company’s revenues and growth, and each executive’s achievement of individual performance goals. The long-term incentive equity component of compensation is designed to retain our executives and incentivize them to achieve long-term financial and strategic objectives.

Table of Contents

The following table summarizes what we do and what we don’t do in connection with executive compensation. The notable features of the Company’s 2020 executive compensation program, which were designed to align with “best practice” compensation governance, are provided below.


What We Do			What We Don’t Do
Make pay decisions aligned with our compensation philosophy			Guarantee short-term cash incentive amounts (other than with respect to Messrs. Schmidt and Gorenstein for fiscal 2020 due to special circumstances as discussed in more detail below)
Regularly review the competitiveness and appropriateness of pay levels for senior executives versus industry peers			Re-price or back-date equity awards
Deliver the majority of executive compensation in “at risk”, variable incentives			Issue equity awards with an exercise price below the closing price of our Shares on the trading date immediately before the grant date
Pay for performance, with the actual value received from incentive awards directly aligned with key Company operating and financial results and individual goals			Gross-up the value of perquisites for taxes paid, other than in limited circumstances for business-related relocations and international business travel-related benefits that are under our control, at our direction and deemed to benefit our business operations
Grant equity-based long-term incentives which vest over multi-year periods			Provide any excise tax gross-ups or other payment or reimbursement of excise taxes on severance in connection with a change of control
Reinforce an ownership culture, with long-term incentives settled in shares and share ownership guidelines adopted in March 2021			Offer off-market executive benefits and perquisites
Prohibit pledging, hedging and other securities transactions intended to lock in the gain on share price growth			Make “single-trigger” payments upon a change of control or maintain any plans that require single trigger change of control acceleration of equity awards to our NEOs upon a change of control (other than in limited cases due to special circumstances(1))
Retain external and independent advisors to support the Compensation Committee on executive compensation decisions throughout the year			Maintain pay policies and practices that pose a material adverse risk to the Company
Adoption of clawback policy in February 2020 that applies to any current or former Company executive officer

(1)Described in more detail under “Potential Payments Upon Termination or Change of Control — Long-Term Incentive Awards under the 2020 Omnibus Plan — Schmidt Agreement”.

Table of Contents

Say-on-Pay

At our 2020 annual and special meeting of Shareholders, our Shareholders demonstrated their strong support of our executive compensation program, with approximately 98% of votes cast in favor of the advisory “say on pay” vote proposal. We believe this vote reflected strong support for our executive compensation program design, which focuses on (i) incentives and metrics that align executive officer interests with Shareholder interests, and (ii) recruitment, engagement, motivation and retention of our executive officers. Although no changes were made to our executive compensation program based on the 2020 say-on-pay vote, we continue to evaluate our executive compensation program to find ways we can further align management incentives with Shareholder interests, which we view to be essential to our long-term success.

Also at our 2020 annual and special meeting of Shareholders, we asked our Shareholders to recommend the frequency of future shareholder advisory votes on the compensation of our NEOs. Shareholders recommended an annual non-binding vote, and we are following that recommendation.

Progress Towards Strategic Objectives: 2020 Highlights

Our compensation decisions for 2020 were driven by our overarching goal of creating value for Shareholders. We seek to create value for Shareholders by focusing on four core strategic priorities:

•growing a portfolio of iconic brands that responsibly elevate the consumer experience;

•developing a diversified global sales and distribution network;

•establishing an efficient global supply chain; and

•creating and monetizing disruptive intellectual property.

In 2020, we sought to build on our 2019 strategic accomplishments, including, among other things, the closing of the Altria Investment, the establishment of Cronos Research Labs, our state-of-the-art Israel-based global research and development (“R&D”) center for innovation, our acquisition of a state-of-the-art GMP-compliant fermentation and manufacturing facility in Winnipeg, Manitoba, which we operate as “Cronos Fermentation,” and the establishment of our U.S. business through the acquisition of four subsidiaries from Redwood Holding Group, LLC (“Redwood”).

In the second quarter of 2020, Cronos Fermentation successfully fermented CBGA, one of the Company’s target cannabinoids under our strategic partnership with Ginkgo Bioworks, Inc. (the “Ginkgo Strategic Partnership”), at research scale. Cronos Fermentation has and will continue to optimize downstream processing and scale up procedures in advance of receiving the final strains and commercial processing license, both of which are required for commercialization.

During 2020, Cronos Israel received all certifications and licenses required for the cultivation, production and marketing of dried flower, pre-rolls and oils in Israel. In June 2020, Cronos Israel commenced sales of PEACE NATURALS™ branded dried flower to the Israeli medical market. Following the launch of dried flower, in October 2020, Cronos Israel commenced sales of PEACE NATURALS™ branded oils to the Israeli medical market. Cronos Israel continues to build distribution and brand awareness through a growing network of pharmacies.

During the fourth quarter of 2020, we launched a new hemp-derived CBD skincare and personal care brand called Happy Dance™, in partnership with Kristen Bell. Happy Dance™ products are made with CBD from premium full-spectrum hemp extract and provide consumers with high quality skincare at an accessible price point.

Table of Contents

The Company looks forward to future introductions of innovative products to the hemp-derived CBD market through the partnership with Ms. Bell.

In 2020, Cronos Growing Company (“Cronos GrowCo”), the Company’s strategic joint venture, fully completed construction of its production facility, including all fixtures within the greenhouse and all post-harvest areas. In November 2020, Cronos Growing Company obtained a cultivation license for the operations contemplated by the first phase of the project. The Company expects the facility to become operational in phases beginning in the first half of 2021.

The Company also expanded its leadership structure during 2020 to drive its next phase of growth. Mr. Schmidt was appointed as President and CEO of the Company, which coincided with Mr. Gorenstein’s appointment to Executive Chairman. Mr. Schmidt brings deep experience in consumer products with decades of leadership experience in the U.S. and overseas. Mr. Schmidt previously served as Director and Chief Executive Officer of Blue Buffalo Company, Ltd. from 2012 through 2016. Prior to joining Blue Buffalo, Mr. Schmidt was Deputy Executive Vice President at Nestlé S.A., where he was responsible for Nestlé Nutrition, including several science-oriented and heavily regulated businesses. He also served as a member of Nestlé’s Executive Committee. Mr. Schmidt joined Nestlé in 2007 as part of Nestlé’s acquisition of Gerber Products Company, where he was the President and Chief Executive Officer from 2004 to 2007. Prior to Gerber, Mr. Schmidt held a variety of leadership roles at Kraft Foods, Inc.

The Company further bolstered its senior leadership team in 2020. In July 2020, Ms. Frein, who joined the Company in January 2020 from Altria, was named General Manager, USA. In August 2020, Ms. Buggy joined the Company as Senior Vice President, Global Head of People. Prior to joining the Company, Ms. Buggy was the Senior Vice President of Global Human Resources for Nielsen where she led human resources strategy for Nielsen Media.

Response to COVID-19

Throughout 2020, the Company devoted significant attention to responding to the COVID-19 pandemic to protect the health and well-being of our employees and to mitigate the impact of COVID-19 on our business, while maintaining focus on our short- and long-term business goals to drive future growth and continue delivering value to our shareholders.

Beginning in March 2020, we began implementing changes in our business to protect and support our employees as well as to assist with efforts to contain and combat the spread of COVID-19. These changes included: (i) reducing the number of personnel working on-site at our production facilities to only the roles that are necessary to be performed on-site, (ii) implementing work-from-home policies for other employees whose work can be performed off-site; (iii) implementing additional health and safety measures such as, among others, enhanced hygiene and sanitation procedures, modified work schedules and social distancing protocols at its production facilities; and (iv) as recommended by certain jurisdictions in which the Company has operations, implementing a documented COVID-19 prevention plan in such locations. The Company has and will continue to act in accordance with guidance from local, federal, and international health and governmental authorities, such as any government-mandated requirements for people to wear facemasks in all indoor communal spaces or at businesses, and is prepared to make additional operational adjustments, as necessary.

Table of Contents

Governance of Executive Compensation

Framework for Compensation Decisions

Role of Compensation Committee

The Compensation Committee is currently comprised of three directors of the Company: Jody Begley (Chair), Jason Adler and James Rudyk. See “Board of Directors, Committees and Governance—Committees of Our Board of Directors—Compensation Committee.”

The Compensation Committee is responsible for reviewing and determining the compensation of the executive officers of the Company and for reviewing and making recommendations to the Board concerning the compensation of directors. Based on the recommendations of the Compensation Committee, the Board is responsible for determining the compensation paid to the directors of the Company.

The Compensation Committee considers the performance of the Company and the individual executive officers in executing their objectives to determine total compensation for the Company’s executive officers. The Compensation Committee also considers compensation data gathered from the Cronos Peer Group and relevant market data in making compensation decisions.

The Compensation Committee’s assessment of corporate performance for executive compensation purposes is based on a number of qualitative and quantitative factors, including execution of ongoing projects and transactions, operational performance and progress on key growth initiatives. The NEOs do not automatically receive any particular award based on the Compensation Committee’s determination of the overall performance of the Company, but rather the determination establishes the background for the Compensation Committee’s subsequent review of each NEO’s individual performance. Further, the Compensation Committee makes its final determination of executive compensation in an executive session not attended by the NEOs whose compensation is being deliberated.

Role of the CEO and the Senior Vice President, Global Head of People

The Compensation Committee works with our CEO and our Senior Vice President, Global Head of People to formulate the specific compensation plan and award designs, including business performance measures, targets and weightings necessary to align our executive compensation program with our business objectives and strategies.

Generally, the CEO and the Senior Vice President, Global Head of People participate in meetings of the Compensation Committee at the Compensation Committee’s request to provide relevant background information regarding the Company’s strategic objectives and to evaluate the performance of and compensation recommendations for the other executive officers. The Compensation Committee utilizes the information provided by the CEO and Senior Vice President, Global Head of People along with advice from its independent compensation consultant and the knowledge and experience of the Compensation Committee members in making compensation decisions.

Role of Compensation Consultant and Independence

The Compensation Committee retained Mercer (Canada) Limited (“Mercer”) in 2018 to assist in evaluating our executive compensation program and in setting executive officer compensation. During fiscal 2020, Mercer assisted the Compensation Committee by providing services, including the following:

Table of Contents

•developing the Compensation Committee’s executive compensation philosophy;

•reviewing and updating the Cronos Peer Group;

•conducting a comparison of the Company’s executive and director compensation programs to those of the Cronos Peer Group;

•updating the Compensation Committee on evolving compensation trends and best practices;

•advising the Compensation Committee on the competitiveness of our executive compensation program design and award values;

•developing share ownership guidelines for the Company’s executives; and

•participating in Compensation Committee meetings, as requested.

Mercer supported the Compensation Committee in evaluating our executive compensation by developing the Cronos Peer Group, which includes cannabis, pharmaceuticals and consumer-packaged goods companies with similar market capitalizations or with which we could potentially compete for talent. Mercer benchmarked components of the total compensation package for each of our executive officers to those for comparable positions in the Cronos Peer Group and, in some cases, other relevant market data.

In 2020, Mercer was engaged directly by the Compensation Committee but regularly consulted with management in performing work requested to be performed by the Compensation Committee. Neither Mercer nor any of its affiliates performed any separate services for management.

The Compensation Committee has determined that Mercer is independent and that its work with the Compensation Committee during fiscal 2020 did not raise any conflict of interest.

In 2019, the Company’s management retained Willis Towers Watson to assist with reviewing and redesigning the long-term incentive plan for key employees, non-employee directors and consultants of the Company. This review continued into 2020, resulting in the adoption of the 2020 Omnibus Equity Incentive Plan (the “2020 Omnibus Plan”) by the Board (as described in more detail below).

Compensation Governance Features

Insider Trading. The Company’s insider trading policy applies to employees, officers, directors, consultants, secondees, interns and any third-party service providers who are in a position to possess inside information in the course of services provided to the Company (the “Covered Personnel”). The insider trading policy prohibits Covered Personnel from trading in our securities (or securities of any other publicly-traded issuer with which the Company does business) while in possession of material nonpublic information or during blackout periods applicable to such Covered Personnel, other than in connection with a Rule 10b5-1 plan adopted in compliance with the policy.

Anti-Hedging Policy. As part of the Company’s insider trading policy, Covered Personnel are prohibited from, directly or indirectly, entering into any speculation, hedging or monetization transactions relating to our securities or otherwise trading in any instrument relating to the future price of our securities, such as a put or call option, futures contract, short sale, collar or other derivative security.

Table of Contents

Anti-Pledging Policy. The Company’s insider trading policy also prohibits Covered Personnel from pledging Shares as collateral for any loan. On a case-by-case basis, the policy’s administrators may grant an exemption to the prohibition, and may subject any such exemption to specific requirements and criteria to prevent any disposition of our securities while Covered Personnel is in possession of inside information.

Anti-Fraud Policy. The Company’s anti-fraud policy sets out the Company’s expectations and requirements relating to the prohibition, recognition, reporting and investigation of suspected fraud, corruption, misappropriation and similar irregularities. Under the anti-fraud policy, any employee or director who violates the terms of such policy may be subject to disciplinary action up to and including termination or removal, as applicable, without notice.

Clawback Policy. The Company’s clawback policy adopted in February 2020 applies to any current or former executive officer of the Company for purposes of Section 16 of the Exchange Act and any other employee who is designated by the Compensation Committee as a covered employee for purposes of the policy. The policy permits the Company to clawback any annual or long-term cash, equity or equity-based incentive or bonus compensation paid, provided or awarded to any covered employee on or after February 28, 2020, the effective date of the clawback policy, that either (i) is outstanding and unpaid, whether vested or unvested, that was awarded to the covered employee; or (ii) was paid to and received by the covered employee (including gains realized through the exercise of Stock Options or share appreciation rights) during the three year period preceding the date of the clawback event. For purposes of the clawback policy, a “clawback event” means the occurrence of any of the following:

•a material restatement of all or a portion of the Company’s financial statements;

•a covered award was awarded to, or received by, the covered employee based on a financial statement, performance goal or metric that was materially inaccurate;

•the indictment, arrest or conviction in a court of law for, or the entering of a plea of guilty or nolo contendere to, (x) a felony offense under U.S. state or federal law, an indictable offense under the Criminal Code (Canada) or a comparable offense under the law of any other jurisdiction or (y) any crime involving moral turpitude, fraud, dishonesty, bribery or theft; or

•engaging in any act (including without restriction, an act of sexual or other harassment as determined by the Company) which is a violation of any law, rule, regulation or the Company’s Code of Business Conduct and Ethics, in each case, that causes material financial, reputational or other harm to the Company, as determined by the Compensation Committee in its sole discretion.

Risk Management. Among other duties, the Compensation Committee is responsible for reviewing the Company’s incentive compensation arrangements and determining whether those arrangements require modification to ensure that they do not encourage inappropriate or unintended risk taking. In its assessment, the Compensation Committee reviewed the Company’s compensation structure and noted numerous ways in which risk is potentially mitigated by practices and policies that include: the balanced mix between short- and long-term incentives; the use of multiple performance measures for short-term cash incentive awards of the NEOs; prohibitions against speculating, short-selling and hedging; the prohibition on pledging of securities; and the existence of anti-fraud and clawback policies. In light of its analysis, the Compensation Committee believes that the architecture of the Company’s compensation programs provides various safeguards to protect against undue risk-taking.

Table of Contents

Tax and Accounting Considerations

The Compensation Committee considers tax deductibility and other tax implications when designing the executive compensation program. However, the Compensation Committee believes that there are certain circumstances where the provision of compensation that is not fully tax deductible, including by reason of Section 162(m) of the Internal Revenue Code (the “Code”), is more consistent with our compensation philosophy and objectives. The Compensation Committee retains discretion and flexibility to award non-deductible compensation to our NEOs as it deems appropriate and in furtherance of its compensation philosophy and objectives.

Discussion and Analysis of 2020 Compensation

Compensation Philosophy

The Compensation Committee believes that Shareholder interests are advanced if the Company assembles, motivates and rewards a high-performing management team. To promote this objective, the Compensation Committee developed an executive compensation program with the following goals in mind:

•position the Company competitively among companies against which we compete for talent;

•tie executive compensation to performance and achievement of the Company’s short- and long-term business goals and ensure that compensation varies based on business performance and achievement of individual objectives.

Benchmarking Target Compensation

Compensation levels for the Company’s NEOs were compared to compensation paid by a group of peer companies approved by the Compensation Committee (the “Cronos Peer Group”). The companies selected to be part of the Cronos Peer Group were cannabis, pharmaceuticals and consumer-packaged goods companies with similar market capitalizations or with which the Company could potentially compete for talent.

Table of Contents

With respect to 2020 NEO pay decisions, the Cronos Peer Group was comprised of the following 16 companies.


Company	Industry	Revenue (last 12 months) ($) (millions)	Market capitalization as of December 31, 2020 ($) (millions)
Amicus Therapeutics, Inc.	Biotechnology	245.6	6,017.0
Aphria Inc.	Pharmaceuticals	448.8	2,186.2
Aurora Cannabis Inc.	Pharmaceuticals	212.9	1,526.9
Cal-Maine Foods, Inc.	Packaged Foods and Meats	1,439.0	1,830.9
Canopy Growth Corporation	Pharmaceuticals	377.4	9,180.4
Charlotte’s Web Holdings, Inc.	Pharmaceuticals	91.1	458.5
Curaleaf Holdings, Inc.	Pharmaceuticals	471.8	7,924.3
FibroGen, Inc.	Biotechnology	119.3	3,375.6
GW Pharmaceuticals plc	Pharmaceuticals	527.2	3,589.7
Intercept Pharmaceuticals, Inc.	Biotechnology	300.9	814.9
J & J Snack Foods Corp.	Packaged Foods and Meats	980.1	2,945.2
Medifast, Inc.	Personal Products	840.6	2,300.7
Reata Pharmaceuticals, Inc.	Pharmaceuticals	8.5	4,464.6
The Simply Good Foods Company	Packaged Foods and Meats	895.6	3,001.8
Tilray, Inc.	Pharmaceuticals	210.5	1,307.2
USANA Health Sciences, Inc.	Personal Products	1,134.6	1,622.0
Cronos Group Inc.	Pharmaceuticals	46.7	2,466.6

(1) All financials in the table above are from S&P Capital IQ as of December 31, 2020.

(2) Revenue values were converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020. Market capitalization values were converted C$ to USD using the December 31, 2020 Bloomberg exchange rate of C$1.00 to $0.7843.

Elements of Compensation

Rather than strictly applying formulas and weightings to forward-looking performance objectives, which may lead to unintended consequences for compensation purposes, the Compensation Committee exercises its discretion and uses its sound judgment in making compensation determinations. For this reason, the Compensation Committee does not measure performance using pre-set formulas in determining compensation awards for NEOs.

The Compensation Committee’s comprehensive assessment of the overall business performance of the Company, including corporate performance against objectives (both quantitative and qualitative), business circumstances and, where appropriate, relative performance against peers, provides the context for individual NEO evaluations for total direct compensation.

The NEOs provide services under employment agreements, described in more detail below, which provide for fixed base salaries and certain benefits. Under their employment agreements, the NEOs are also eligible to

Table of Contents

receive performance-based incentive compensation. Fixed compensation and performance-based incentive compensation together represent total direct compensation.

Given the highly regulated and rapidly evolving nature of the cannabis industry, markets and products, it is challenging to design a compensation structure to attract and retain the kind of executive talent required to support the Company’s growth and expansion plans. Industry practices are variable and therefore compensation data analysis requires significant business judgment and interpretation of underlying business conditions. The Compensation Committee considers the Company’s business strategy, the expertise of its executives, and the ongoing evolution of industry and competitive compensation practices in establishing a tailored pay program that will attract and retain its executive talent.

In determining appropriate compensation levels, the Compensation Committee considers, in addition to market data and practices:

•the executive’s experience, performance, contributions and job proficiency;

•retention risks and succession planning considerations;

•best practices and regulatory considerations; and

•internal equity relative to other executives.

Base Salary

Base salaries for our NEOs are intended to reflect the scope of their responsibilities, performance, skills and experience as compared with relevant and comparable market talent. Base salaries are fixed pursuant to each NEO’s employment agreement and are reviewed periodically by the Compensation Committee.


NEO	Base Salary as of 12/31/2019(1)	Base Salary as of 12/31/2020(2)	Rationale for Change
Kurt Schmidt	—	$520,000	—
Michael Gorenstein	$387,764	$394,000	2% increase resulting from converting base salary from Canadian dollars to U.S. dollars
Jerry Barbato	$223,710	$223,514	—
Xiuming Shum	$223,710	$279,638	25% increase to improve alignment with comparable base salaries among the Cronos Peer Group
Todd Abraham	$216,253	$219,730	2% increase resulting from converting base salary from Canadian dollars to U.S. dollars
Anna Shlimak(3)	—	$230,000	—

(1) The amounts reported for each of Messrs. Gorenstein and Barbato, Ms. Shum and Dr. Abraham are converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

Table of Contents

(2) Reflects base salaries in effect on December 31, 2020. The amounts reported for each of Mr. Barbato and Ms. Shum are converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(3) Ms. Shlimak was engaged by the Company during 2018 and 2019 as a consultant.

Short-Term Incentive Compensation

Short-term cash incentives are intended to reward executives for achieving the Company’s financial and business objectives (the “Business Performance”) and each executive’s own individual performance (the “Individual Performance”). The 2020 short-term cash incentive target as a percentage of base salary for each NEO was determined by the Compensation Committee after consideration of the executive’s position, scope of responsibilities, ability to influence Company results and competitive pay practices among the Cronos Peer Group and relevant market data. Short-term cash incentives are paid only after both the Business Performance and the Individual Performance results are assessed against targeted levels of performance. Except with respect to Messrs. Schmidt and Gorenstein, whose employment agreements provide for minimum bonuses for 2020 as described in more detail below, no individual is guaranteed a short-term incentive bonus amount.

Target Incentive Amounts

The table below shows the target 2020 short-term incentive opportunities for each of our NEOs, expressed as a percentage of base salary and in dollars (each, a “Target Incentive Amount”).


NEO	Base Salary as of 12/31/2020	Short-Term Incentive Target as Percentage of Base Salary	Target Incentive Amount for 2020
Kurt Schmidt	$520,000	150%	$243,616(1)
Michael Gorenstein	$394,000	150%	$591,000(2)
Jerry Barbato	$223,710(3)	100%	$223,514(3)
Xiuming Shum	$279,638(3)	100%	$230,163(3)(4)
Todd Abraham	$216,253(3)	86%	$185,978(3)
Anna Shlimak	$230,000	86%	$197,800

(1) Pursuant to the terms of his employment agreement, Mr. Schmidt’s minimum bonus for 2020 is his target bonus opportunity multiplied by a fraction where the numerator is the number of calendar days in 2020 which Mr. Schmidt was employed by the Company, and the denominator is 365.

(2) Effective September 9, 2020, Mr. Gorenstein transitioned from the position of President and CEO to the position of Executive Chair of the Board. Pursuant to the terms of his employment agreement, Mr. Gorenstein will be eligible to receive his 2020 short-term incentive compensation in an amount equal to 150% of his base salary.

(3) The amount reported is a percentage of the 2020 base salary converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(4) Ms. Shum’s target incentive amount reflects the portion of the year when her base salary was C$300,000 and the portion of the year for which the increase in her base salary to C$375,000 was in effect.

Performance Measures

For 2020, 60% of the actual amount of an NEO’s short-term incentive compensation payout under the 2020 STIC Program (the “NEO 2020 Bonus Amount”) is based on the Company’s Business Performance results as compared to performance targets (the “Business Performance Rating”), with quantitative Business Performance

Table of Contents

results adjusted based on qualitative Business Performance factors. The remaining 40% of the NEO 2020 Bonus Amount is based on Individual Performance results (the “Individual Performance Rating”).

2020 Short-Term Incentive Payout

The actual amount of an NEO’s 2020 short-term incentive payout will be determined by the following formula, subject to a maximum payout equal to 142% of the Target Incentive Amount:

In the first quarter of 2020, the Audit Committee, with the assistance of outside counsel and forensic accountants, conducted a review of certain bulk resin purchases and sales of products through the wholesale channel. As a result of this investigation, the Company determined that it was required to restate its previously issued unaudited interim financial statements for the first, second and third quarters of 2019 (the “Restatement” and such interim financial statements, the “Interim Financial Statements”). In light of the Restatement, and the subsequent investigation initiated by the SEC on the Company in connection with the Restatement, the Compensation Committee decided to defer making final determinations of the 2020 short-term incentive payouts for Messrs. Gorenstein and Barbato until the conclusion of such investigation. Once determined, the Company will report the final 2020 short-term incentive payments on Form 8-K.

Business Performance Rating

The metrics used to determine the Business Performance Rating for an NEO were based on the NEO’s scope of responsibilities and ability to influence the results of the measures used to evaluate such metrics. Such metrics consisted of Corporate Metrics, United States Metrics and Rest of World Metrics (each, a “Business Performance Component”). Each Business Performance Component was evaluated using two measures, net revenue and adjusted operating loss, each of which were weighted equally and are described in more detail below. Targets for the measures for each Business Performance Component were aligned to what we believed to be the expectations of our investors at the time of setting the Company’s 2020 annual budget. The rating for each Business Performance

Table of Contents

Component is calculated by taking the average of the ratings for each measure. The Business Performance Rating is calculated by taking the average of the ratings for each Business Performance Component and, subject to the sole discretion of the Compensation Committee, adjusting this result up or down based on qualitative Business Performance factors identified by the Compensation Committee.

The Business Performance Components for 2020 are:

•Corporate Metrics.

▪Net revenue for purposes of the Corporate Metrics Business Performance Component is the Company’s net revenue on a consolidated basis, which the Company considers to be a key measure of growth and expansion of the Company’s business.

▪Adjusted operating loss* for purposes of the Corporate Metrics Business Performance Component is the Company’s reported operating loss on a consolidated basis, excluding the one-time share-based payment costs in connection with the acceleration of vesting of Restricted Share Units pursuant to separation agreements with certain employees in the U.S. segment that occurred in the third quarter of 2020 and non-recurring financial statement review costs related to the Restatement, the Company’s responses to the reviews of the Interim Financial Statements by various regulatory authorities and legal costs defending shareholder class action complaints brought against the Company as a result of the Restatement, which are expense items that the Company believes are not part of the Company’s underlying operations.

•U.S. Metrics.

▪Net revenue for purposes of the U.S. Metrics’ Business Performance Component is the net revenue for the Company’s U.S. segment.

▪Adjusted operating loss* for purposes of the U.S. Metrics Business Performance Component is the reported operating loss for the U.S. segment, excluding the one-time share-based payment costs in connection with the acceleration of vesting of Restricted Share Units pursuant to separation agreements with certain employees in the U.S. segment that occurred in the third quarter of 2020, which represents an expense item that the Company believes are not part of the Company’s underlying operations.

•Rest of World Metrics.

▪Net revenue for purposes of the Rest of World Metrics’ Business Performance Component is the net revenue for the Company’s Rest of World segment, excluding net revenue attributable to Cronos Israel.

▪Adjusted operating loss* for purposes of the Rest of World Metrics’ Business Performance Component is the reported operating loss for the Rest of World segment, excluding operating losses attributable to Cronos Israel and certain income and expense items that the Company believes are not part of the Company’s underlying operations.

* Adjusted operating loss is a non-GAAP financial measure.

Table of Contents

Under the 2020 STIC Program, each Business Performance Component rating may range from 0% to 150%, where achieving the Target corresponds to a 100% rating for the Business Performance Component. Each of the Business Performance Components is subject to a minimum performance threshold (the “Threshold”) and a maximum performance level (the “Maximum”). If a Threshold is not met for a particular Business Performance Component, it will be scored as 0% when calculating the Business Performance Rating. Actual Business Performance results that meet or exceed the Maximum will result in a score of 150% for the corresponding Business Performance Component.

For 2020, the rating for each Business Performance Component can be calculated as follows:


Business Performance Component Actual Result			Business Performance Component Rating Calculation (expressed as a %)
Below Threshold			0
Greater than Threshold, less than Target			((actual result – Threshold) / (Target – Threshold)) * 100
Equal to Target			100
Greater than Target, less than Maximum			(((actual result – Target) / (Maximum – Target)) * 50) + 100
Equal to or greater than Maximum			150

The table below shows the (i) Threshold, (ii) Target and (iii) Maximum targets for each measure of each Business Performance Component established by the Compensation Committee for the 2020 STIC Program, each of which were set in the second quarter of 2020, (iv) the actual results achieved for each measure in 2020, (v) the rating for each measure for each Business Performance Component, and (vi) the combined ratings for each Business Performance Component.


Business Performance Component	Threshold	Target	Maximum	2020 Actual	Measure Rating	Component Rating
Corporate Metrics
Net revenue (in millions)	$23.8	$41.6	$58.2	$46.7	115.4%	91.6%
Adjusted operating loss* (in millions)	$(190.8)	$(152.6)	$(133.5)	$(164.7)	67.9%
U.S. Metrics
Net revenue (in millions)	$7.3	$12.2	$17.1	$9.5	44.6%	22.3%
Adjusted operating loss* (in millions)	$(29.5)	$(23.6)	$(20.7)	$(31.8)	—
Rest of World Metrics
Net revenue (in millions)	$15.7	$26.2	$36.6	$34.5	140.1%	103.9%
Adjusted operating loss* (in millions)	$(121.2)	$(96.9)	$(84.8)	$(105.2)	67.7%

* Adjusted operating loss is a non-GAAP financial measure. Please refer to the definition set forth above for the adjusted operating loss-to-operating loss reconciliation.

Table of Contents

Based on the Business Performance Component ratings above, the overall quantitative Business Performance Rating was 91.6%, which may be adjusted by the Compensation Committee in consideration of other qualitative achievements of the Company, in order to arrive at a final Business Performance Rating. As discussed above, in light of the Restatement, and the subsequent investigation initiated by the SEC on the Company in connection with the Restatement, the Compensation Committee decided to defer determining the final 2020 short term incentive payouts for Messrs. Gorenstein and Barbato until the conclusion of such investigation.

For 2021, the Compensation Committee has implemented changes to our STIC Program in order to align the Company’s STIC Program for 2021 with the direction of the business. With respect to the Corporate Metrics, adjusted operating loss (a non-GAAP measure) will be replaced by adjusted EBITDA, a non-GAAP measure which excludes non-cash items or items that do not reflect the Company’s assessment of on-going business performance. The Company defines adjusted EBITDA as net income (loss) before interest, tax expense, depreciation and amortization adjusted for: impairment loss on goodwill and intangible assets, repurposing charges, financing and transaction costs, loss (gain) on revaluation of derivative liabilities, loss (gain) on disposal of investments, share of loss (income) from equity accounted investees, loss from discontinued operations, other loss (income), review costs related to the Restatement, the Company’s responses to the reviews of the Restatement by various regulatory authorities and legal costs defending shareholder class action complaints brought against the Company as a result of the Restatement, and share-based payments. This measure will ensure that growth is achieved in a cost-effective manner and that cost efficiencies and productivity enhancements are pursued throughout the Company. With respect to U.S. Metrics and Rest of World Metrics, adjusted operating loss (a non-GAAP measure) will be replaced by adjusted direct profit, which is a segment’s net revenue, excluding cost of goods sold and costs associated with sales, marketing and customer care, but including costs associated with consumer insights.

Individual Performance Measures

Incentive awards are differentiated based on Individual Performance, with 40% of the Target Incentive Amount for our executives based on Individual Performance. For each NEO, the Individual Performance Rating can range from 0% to 130%.

Individual Performance factors were specific to each NEO’s job function. In determining the Individual Performance of our NEOs, the Compensation Committee noted the highlights of the 2020 performance of each NEO as described below.

•Mr. Barbato led our finance function, including leading the implementation of a new enterprise resource planning system across the Canadian business during 2020, which will be a meaningful component of the Company’s internal control over financial reporting and is expected to enable the Company to realize efficiencies throughout its supply chain and operations. Mr. Barbato also oversaw an enterprise-wide COVID-19 and cultural survey in furtherance of the Company’s focus on its response to the COVID-19 pandemic and developing and retaining its talent. In addition, Mr. Barbato created an enterprise initiative framework to enhance the disciplined execution of corporate and operations initiatives.

•Ms. Shum led our legal and regulatory affairs function, overseeing the development and implementation of an integrated global quality management system and a global compliance program to institute an enterprise-wide compliance and quality mindset throughout the Company. Ms. Shum also continued to advise on and manage the Company’s U.S. federal and state regulatory matters in connection with the Company’s U.S.

Table of Contents

product portfolio. In addition, Ms. Shum supported the Company’s brand and product launches Canada, the U.S. and Israel in 2020, including successfully obtaining regulatory licenses required for sales and exports.

•Dr. Abraham led our research and development (“R&D”) function, including overseeing product development and plans for commercialization as well as the Company’s R&D initiatives in cannabinoids under our Ginkgo Strategic Partnership. Dr. Abraham also oversaw the development and implementation of enterprise-wide research infrastructure to enable cohesive monitoring of global cannabinoid research and designing and execution of new research programs in support of the Company’s strategic goals.

•Ms. Shlimak led our internal and external communication, government affairs, corporate strategy and investor relation functions. Ms. Shlimak oversaw the development and implementation of enterprise-wide processes and systems to enhance employee communication and engagement including during the challenging environment caused by COVID-19. Ms. Shlimak also oversaw the development of the Company’s governmental affairs department, which included engagement with key industry associations and regulatory and legislative agencies. Ms. Shlimak continued to oversee and manage the Company’s engagement with the investment and sell-side community.

Effective September 9, 2020, Mr. Gorenstein transitioned from the position of President and CEO to the position of Executive Chair of the Board, and Mr. Schmidt was appointed as President and CEO of the Company. Pursuant to the terms of his employment agreement, Mr. Gorenstein’s annual bonus will be 150% of his base salary of $394,000 for the Company’s 2020, 2021 and 2022 fiscal years. Pursuant to the terms of his employment agreement, Mr. Schmidt will be eligible to receive his 2020 short-term incentive compensation in a minimum amount equal to 150% of his base salary of $520,000, pro-rated for the number of calendar days he was employed with the Company in 2020. The Compensation Committee elected not to exercise its discretion to increase such bonus, and, accordingly, approved a 2020 Bonus Amount for Mr. Schmidt equal to $243,616. Accordingly, Messrs. Gorenstein and Schmidt’s Individual Performance were not evaluated for purposes of their 2020 short-term incentive compensation.

NEO 2020 Bonus Amounts

Based on the considerations described above, the Compensation Committee approved the following NEO 2020 Bonus Amounts:


NEO	Target Incentive Amount for 2020	Business Performance Rating	Individual Performance Rating	Actual NEO 2020 Bonus Amount Approved
Xiuming Shum	$230,163(1)	91.6%	110.0%	$227,510(1)
Todd Abraham	$185,978(1)	91.6%	115.0%	$198,941(1)(2)
Anna Shlimak	$197,800	91.6%	110.0%	$195,767

(1) The amount reported is a percentage of the 2020 base salary converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(2) The amount approved by the Compensation Committee, or C$251,824, was remitted to Dr. Abraham in USD using the Bloomberg exchange rate as of March 9, 2021, which was $0.7900. As a result, Dr. Abraham was paid $198,941 in connection with his NEO 2020 Bonus Amount.

Table of Contents

As discussed above, in light of the Restatement, and the subsequent investigation initiated by the SEC on the Company in connection with the Restatement, the Compensation Committee decided to defer making final determinations of the 2020 short term incentive payouts for Messrs. Gorenstein and Barbato until the conclusion of such investigation.

Long-Term Incentive Compensation

Long-term incentives are intended to attract, retain and motivate our executive officers, align the interests of our executive officers with Shareholders, and promote ownership of the Company’s equity by our executives. Through ownership in our common shares, executive officers are able to benefit from share price appreciation resulting from the achievement of positive and long-term business results.

The Compensation Committee is responsible for approving equity grants for executive officers. Prior to 2019, equity grants to executive officers were generally made in the form of Stock Options and determined on an ad hoc basis. Beginning in 2020, the Company introduced grants of long-term incentives in the form of Restricted Share Units, intended to reinforce share ownership and retention of participants. The Restricted Share Units complement outstanding grants of Stock Options to provide a balanced focus on Shareholder value creation and share price appreciation. Equity awards approved by the Compensation Committee are granted on the first trading day after the end of any scheduled blackout period following such approval to ensure that equity grants are made in coordination with the release of material non-public information.

Grants of Restricted Share Units made to Mses. Shum and Shlimak and Dr. Abraham for 2020 will vest ratably over three years and settle in newly issued Shares from treasury. Post-vesting and settlement in Shares, the actual value of compensation received from Restricted Share Units will be dependent on the value of the Share price on the date that a participant elects to sell his or her Shares. This relationship reinforces direct alignment with the interests of our Shareholders. In 2020, the Compensation Committee considered equity compensation practices of the Cronos Peer Group and general industry market data. Based on these considerations, the Compensation Committee approved the following long-term incentive grant values for NEOs:


NEO	Number of Restricted Share Units	2020 Long-Term Incentive Grant Value ($)
Xiuming Shum	58,130	366,288(1)
Todd Abraham	38,937	211,036
Anna Shlimak	84,871(2)	460,000(2)

(1) The long-term incentive grant value reported for Ms. Shum is converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020. Includes C$91,200 of Restricted Share Units in respect of one-time retention award granted on November 5, 2020.

(2) Includes $230,000 of Restricted Share Units in respect of services provided by Ms. Shlimak during 2019 when she was a consultant for the Company, which were granted in 2020.

In light of the Restatement, and the subsequent investigation initiated by the SEC on the Company in connection with the Restatement, the Compensation Committee deferred making final determinations of the 2020 long-term incentive equity grants for Messrs. Gorenstein and Barbato until the conclusion of such investigation.

Table of Contents

CEO Sign-on Awards

In connection with Mr. Schmidt’s appointment as President and CEO, he received one-time grants of 2,000,000 Stock Options that vest ratably on an annual basis over a five-year period following the date of grant and 450,000 Restricted Share Units that vest on the third anniversary of their grant date and settle in Shares on a one-for-one basis.

One-Time Retention Awards

In recognition of Dr. Abraham’s and Ms. Shum’s contributions to the Company and in order to retain executive talent, in March 2020, Dr. Abraham received a one-time cash retention bonus of $57,181, and, in November 2020, Ms. Shum received a one-time retention award in the form of Restricted Share Units with a value of C$91,200 ($68,008 based on the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020), which vest ratably on an annual basis over three years beginning on the first anniversary of the date of grant.

Employment Agreements

Each of the NEOs provides services pursuant to an employment agreement. The severance and change of control provisions of our NEOs’ employment agreements and other arrangements are described in detail in the section entitled “Potential Payments Upon Termination or Change of Control.”

Schmidt Agreement

Cronos USA Client Services LLC (“Cronos USA”) and the Company entered into an employment agreement dated September 9, 2020 with Kurt Schmidt (the “Schmidt Agreement”). Pursuant to the Schmidt Agreement, Mr. Schmidt acts in the capacity of President and Chief Executive Officer. The Schmidt Agreement provides for an annual base salary of $520,000, less applicable deductions and withholdings, for acting in such capacity plus reasonable travel and other out-of-pocket expenses incurred in connection with Mr. Schmidt’s duties. Mr. Schmidt is eligible to participate in the employee benefit programs of Cronos USA or the Company, as applicable, and in the Company’s annual cash bonus plan as may be in effect from time to time. Mr. Schmidt’s annual target bonus opportunity is initially 150% of base salary, provided that the actual bonus amount, if any, will be determined pursuant to the terms of the applicable annual bonus plan. The Schmidt Agreement provides that Mr. Schmidt’s minimum bonus for 2020 shall be his target bonus multiplied by a fraction where the numerator is the number of calendar days in 2020 which Mr. Schmidt was employed by the Company, and the denominator is 365. Mr. Schmidt is eligible to receive annual grants of equity-based awards with an initial target incentive opportunity of $1,300,000 (based on the grant date fair value of such awards), provided that the actual amount, if any, of the grants will be determined by the Board or the Compensation Committee, as applicable, at its sole discretion.

In connection with his appointment as the Company’s President and Chief Executive Officer, Mr. Schmidt received a one-time sign-on grant of equity-based awards, comprised of (a) 2,000,000 Stock Options that vest ratably on an annual basis over a five-year period following the date of grant; and (b) 450,000 Restricted Share Units that vest on the third anniversary of the grant date and settle in Shares.

Gorenstein Agreement

Cronos USA and the Company entered into an amended and restated employment agreement with Mr. Gorenstein on September 9, 2020 (the “Gorenstein Agreement”), pursuant to which Mr. Gorenstein ceased serving

Table of Contents

as President and Chief Executive Officer of the Company as of such date and will continue his service on the Board and employment with Cronos USA as Executive Chairman of the Board for a period of up to 18 months thereafter (the “Employment Period”). If the Board terminates Mr. Gorenstein’s service as Executive Chairman of the Board other than for Just Cause (as described in more detail in the section entitled, “Potential Payments Upon Termination or Change of Control”) prior to the end of the Employment Period, Mr. Gorenstein will provide consulting services to the Company for the remainder of the 18-month term (the “Consulting Period”). The Gorenstein Agreement provides for an annual base salary of $394,000, less applicable deductions and withholdings, plus reasonable expenses incurred in connection with Mr. Gorenstein’s duties. During the Consulting Period, if any, Mr. Gorenstein will be entitled to receive a monthly consulting fee in the amount of $83,000. Mr. Gorenstein is eligible to participate in the benefit plans that may be provided by Cronos USA or the Company, as applicable, and in the Company’s annual cash bonus plan as may be in effect from time to time. Mr. Gorenstein’s annual bonus for the Employment Period will be 150% of his base salary for the Company’s 2020, 2021 and 2022 fiscal years. During the term, Mr. Gorenstein will generally remain eligible to receive annual grants of Restricted Share Units equal to $985,000 for the Company’s 2021 fiscal year and $493,000 for the Company’s 2022 fiscal year each based on a price of our Shares of $5.24 (each, a “Gorenstein LTI Grant”). The Gorenstein Agreement acknowledged that Mr. Gorenstein is eligible to receive an annual cash bonus in respect of the Company’s 2019 fiscal year in an amount of $473,000 and an annual grant of Restricted Share Units equal to $985,000 for the Company’s 2020 fiscal year each based on a price of our Shares of $5.24. Any annual bonus and long-term incentive award Mr. Gorenstein is eligible to receive under the Gorenstein Agreement is contingent on the conclusion of the investigation by the SEC into the Company, and the investigation not resulting in a penalty being levied by the SEC against Mr. Gorenstein personally or against the Company on account of any misconduct or mismanagement by Mr. Gorenstein. Any outstanding equity-based awards that are held by Mr. Gorenstein as of the last day of the Employment Period will vest as of that date, except in the event of a termination for Just Cause, and any Gorenstein LTI Grants made during the Consulting Period will be fully vested as of the date of grant.

Prior to the Gorenstein Agreement, the Company had entered into an employment agreement with Mr. Gorenstein, which originally provided for an annual base salary of C$200,000 and was orally amended effective June 2019 to provide for an increased annual base salary of C$520,000, less applicable deductions and withholdings, and provided for reasonable expenses incurred in connection with Mr. Gorenstein’s employment. Mr. Gorenstein was also eligible to participate in the Company’s employee benefit plan, program or arrangement and to receive an annual bonus as a lump sum cash payment and/or Stock Options to purchase Shares within 90 days following the end of each calendar year.

Barbato Agreement

Hortican Inc. (“Hortican”) and the Company entered into an employment agreement dated April 2, 2019 with Jerry Barbato (the “Barbato Agreement”). Pursuant to the Barbato Agreement, Mr. Barbato acts in the capacity of CFO. The Barbato Agreement provides for an annual base salary of C$300,000 less applicable deductions and withholdings for acting in such capacity plus reasonable travel and other out-of-pocket expenses incurred in connection with Mr. Barbato’s duties. Mr. Barbato is also eligible to participate in the Company’s benefits programs and in the Company’s annual cash bonus plan as may be in effect from time to time. Mr. Barbato’s annual target bonus opportunity is initially 100% of base salary, provided that the actual bonus amount, if any, will be determined pursuant to the terms of the applicable annual bonus plan. Mr. Barbato is eligible to receive annual grants of equity-based awards with an initial target incentive opportunity of C$400,000 (based on the grant date fair value of such awards), provided that the actual amount, if any, of the grants shall be determined by the Board at its sole discretion.

Table of Contents

Shum Agreement

Hortican and the Company entered into an employment agreement dated May 18, 2019 with Xiuming Shum (the “Shum Agreement”). Pursuant to the Shum Agreement, Ms. Shum acts in the capacity of Executive Vice President, Legal and Regulatory Affairs of the Company. The Shum Agreement originally provided for an annual base salary of C$300,000, less applicable deductions and withholdings, plus reasonable travel and other out-of-pocket expenses incurred in connection with Ms. Shum’s duties. The Compensation Committee determined to increase her annual base salary to C$375,000, less applicable deductions and withholdings, effective on November 7, 2020 to align her base salary with comparable base salaries among the Cronos Peer Group and in recognition of her contributions to the Company. Ms. Shum is also eligible to participate in the Company’s benefits programs and in the Company’s annual cash bonus plan as may be in effect from time to time. Ms. Shum’s annual target bonus opportunity is initially 100% of base salary, provided that the actual bonus amount, if any, will be determined pursuant to the terms of the applicable annual bonus plan. Ms. Shum is eligible to receive annual grants of equity-based awards with an initial target incentive opportunity of C$400,000 (based on the grant date fair value of such awards), provided that the actual amount, if any, of the grants shall be determined by the Board at its sole discretion.

Abraham Agreement

Hortican and the Company entered into an employment agreement dated November 1, 2019 with Todd Abraham (the “Abraham Agreement”). Pursuant to the Abraham Agreement, Dr. Abraham acts in the capacity of Chief Innovation Officer of the Company. The Abraham Agreement provides for an annual base salary of C$290,000, less applicable deductions and withholdings, plus reasonable travel and other out-of-pocket expenses incurred in connection with Dr. Abraham’s duties. Dr. Abraham is also eligible to participate in the Company’s benefits programs and in the Company’s annual cash bonus plan as may be in effect from time to time. Dr. Abraham’s annual target bonus opportunity is initially 86% of base salary, provided that the actual bonus amount, if any, will be determined pursuant to the terms of the applicable annual bonus plan. Dr. Abraham is eligible to receive annual grants of equity-based awards with an initial target incentive opportunity of C$280,000 (based on the grant date fair value of such awards), provided that the actual amount, if any, of the grants shall be determined by the Board at its sole discretion.

Shlimak Agreement

Cronos USA and the Company entered into an employment agreement dated February 20, 2020 with Anna Shlimak (the “Shlimak Agreement”). Pursuant to the Shlimak Agreement, Ms. Shlimak acts in the capacity of Senior Vice President, Communications, Investor Relations and Government Affairs of the Company. Ms. Shlimak’s official title is Senior Vice President, Corporate Affairs. The Shlimak Agreement provides for an annual base salary of $230,000, less applicable deductions and withholdings, plus reasonable travel and other out-of-pocket expenses incurred in connection with Ms. Shlimak’s duties. The Shlimak Agreement also provided for a monthly payment of $1,348.81 as reimbursement for out-of-pocket expenses incurred by Ms. Shlimak in respect of her health and dental insurance premiums until June 30, 2020, which reimbursement was not utilized by Ms. Shlimak. After June 30, 2020, Ms. Shlimak is eligible to participate in Cronos USA’s benefits programs and in the Company’s annual cash bonus plan as may be in effect from time to time. Ms. Shlimak’s annual target bonus opportunity is initially 86% of base salary, provided that the actual bonus amount, if any, will be determined pursuant to the terms of the applicable annual bonus plan. Ms. Shlimak is eligible to receive annual grants of equity-based awards with an initial target incentive opportunity of $230,000 (based on the grant date fair value of such awards), provided that the actual amount, if any, of the grants shall be determined by the Board at its sole discretion. Ms. Shlimak received a one-time cash signing bonus of $197,800 in February 2020 in connection with her appointment.

Table of Contents

COMPENSATION COMMITTEE REPORT

The members of the Compensation Committee have reviewed and discussed the contents of the CD&A with management. Based on such review and discussion with management, and subject to the limitations on the role and responsibility of the Compensation Committee, the Compensation Committee recommended to the Board that the CD&A be included in this Proxy Statement issued in connection with our Annual Meeting and incorporated into our Form 10-K for the year ended December 31, 2020.

Compensation Committee

Jody Begley, Chairman

Jason Adler

James Rudyk

Table of Contents

EXECUTIVE COMPENSATION

Summary Compensation Table

The table below summarizes the total compensation paid or earned by each of the NEOs for the fiscal years ended December 31, 2020, 2019 and 2018.


Name and Principal Position	Year	Salary ($)(1)	Bonus ($)	Stock Awards ($)(2)(3)	Option Awards ($)(1)(3)	Non-Equity Incentive Plan Compensation ($)(1)(4)	All Other Compensation ($)(1)(5)	Total ($)
Kurt Schmidt President and CEO(6)	2020	146,000	—	2,376,000	7,349,600	243,616	—	10,115,216
Michael Gorenstein Executive Chairman(7)	2020	477,381(8)	—	—	—	—	16,159	493,540
	2019	318,561(8)	—	—	10,996,213	—	15,010	11,329,784
	2018	205,839(8)	—	—	430,274	—	11,368	647,481
Jerry Barbato CFO(9)	2020	239,535	—	—	—	—	9,708	249,243
	2019	156,536	—	—	301,392	—	79,536	537,464
Xiuming Shum EVP, Legal and Regulatory Affairs	2020	247,372	—	366,288(10)	—	227,510	—	841,170
	2019	189,873	—	—	301,392	157,373	305	648,943
	2018	134,948	—	—	717,123	—	—	852,071
Todd Abraham Chief Innovation Officer	2020	227,914	57,181(11)	211,036(12)	—	198,941(13)	4,656	699,728
Anna Shlimak SVP, Corporate Affairs(14)	2020	191,077	197,800(15)	460,000(16)	—	195,767	38,660	1,083,303

(1) The amounts reported for each of Mr. Barbato, Dr. Abraham and Ms. Shum are converted from C$ to USD using the Bloomberg average exchange rate (a) for 2020 of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020, (b) for 2019 of C$1.00 to $0.7537 for the 12-month period ended December 31, 2019, and (c) for 2018 of C$1.00 to $0.7711 for the 12-month period ended December 31, 2018. Amounts reported as Salary include lump sum payments made for unused and accrued vacation days as of December 31, 2020 as follows: for Mr. Gorenstein, $73,024; for Mr. Barbato, $15,918; for Ms. Shum, $17,209; and for Dr. Abraham, $8,318.

(2) As discussed in more detail above, in light of the Restatement, and the subsequent investigation initiated by the SEC on the Company in connection with the Restatement, the Compensation Committee deferred making final determinations of the 2020 long-term incentive equity grants for Messrs. Gorenstein and Barbato until the conclusion of such investigation.

(3) The amounts in these columns represent the aggregate grant date fair value of the relevant award(s) presented, as determined in accordance with FASB ASC Topic 718, “Compensation—Stock Compensation” (“ASC 718”). See note 16 of the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 regarding assumptions underlying valuation of equity awards. Amounts set forth for Mr. Schmidt reflect his one-time sign-on grants of 2,000,000 Stock Options and 450,000 Restricted Share Units as described in more detail above.

(4) Incentive plan amounts determined as more specifically discussed under “—Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Compensation.” The amounts in this column for 2020 represent short-term

Table of Contents

cash incentive awards earned for 2020 to be paid in 2021. As discussed in more detail above, in light of the Restatement, and the subsequent investigation initiated by the SEC on the Company in connection with the Restatement, the Compensation Committee decided to defer making final determinations of the 2019 and 2020 short-term incentive payouts for Messrs. Gorenstein and Barbato until conclusion of such investigation. Once determined, the Company will report the final 2019 and 2020 short-term incentive payments on Form 8-K. Ms. Shum’s 2019 short-term incentive payout was reported for the first time in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.

(5) The items comprising “All Other Compensation” for 2020 are:


Name	Perquisites and Other Personal Benefits (a) ($)	Consulting Fees(b) ($)	Total ($)
Michael Gorenstein	16,159	—	16,159
Jerry Barbato	9,708	—	9,708
Todd Abraham	4,656	—	4,656
Anna Shlimak	12,432	26,228	38,660

(a) Reflects tax preparation and consultation fees for Messrs. Gorenstein and Barbato, Dr. Abraham and Ms. Shlimak, and, with respect to only Mr. Barbato, includes reimbursement paid in 2020 for 2019 relocation expenses. Amounts are reported in USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(b) Reflects consulting fees paid to Ms. Shlimak in 2020 while she was engaged as a consultant for the Company prior to her appointment as Senior Vice President, Corporate Affairs effective February 21, 2020.

(6) Mr. Schmidt commenced employment as President and CEO effective September 9, 2020.

(7) Mr. Gorenstein transitioned to his role as Executive Chairman of the Board of the Company effective September 9, 2020.

(8) The Gorenstein Agreement provides for an annual base salary of $394,000 effective September 9, 2020. Prior to the Gorenstein Agreement, Mr. Gorenstein’s annual base salary was C$520,000 effective in July 2019. The portion of Mr. Gorenstein’s 2020 base salary that was in effect prior to his transition to his role as Executive Chairman of the Board is reported in USD using the Bloomberg average exchange rate of C$1.00 to $0.7547 for the 12-month period ended December 31, 2020.

The amount reported is converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7537 for the 12-month period ended December 31, 2019. Mr. Gorenstein’s employment agreement in effect in 2018 provided for an annual base salary of $200,000, which was remitted to Mr. Gorenstein in 2018 in C$. Salary is reported in USD using the Bloomberg average exchange rate of C$1.00 to $0.7711 for the 12-month period ended December 31, 2018.

(9) Mr. Barbato commenced employment as CFO effective April 15, 2019.

(10) In addition to receiving her annual grant of equity-based awards with a value of C$400,000, Ms. Shum received an additional one-time retention award on November 6, 2020 in the form of Restricted Share Units with a value of C$91,200. The amount reported is converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(11) Reflects a one-time cash retention bonus granted to Dr. Abraham on March 31, 2020.

(12) The amount reported reflects the conversion from C$280,000 to USD using the Bloomberg average exchange rate of C$1.00 to $0.7537 for the 12-month period ended December 31, 2019, which rate was used to determine the number of Restricted Share Units to be issued to Dr. Abraham.

(13) The NEO 2020 Bonus Amount approved by the Compensation Committee for Dr. Abraham, or C$251,824, was remitted to Dr. Abraham in USD using the Bloomberg exchange rate as of March 9, 2021, which was $0.7900. As a result, Dr. Abraham was paid $198,941 in connection with his NEO 2020 Bonus Amount.

(14) Ms. Shlimak was appointed as Senior Vice President, Corporate Affairs effective February 21, 2020.

(15) Reflects a one-time cash signing bonus in connection with Ms. Shlimak’s appointment in February 2020.

(16) Includes $230,000 of Restricted Share Units in respect of services provided by Ms. Shlimak during 2019 when she was a consultant for the Company, which were granted in 2020.

Table of Contents

Grants of Plan-Based Awards in 2020

The table below summarizes the equity and non-equity awards granted to the NEOs in 2020.


Name	Grant Date	Estimated Future Payouts Under Non-Equity Incentive Plan Awards			All Other Stock Awards: Number of Shares of Stock or Units (#)	All Other Option Awards: Number of Securities Underlying Options (#)	Exercise or Base Price of Option Awards ($/Sh)	Grant Date Fair Value of Stock and Option Awards ($)(1)
		Threshold ($)(2)	Target ($)(2)	Maximum ($)(2)
Kurt Schmidt		243,616	243,616	243,616	—	—	—	—
	9/10/2020	—	—	—	450,000	—	—	7,349,600
	9/10/2020	—	—	—	—	2,000,000	$5.28	2,376,000
Michael Gorenstein		591,000	591,000	591,000	—	—	—	—
Jerry Barbato		—	223,514	317,390	—	—	—	—
Xiuming Shum		—	232,144	329,644	—	—	—	—
	11/6/2020	—	—	—	47,337	—	—	298,280
	11/6/2020	—	—	—	10,793	—	—	68,008
Todd Abraham		—	188,968	268,335	—	—	—	—
	6/25/2020	—	—	—	38,937	—	—	211,036
Anna Shlimak		—	197,800	280,876	—	—	—	—
	6/25/2020	—	—	—	84,871	—	—	460,000

(1) The aggregate grant date fair value of awards presented in this column is calculated in accordance with ASC 718. Amounts reported for Ms. Shum are converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(2) Represents the threshold, target and maximum applicable to short-term incentives. As described under “—Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Compensation” above, 60% of the funding of the short-term cash incentive is based on Business Performance results as compared to pre-established goals; the remaining 40% of the Target Incentive Amount is based on Individual Performance results. The Compensation Committee retains discretion to pay short-term incentive amounts above or below the estimated range shown in the table above. The actual short-term incentive amounts to be paid to Messrs. Barbato and Gorenstein for 2020 performance have not yet been determined, and therefore are not included in the Non-Equity Incentive Plan Compensation column of the Summary Compensation Table.

Additional Information about Grants of Plan-Based Awards

2020 Omnibus Equity Incentive Plan

Employees (including prospective employees), non-employee directors and consultants of the Company, including each of the NEOs, are eligible to participate in the 2020 Omnibus Plan, which was adopted by the Board on March 29, 2020 and approved by Shareholders on June 25, 2020, and replaced the 2018 Stock Option Plan (the “2018 Option Plan”), the Amended and Restated Stock Option Plan (the “2015 Option Plan”) and the Cronos Group Inc. Employment Inducement Award Plan #1 (collectively, the “Predecessor Plans”). The terms and conditions of

Table of Contents

the Predecessor Plans continue to remain in effect with respect to awards that were granted under the Predecessor Plans.

The 2020 Omnibus Plan provides for grants of Stock Options (both Stock Options intended to meet the requirements of “incentive stock options” under Section 422 of the Code and “non-qualified stock options” that do not meet such requirements) (collectively, “Stock Options”), share appreciation rights, restricted shares, restricted share units, dividend equivalent rights and performance-based and other share-based or cash-based awards. The 2020 Omnibus Plan is administered by the Compensation Committee. Restricted Share Units and Stock Options reported in the Summary Compensation Table as compensation for the 2020 fiscal year were granted under the 2020 Omnibus Plan.

As discussed under “—Compensation Discussion and Analysis—Elements of Compensation—Long-Term Incentive Compensation” above, Restricted Share Units granted to Mses. Shum and Shlimak and Dr. Abraham in 2020 vest on an annual basis over three years. Restricted Share Units granted to Mr. Schmidt in 2020 vest on the third anniversary of the grant date, and Stock Options granted to Mr. Schmidt in 2020 vest on an annual basis over five years beginning on September 10, 2021 and expire seven years from the date of the grant.

2018 Option Plan

The 2018 Option Plan is administered by the Board and was last approved by Shareholders on June 28, 2018, replacing the 2015 Option Plan. Stock Options granted between June 28, 2018 and March 29, 2020 were granted under the 2018 Option Plan. The term of each outstanding Stock Option award under the 2018 Option Plan was established by the Board and set out in the Stock Option grant agreement, provided that, pursuant to the terms of the 2018 Option Plan, the term of a Stock Option may not exceed seven years from the date of the grant. Stock Options that would expire during a trading black-out period may be exercised within ten business days following the end of such trading black-out period.

The 2018 Option Plan also provided for the issuance of “share appreciation rights” in tandem with Stock Options. Such “share appreciation rights” are not separate grants of equity-based awards, but rather reflect the participant’s right to cashless exercise of the Stock Options. Under the terms of the 2018 Option Plan, each “share appreciation right” entitles the holder to surrender to the Company, unexercised, the right to subscribe for Shares pursuant to the related Stock Option and to receive from the Company a number of Shares, rounded down to the next whole Share, with a fair market value on the date of exercise of each such that is equal to the difference between such fair market value and the exercise price under the related Stock Option, multiplied by the number of Shares that cease to be available under the Stock Option as a result of the exercise of the “share appreciation right,” subject to satisfaction of applicable withholding taxes and other source deductions.

Each unexercised “share appreciation right” terminates when the related Stock Option is exercised or the Stock Option terminates, including upon a Change of Control (as discussed below). Upon each exercise of a “share appreciation right,” in respect of a Share covered by a Stock Option, such Stock Option shall be cancelled and shall be of no further force or effect in respect of such Share. If any Stock Option is cancelled in connection with the exercise of the related “share appreciation right,” the aggregate number of Shares that may be issued pursuant to the 2018 Option Plan shall be reduced by the number of Stock Options cancelled in connection with the exercise of such “share appreciation right.”

Table of Contents

2015 Option Plan

Stock Options granted prior to June 28, 2018 were granted under the 2015 Option Plan. On May 18, 2018, the Board approved amendments to the terms of all outstanding Stock Option grants under the 2015 Option Plan to reflect certain of the provisions of the 2018 Option Plan. Specifically, the Stock Option grants were amended to incorporate the automatic extension of the expiry date of a Stock Option where the original expiry date of a Stock Option falls during a trading black-out period and the termination of employment and change of control provisions of the 2018 Option Plan. Under the 2015 Option Plan, Stock Options can similarly be exercised cashlessly pursuant to the issuance of tandem “share appreciation rights.”

Outstanding Equity Awards at Fiscal Year-End

As of December 31, 2020, our NEOs held outstanding equity-based awards of the Company as listed in the table below.


	Option Awards				Stock Awards
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)(1)
Kurt Schmidt	—	2,000,000	$5.28	9/10/27(2)	—	—
	—	—	—	—	450,000(3)	3,123,000
Michael Gorenstein	487,500	—	C$0.50	8/5/2021	—	—
	1,200,000	—	C$1.23	10/6/2021	—	—
	1,191,666	108,334	C$3.14	4/12/2022(4)	—	—
	416,666	83,334	C$2.42	8/24/2022(5)	—	—
	96,875	53,125	C$7.57	5/17/2023(6)	—	—
	411,671	686,120	C$20.65	5/11/2024(7)	—	—
Jerry Barbato	11,283	18,806	C$20.65	5/11/2024(7)	—	—
Xiuming Shum	219,166	43,834	C$2.42	8/24/2022(5)	—	—
	161,458	88,542	C$7.57	5/17/2023(6)	—	—
	11,283	18,806	C$20.65	5/11/2024(7)	—	—
	—	—	—	—	58,130(8)	403,422
Todd Abraham	7,165	15,763	C$17.68	8/12/2024(9)	—	—
	—	—	—	—	38,937(10)	270,223
Anna Shlimak	129,166	70,834	C$7.57	5/17/2023(6)	—	—
	—	—	—	—	84,871(10)	589,005

(1) Amounts in these columns reflect a closing price of our Shares on Nasdaq of $6.94 on December 31, 2020 (the last business day in 2020).

(2) Stock Options vest ratably on an annual basis over a five-year period from the grant date of September 10, 2020.

(3) Restricted Share Units vest on the third anniversary of the grant date of September 10, 2020.

(4) Stock Options vest on a monthly basis over a four-year period following the grant date of April 12, 2017.

(5) Stock Options vest on a monthly basis over a four-year period following the grant date of August 24, 2017.

(6) Stock Options vest on a monthly basis over a four-year period following the grant date of May 17, 2018.

(7) Stock Options vest every three months over a four-year period following the grant date of May 11, 2019.

(8) Restricted Share Units vest ratably on an annual basis over a three-year period from the grant date of November 6, 2020.

(9) Stock Options vest ever three months over a four-year period following the grant date of August 12, 2019.

(10) Restricted Share Units vest ratably on an annual basis over a three-year period from the grant date of May 11, 2020.

Table of Contents

Stock Option Exercises and Stock Vested in 2020

None of the NEOs exercised any Stock Options and none of the NEO’s Restricted Share Units vested in 2020.

Pension Benefits

The Company does not maintain any defined benefit pension plans.

Nonqualified Deferred Compensation

The Company does not maintain any deferred compensation plans for employees.

Potential Payments Upon Termination or Change of Control

Employment Agreements

Schmidt Agreement

Under the Schmidt Agreement, in the event Mr. Schmidt’s employment is terminated by Cronos USA without Just Cause or he resigns for Good Reason (each, as defined below), subject to the execution of a release in favor of the Company, he would be entitled to:

(i)a lump sum severance payment in the amount of his annual base salary;

(ii)employee benefit continuation for up to one year following termination; and

(iii)a pro-rated annual bonus for the year of termination.

Upon a termination of employment without Just Cause or a resignation for Good Reason, treatment of any outstanding equity-based awards will be governed by the terms and conditions of any applicable plan and award agreement.

In the event of Mr. Schmidt’s employment ceases due to death or Disability, Mr. Schmidt would be entitled to a pro-rated annual bonus for the year of termination.

For purposes of the Schmidt Agreement, “Just Cause” generally means (i) any act or omission constituting “just cause” under applicable law; (ii) Mr. Schmidt’s repeated failure or refusal to perform his principal duties and responsibilities; (iii) misappropriation of the funds or property of Cronos USA; (iv) use of alcohol or drugs in violation of Cronos USA’s policies or that interferes with Mr. Schmidt’s obligations under the Schmidt Agreement; (v) the indictment, arrest or conviction in a court of law for, or the entering of a plea of guilty or nolo contendere to, a summary or indictable offence or any crime involving moral turpitude, fraud, dishonesty or theft; (vi) engaging in any act which is a violation of any law, regulation or Company policy, that, if violated, injures or could reasonably be expected to injure the reputation, business or business relationships of the Company, Cronos USA and their respective affiliates (excluding Altria and its subsidiaries) (the “Group”); (vii) engaging in any act which is a violation of any Company policy with respect to sexual harassment, discrimination or similar or related policies; or (viii) any willful or intentional act which injures or could reasonably be expected to injure the reputation, business or business relationships of the Group.

Table of Contents

For purposes of the Schmidt Agreement, “Good Reason” generally means the occurrence of any of the following events without Mr. Schmidt’s consent: (i) the assignment to Mr. Schmidt of duties materially different than the duties under the Schmidt Agreement; (ii) a material diminution in title, status, seniority, reporting relationship, responsibilities or authority; (iii) a material reduction in base salary; or (iv) relocation of Mr. Schmidt’s primary work location more than 35 miles from its current location.

For purposes of the Schmidt Agreement, “Disability” generally means a physical or mental incapacity of Mr. Schmidt that has prevented Mr. Schmidt from performing his duties for 180 calendar days, whether or not consecutive, out of any 12 consecutive months and that in the opinion of the Board or any committee thereof is likely to continue to a similar degree.

Upon termination of his employment for any reason, Mr. Schmidt is subject to ongoing confidentiality and mutual non-disparagement provisions, non-competition and customer non-solicitation covenants for the one-year period following termination and an employee non-solicitation covenant for the two-year period following termination.

Gorenstein Agreement

Under the Gorenstein Agreement, upon (i) termination of Mr. Gorenstein’s employment or consulting services, as applicable, by Cronos USA or Mr. Gorenstein upon the completion of the 18-month term, (ii) earlier termination of Mr. Gorenstein’s employment or consulting services by Cronos USA other than for Just Cause or (iii) resignation by Mr. Gorenstein due to a material breach of the Gorenstein Agreement by Cronos USA, in each case, subject to Mr. Gorenstein’s execution and delivery of a release in favor of the Company, Mr. Gorenstein would be entitled to:

(i)a lump sum severance payment equal to 12 months’ base salary and annual bonus (at target);

(ii)a pro-rated annual bonus (at target), if any, for the period worked in the year of termination;

(iii)immediate vesting of all then unvested equity-based awards (and, if applicable, any equity which has not then been granted pursuant to the terms of the Gorenstein Agreement would be immediately granted on a fully vested basis), subject to the conclusion of the SEC’s investigation into the Company and such investigation does not result in a penalty being levied by the SEC against Mr. Gorenstein or the Company on account of any misconduct or mismanagement by Mr. Gorenstein; and

(iv)continued eligibility to participate in any group health or other insurance benefit plans of the Company for a period of up to 12 months following the date of termination.

In the event that Mr. Gorenstein’s employment ceases because of his death or, at the discretion of Cronos USA, his Disability (as defined below), Mr. Gorenstein would be entitled to the payments and benefits set forth in prongs (ii) and (iii) above, among other things.

For purposes of the Gorenstein Agreement, actions by Mr. Gorenstein constituting “Just Cause” include: (i) conduct that would reasonably be expected to result in a penalty being levied by the SEC against Mr. Gorenstein personally or against the Company on account of any misconduct or mismanagement by Mr. Gorenstein; (ii) willful or gross misconduct involving the property, business or affairs of the Company; (iii) any act of theft or fraud, including, without limitation, misappropriation of funds; (iv) conviction or plea of guilty or nolo contendere to any

Table of Contents

felony or crime of moral turpitude; or (v) engaging in any act of harassment (including sexual harassment or unlawful discrimination).

For purposes of the Gorenstein Agreement, “Disability” has a substantially similar meaning as the term used in the Schmidt Agreement.

Mr. Gorenstein is subject to ongoing confidentiality, intellectual property and mutual non-disparagement provisions, and non-competition and non-solicitation requirements for the term of the Gorenstein Agreement.

Employment Agreements with Mr. Barbato, Mses. Shum and Shlimak and Dr. Abraham

Pursuant to the employment agreements with each of Mr. Barbato, Mses. Shum and Shlimak and Dr. Abraham (collectively, the “Other NEO Agreements”), upon a termination by the Company of the applicable NEO’s employment without Just Cause at any time or a resignation by such NEO for Good Reason within 24 months of the occurrence of a Change of Control, subject to the NEO’s execution of a release in favor of the Company, the Company would be required to:

(i)in lieu of notice, pay the NEO the greater of (a) one month of base salary in effect at the time of termination for each completed year of service with the Company, up to a maximum of 12 months of base salary, and (b) the minimum termination pay and severance pay entitlements of the NEO pursuant to applicable employment standards legislation; and

(ii)continue the NEO’s group insured benefits, if any, until the end of the severance period calculated under (i) above or the date on which the NEO obtains alternate benefit coverage, whichever occurs first, subject to the minimum requirements of applicable employment standards legislation.

Upon a qualifying termination as described above, the NEO’s entitlements in respect of equity-based awards will be determined in accordance with the terms and conditions of the applicable plan and award agreement.

For purposes of the Other NEO Agreements, actions constituting “Just Cause” include (i) any act or omission constituting “just cause” for dismissal without notice under applicable law; (ii) the NEO’s repeated failure or refusal to perform his or her principal duties and responsibilities after notice from the Board, the CEO or other officer of the Company, as applicable; (iii) misappropriation of the funds or property of the Company; (iv) use of alcohol or drugs in violation of the Company’s policies on such use or that interferes with the NEO’s obligations under the applicable agreement, continuing after a single warning; (v) the indictment, arrest or conviction in a court of law for, or the entering of a plea of guilty to, a summary or indictable offense or any crime involving moral turpitude, fraud, dishonesty or theft; (vi) the misuse of Company computers or computer network systems for non-Company business; (vii) engaging in any act (including, without restriction, an act of sexual harassment as determined by the Company) which is a violation of any law, regulation or Company policy; or (viii) any willful or intentional act which injures or could reasonably be expected to injure the reputation, business or business relationships of the Company.

For purposes of the Other NEO Agreements, “Change of Control” generally means:

(i)the consummation of any transaction or series of transactions including any reorganization, recapitalization, statutory share exchange, consolidation, amalgamation, arrangement, merger or issue of voting shares in the capital of the Company, the result of which is that any person or group of persons acting jointly or in concert for purposes of such transaction or series of transactions becomes

Table of Contents

the beneficial owner, directly or indirectly, of more than 50% of the voting securities in the capital of the entity resulting from such transaction or series of transactions or the entity that acquired all or substantially all of the business or assets of the Company in a transaction or series of transactions described in paragraph (ii) below (in each case, the “Surviving Company”) or the ultimate parent entity that has beneficial ownership of sufficient voting power to elect a majority of the board of directors (or analogous governing body) of the Surviving Company (the “Parent Company”), measured by voting power of the outstanding voting securities eligible to elect members of the board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent Company, the Surviving Company) rather than number of securities (but shall not include the creation of a holding company or other transaction that does not involve any substantial change in the proportion of direct or indirect beneficial ownership of the voting securities of the Company prior to the consummation of the transaction or series of transactions), provided that the exercise by Altria Summit LLC (or any of its affiliates) of the Purchased Warrant (as defined in the Subscription Agreement by and among the Company, Altria Summit LLC and Altria Group, Inc. dated as of December 7, 2018) shall not constitute a Change of Control pursuant to clause (i);

(ii)the direct or indirect sale, transfer or other disposition, in one or a series of transactions, of all or substantially all of the business or assets of the Company, taken as a whole, to any person or group of persons acting jointly or in concert for purposes of such transaction or series of transactions (other than to any affiliates of the Company); or

(iii)Incumbent Directors during any consecutive 12-month period ceasing to constitute a majority of the Board of the Company (for the purposes of clause (iii), an “Incumbent Director” shall mean any member of the Board who is a member of the Board immediately prior to the occurrence of a contested election of directors of the Company).

The Altria Investment does not constitute a change of control for purposes of the Other NEO Agreements, which were entered into following the Altria Investment.

For purposes of the Other NEO Agreements, “Good Reason” has a substantially similar meaning as the term used in the Schmidt Agreement, although the definitions vary in some respects among the Other NEO Agreements and are described in greater detail in such agreements.

For purposes of the Other NEO Agreements, “Disability” generally has a substantially similar meaning as the term used in the Schmidt Agreement, except the determination is made by the Company instead of the Board or a committee thereof.

The NEOs are subject to indefinite confidentiality provisions, and non-competition and non-solicitation requirements for a period of one year immediately following termination of employment for any reason.

Long-Term Incentive Awards under the 2020 Omnibus Plan

Mr. Schmidt

Terms of awards granted to Mr. Schmidt under the 2020 Omnibus Plan are set forth in his award agreements. Pursuant to the terms of his award agreements, in the event of the termination of Mr. Schmidt’s employment due to death, unvested outstanding Stock Options and Restricted Share Units will vest immediately, and Stock Options will be exercisable by his estate within six months from the date of such termination. In the event

Table of Contents

that his employment is terminated due to Disability, the Stock Options and the Restricted Share Units will remain outstanding, will continue to vest in accordance with their applicable vesting schedule, and all vested Stock Options may be exercised by Mr. Schmidt within 12 months from the date of such termination. In the event that Mr. Schmidt’s employment terminates without Just Cause or he resigns for Good Reason, the Stock Options and Restricted Share Units will vest, and the Stock Options will be exercisable at any time within 12 months from the date of such termination (subject to the Stock Options’ expiration date).

Although the Company does not typically provide for single trigger acceleration of equity awards upon a change of control, in order to attract the type of executive talent required to support the Company’s growth and expansion plans, the Company determined in this particular instance to grant one-time equity awards that vest in part upon a change of control. In the event of a Change of Control involving the purchase of the Company’s securities described in Rule 13e-3 to the Exchange Act, 4/5 of the Stock Options and Restricted Share Units will vest immediately, and the remaining 1/5 of the Stock Options and Restricted Share Units will vest on the earlier of the 12-month anniversary of such Change of Control and the final vesting date of such Stock Options or Restricted Share Units, as applicable (the “Final Vesting Date”); provided that, if the Company ceases to be publicly-traded following the Change of Control, then (i) 4/5 of the Stock Options shall immediately become fully vested and converted in the right to receive an amount equal to the spread value based on the per share merger consideration, and (ii) the remaining 1/5 of the Stock Options shall become vested and converted into the right to receive an amount equal to the spread value based on the per share merger consideration, payable on the earlier of the 12-month anniversary of the Change of Control and the Final Vesting Date; provided further that if Mr. Schmidt’s employment terminates without Just Cause or for Good Reason, or due to death or Disability, prior to the Final Vesting Date, then the remaining 1/5th of the Stock Options and Restricted Share Units will vest on the date of such termination.

If Mr. Schmidt’s employment terminates for any other reason, unvested Stock Options and Restricted Share Units will be forfeited.

Restricted Share Unit Agreements

Terms of Restricted Share Units granted to Mses. Shum and Shlimak and Dr. Abraham under the 2020 Omnibus Plan are set forth in their respective award agreements. In the event that the NEO’s employment terminates because of death, all unvested Restricted Share Units will vest. In the event that the NEO’s employment terminates due to Disability, unvested Restricted Share Units will continue to vest in accordance with their vesting schedule set forth in the agreements. In the event that the NEO’s employment terminates without Just Cause or the NEO resigns for Good Reason, in each case, on or within one year after a Change of Control, all unvested Restricted Share Units will become fully vested. This reflects the Company’s determination to generally structure accelerated vesting of equity awards in connection with a change of control to be “double trigger” in order to align our executive compensation program with good governance practices. If the NEO’s employment terminates for any other reason, unvested Restricted Share Units will be forfeited.

For the purposes of the 2020 Omnibus Plan, “Disability” generally has a substantially similar meaning as the term used in the Schmidt Agreement, except the determination is made by the Company instead of the Board or a committee thereof.

For purposes of the 2020 Omnibus Plan, “Change of Control” has a substantially similar meaning as the term used in the Other NEO Agreements, although the definition varies in some respects as is described in greater detail in the 2020 Omnibus Plan, including that the Board has discretion to determine whether the exercise by Altria

Table of Contents

Summit LLC (or any of its affiliates as of the Effective Date) of the Purchased Warrant constitutes a change of control pursuant to the 2020 Omnibus Plan.

Stock Option Plans

In the event of the termination of a participant’s employment, the treatment of Stock Options under the 2018 Option Plan and the 2015 Option Plan is subject to the discretion of the Board on a case-by-case basis. In the event of the termination of the participant’s employment with the Company for cause, each vested and unvested Stock Option granted to that participant immediately terminates and ceases to be exercisable, subject to the discretion of the Board. If a participant’s employment with the Company is terminated other than for cause (as defined in an employment agreement with the participant), each Stock Option granted to such participant that has not vested will immediately terminate, subject to the discretion of the Board, and each Stock Option that has vested may be exercised at any time within six months of the date of termination, death or ceasing to act as a director of the Company, as the case may be.

If the Company proposes to undertake a Change of Control, the Board may, in its discretion, accelerate the vesting of all outstanding Stock Options such that each outstanding Stock Option will be fully vested and either (as determined by the Board in its discretion) conditionally (i) exercisable for Shares or (ii) surrendered for a cash payment equal to the difference between the per Share consideration receivable by Shareholders in connection with the transaction resulting in the Change of Control and the exercise price of such Stock Option multiplied by the number of Shares that may be acquired under the particular Stock Option, upon (or where permitted by the Board, prior to) the completion of the Change of Control, provided that the Board may not, in any case, authorize the exercise or surrender of Stock Options beyond the expiration of the original exercise term of the Stock Options.

If, in connection with a Change of Control, the Board does not accelerate the vesting of Stock Options in accordance with the foregoing paragraph and the Stock Options continue, or are assumed, or rights equivalent to the Stock Options are substituted for the Stock Options, by the Surviving Company or Parent Company, or an affiliate thereof, and a participant’s employment is terminated by the Company or the Surviving Company or Parent Company or an affiliate of the Company or a successor thereto without cause in the 24-month period following the Change of Control, all unvested Stock Options or substituted rights outstanding on the participant’s termination date shall immediately vest, and the participant may exercise such vested Stock Options or substituted rights until the earlier of the expiration of the original exercise term of such Stock Option (or the Stock Option for which the right was substituted) and 12 months following the participant’s termination date, following which any unexercised Stock Options or substituted rights shall terminate and cease to be exercisable.

For the purposes of the 2015 Option Plan and the 2018 Option Plan, “Change of Control” generally has the same meaning as in the Other NEO Agreements, except that the proviso in prong (i) regarding exercise by Altria Summit LLC (or any of its affiliates) of the Purchased Warrant does not apply to the 2015 Option Plan.

Potential Payments Upon Termination or Change of Control

The following table and footnotes describe certain potential payments that each NEO would receive upon certain terminations of employment and/or Change of Control, assuming that the termination event and/or Change of Control was effective as of December 31, 2020 and the value of our Shares is $6.94, which was the closing price of our Shares on Nasdaq on December 31, 2020, the last business day in 2020.

Table of Contents


NEO	Cash Severance ($)(1)	Group Insured Benefits ($)	Accelerated Stock Options ($)	Accelerated Restricted Share Units ($)	Total ($)
Kurt Schmidt
Termination without Just Cause or resignation for Good Reason (absent a Change of Control)	763,616	50,266	7,349,600	2,376,000	10,539,482
Termination without Just Cause or resignation for Good Reason in connection with a Change of Control	763,616	50,266	7,349,600	2,376,000	10,539,482
Termination due to death or Disability after a Change of Control	243,616	—	7,349,600	2,376,000	9,969,216
Change of Control	—	—	5,879,680	1,900,800	7,780,480
Death or Disability	243,616	—	7,349,600	2,376,000	9,969,216
Michael Gorenstein
Termination without Just Cause or resignation for uncured breach	1,458,000	8,531	7,147,593	985,000	9,599,124
Death or Disability	1,064,000	—	7,147,593	985,000	9,196,593
Jerry Barbato
Termination without Just Cause (absent a Change of Control)	18,643	2,113	—	—	20,756
Termination without Just Cause in connection with a Change of Control	18,643	2,113	186,374	—	207,130
Resignation for Good Reason in connection with a Change of Control	18,643	2,113	—	—	20,756
Death or Disability	—	—	—	—	—
Xiuming Shum
Termination without Just Cause (absent a Change of Control)	69,909	1,036	—	—	437,233
Termination without Just Cause in connection with a Change of Control	69,909	1,036	469,907	366,288	907,140
Resignation for Good Reason in connection with a Change of Control	69,909	1,036	—	366,288	437,233
Death or Disability	—	—	—	366,288	366,288
Todd Abraham
Termination without Just Cause (absent a Change of Control)	18,021	1,310	—	—	230,367
Termination without Just Cause in connection with a Change of Control	18,021	1,310	143,522	211,036	373,889
Resignation for Good Reason in connection with a Change of Control	18,021	1,310	—	211,036	230,367
Death or Disability	—	—	—	211,036	211,036
Anna Shlimak

Table of Contents


Termination without Just Cause (absent a Change of Control) (2)	—	—	—	—	460,000
Termination without Just Cause of connection with a Change of Control(2)	—	—	196,494	460,000	656,494
Resignation for Good Reason in connection with a Change of Control(2)	—	—	—	460,000	460,000
Death or Disability	—	—	—	460,000	460,000

(1) For Mr. Barbato, Mses. Shum and Shlimak and Dr. Abraham, reflects one month of base salary for each completed year of service and does not reflect minimum termination pay and severance pay entitlements, if any, pursuant to applicable employment standards legislation. Amounts for accrued and unpaid vacation as of December 31, 2020 were excluded.

(2) As of December 31, 2020, Ms. Shlimak had not yet completed one year of service with the Company.

Table of Contents

CEO PAY RATIO

Set forth below is disclosure regarding the ratio of the annualized total compensation of Mr. Schmidt, who was appointed to President and CEO of the Company effective September 9, 2020, to that of our median employee (excluding our CEO but including our Executive Chairman).

•For 2020, our last completed fiscal year, the annualized total compensation of Mr. Schmidt was $10,489,187, which amount equals the CEO’s compensation as reported in the “Summary Compensation Table” plus an additional amount that reflects the annualizing of his base salary consistent with the applicable SEC guidance;

•the annual total compensation of the median Cronos employee (excluding our CEO but including our Executive Chairman) was $48,260; and

•the ratio of our CEO’s annual total compensation on an annualized basis to that of the median Cronos employee was 217 to 1.

To identify the median employee, we used the following methodology:

•We used our entire employee population as of December 18, 2020. The jurisdictions included in the analysis were Canada, the United States and Israel.

•We calculated the amount of annual total cash compensation paid to all of our employees (other than our CEO) using a consistently applied compensation measure defined as the sum of base pay and bonuses and other cash wages and allowances.

•Employees with partial year earnings were annualized to full year earnings, assuming consistent earnings.

•All figures shown are in U.S. dollars. The amounts originally in non-U.S. dollars were converted to U.S. dollars using the Bloomberg average exchange rate of C$1.00 to $0.7457 and ILS 1 to $0.2908, as applicable, in each case for the 12-month period ended December 31, 2020.

After identifying the median employee, we then determined the median employee’s total compensation for the year ended December 31, 2020 in accordance with the requirements of the executive compensation rules for the Summary Compensation Table (Item 402(c)(2)(x) of Regulation S-K).

The pay ratio described above is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described above. Because the SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices, the pay ratio reported by other companies, including companies in the Cronos Peer Group, may not be comparable to the pay ratio reported above. Other companies may have different employment and compensation practices, different geographic breadth, perform different types of work, and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. This information is being provided for informational purposes. Neither the Compensation Committee nor management of the Company used the pay ratio measure in making compensation decisions.

Table of Contents

DIRECTOR COMPENSATION

Framework for Director Compensation

On August 7, 2019, the Board adopted a remuneration policy for its directors (the “Board Remuneration Policy”), pursuant to which each non-employee director (other than Altria nominees) receives $37,285 (C$50,000) per year for services as a director, an additional $11,186 (C$15,000) per year for the chair of the Audit Committee, and an additional $11,186 (C$15,000) per year for the chair of the Compensation Committee. Cash fees with respect to Board membership or service as a committee chair are paid assuming 12 consecutive months of service from the date the particular membership or service commences and are paid in quarterly installments. Directors who are executive officers of the Company, within the meaning of such term under the applicable NASDAQ Rules, and Altria nominees do not receive compensation from the Company for their service as directors. In 2020, the Compensation Committee conducted a review of our director compensation program against director compensation programs of companies in the Cronos Peer Group with the assistance of Mercer, its independent compensation consultant, in order to ensure that it continues to be reasonable.

Under the Board Remuneration Policy, each director, other than directors who are executive officers and Altria nominees, is required to hold Shares and/or equity awards, including Deferred Share Units (as defined below), with a market value equal to three times such director’s annual cash retainer within five years of such director’s appointment or election to the Board.

Deferred Share Unit Plan

On August 7, 2019, the Board adopted the Deferred Share Unit Plan for Non-Executive Directors, pursuant to which each non-employee director (other than Altria nominees) received in 2019 and 2020 an annual equity grant in the form of cash-settled deferred share units (“Deferred Share Units”) with a grant date fair value (as determined for financial reporting purposes) of $111,855 (C$150,000).

Incentive Plan Awards

All directors were entitled to participate in the 2020 Omnibus Plan, the 2018 Option Plan and the 2015 Option Plan. During the year ended December 31, 2020, no Stock Options were granted to, and no Stock Options were exercised by, non-employee directors (other than Altria nominees) under either the 2018 Option Plan or the 2015 Option Plan. No equity awards were granted to any non-employee director under the 2020 Omnibus Plan.

The Board adopted the 2020 Omnibus Plan on March 29, 2020, which was subsequently approved by Shareholders at its annual general and special meeting held on June 25, 2020. The 2020 Omnibus Plan provides for the grant of equity awards and replaced the 2018 Option Plan. Pursuant to the 2020 Omnibus Plan, each non-employee director (other than Altria nominees) may not be granted (in any calendar year) total compensation with a value in excess of $500,000, with the value of any equity-based awards based on the accounting grant date value, except for the calendar year in which a non-employee director (other than Altria nominees) is newly appointed as a member of the Board or is designated the Chairman of the Board or Lead Director, when the limit is $1,000,000.

Table of Contents

2020 Director Compensation Table

The following table lists the individuals who received compensation in 2020 for their service as non-employee directors of the Company. Mr. Gorenstein’s compensation is reflected in the Summary Compensation Table above.


Name	Fees Earned or Paid in Cash ($)(1)	Stock Awards ($)(2)	Total ($)
Jason Adler	37,285	111,855	149,140
Jody Begley	—	—	—
Bronwen Evans	37,285	111,855	149,140
Murray Garnick	—	—	—
Bruce Gates(3)	—	—	—
Heather Newman	—	—	—
James Rudyk	48,471	111,855	160,326

(1) The amounts in this column represent annual cash retainers and committee chair fees. Amounts are converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020.

(2) Pursuant to the Company’s Deferred Share Unit Plan for Non-Executive Directors, non-employee directors (other than Altria nominees) receive an annual equity grant in the form of Deferred Share Units with a grant date fair value of $111,855 (C$150,000), which are settled in cash upon a director’s departure from the Board. As of December 31, 2020, Mr. Adler held 27,764.36 Deferred Share Units, Ms. Evans held 27,764.36 Deferred Share Units and Mr. Rudyk held 27,764.36 Deferred Share Units. The amounts in this column represent the grant date fair value of Deferred Share Units computed in accordance with stock-based compensation accounting rules (FASB ASC Topic 718) for 2020.

(3) Mr. Gates resigned from the Board effective March 16, 2020.

Table of Contents

AUDIT COMMITTEE REPORT

The Audit Committee, which consists entirely of directors who meet the independence requirements of applicable SEC regulations and the NASDAQ Rules for audit committee members, has furnished the following report:

Report of the Audit Committee

The purpose of the Audit Committee is to oversee the accounting and financial reporting processes of the Company and the audits of the financial statements of the Company. The Audit Committee operates pursuant to a Charter that was last amended and restated by the Board on August 5, 2020. As set forth in the Charter, management of the Company is responsible for the preparation, presentation and integrity of the Company’s financial statements and for the effectiveness of internal control over financial reporting. Management is responsible for maintaining the Company’s accounting and financial reporting principles and internal controls and procedures designed to assure compliance with accounting standards and applicable laws and regulations. The independent auditors are responsible for auditing the Company’s financial statements, expressing an opinion as to their conformity with generally accepted accounting principles and annually auditing the Company’s internal control over financial reporting.

Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting at December 31, 2020, and based on this assessment, management concluded that its internal control over financial reporting was not effective as of December 31, 2020 due to a material weakness resulting from management’s failure to properly design and execute sufficient procedures to verify inventory quantities. Specifically, while inventory counts were performed in the fourth quarter of 2020, (i) the aggregate value of items excluded from the count exceeded the Company’s materiality threshold, and (ii) human error in count execution, data transposition and reconciliation analysis resulted in inaccurate adjustments. This deficiency did not result in errors that were quantitatively material. Nevertheless, the deficiency creates a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.

In light of this material weakness, the Company will take the following actions: (i) enhance its count procedures to ensure appropriate consideration and coverage of its total inventory balance, (ii) implement cycle counts as a redundant control to supplement the annual physical count, and (iii) provide training to inventory teams on count procedures and inventory management control expectations. The Audit Committee is focused on the Company remediating the identified material weakness in internal control over financial reporting and implementing enhanced controls to ensure a proper control environment. However, in light of the nature of the material weakness (the year-end inventory count), the Audit Committee does not expect this material weakness to be remediated until the fourth quarter of 2021.

In connection with the Company’s restatement of its unaudited condensed interim consolidated financial statements for the three months ended March 31, 2019, the six months ended June 30, 2019, and the three and nine months ended September 30, 2019, as a result of three material weaknesses in internal control over financial reporting, the Company implemented a plan to remediate the three material weaknesses that included: (i) enhancement of the Company’s quarterly review of the risk assessment model and its risk control matrices, (ii) establishing a risk committee, which reviews the risk assessment for changes in the business on a quarterly basis, (iii) enhancement of the Company’s delegation of authority matrix, to further limit groups that may authorize sales or purchases of inventory, (iv) the establishment of a review process and internal database to identify entities that are both vendors and customers of the Company, in order to identify potential related transactions, (v) the implementation of revenue recognition training, (vi) the creation and implementation of a non-routine transaction

Table of Contents

policy, (vii) implementation of procedures for the preparation of business cases for all non-routine business-to-business unbranded sales and purchases, and (viii) expansion of the sub-certification processes to additional members of management to ensure that non routine transactions are identified.

During the fourth quarter of 2020, the Company completed its testing of the operating effectiveness of the implemented controls and found them to be effective. As a result, the Company concluded that the material weaknesses reported in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2019 had been remediated as of December 31, 2020.

In the performance of its oversight function, the Audit Committee has considered and discussed the audited financial statements with management and the independent auditors. The Audit Committee has also discussed with the independent auditors the matters required to be discussed by applicable standards of the Public Company Accounting Oversight Board. Finally, the Audit Committee has received the written disclosures and the letter from the independent auditors required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent auditors’ communications with the Audit Committee concerning independence, and has discussed with the auditors the auditors’ independence.

The members of the Audit Committee are not full-time employees of the Company and are not performing the functions of auditors or accountants. As such, it is not the duty or responsibility of the Audit Committee or its members to conduct “field work” or other types of auditing or accounting reviews or procedures or to set auditor independence standards. Members of the Audit Committee necessarily rely on the information provided to them by management and the independent accountants. Accordingly, the Audit Committee’s considerations and discussions referred to above do not assure that the audits of the Company’s financial statements and internal control over financial reporting have been carried out in accordance with generally accepted auditing standards, that the financial statements are presented in accordance with generally accepted accounting principles or that the Company’s auditors are in fact “independent.”

Based upon the reports and discussions described in this report, and subject to the limitations on the role and responsibilities of the Audit Committee referred to above and in the Charter, the Audit Committee recommended to the Board that the audited financial statements be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC.

SUBMITTED BY THE AUDIT COMMITTEE

OF THE COMPANY’S BOARD OF DIRECTORS


James Rudyk (Chair)			Jason Adler			Bronwen Evans

Table of Contents

PRINCIPAL ACCOUNTANT FEES

The following table presents fees for professional audit services rendered by KPMG for the audits of the Company’s annual consolidated financial statements as of and for the fiscal years ended December 31, 2020 and 2019 and internal control over financial reporting as of December 31, 2020 and 2019 and fees billed for other services rendered by KPMG during those periods.


	2020(1)	2019(1)
Audit Fees	$ 2,026,663	$ 1,658,140
Audit-Related Fees	—	—
Tax Fees(2)	209,240	495,518
Total	$ 2,235,903	$ 2,153,658

(1) The amount reported for the fees are converted from C$ to USD using the Bloomberg average exchange rate of C$1.00 to $0.7457 for the 12-month period ended December 31, 2020 and C$1.00 to $0.7537 for the 12-month period ended December 31, 2019.

(2) Tax fees relate to tax compliance and tax advisory services and preparation of U.S. federal and state income tax returns.

PRE-APPROVAL POLICY

The Audit Committee’s policy is to pre-approve all audit and permissible non-audit services expected to be performed by the Company’s independent registered public accounting firm. Pursuant to such policy, the Company’s independent registered public accounting firm cannot be engaged to provide any audit or non-audit services to the Company unless the engagement is pre-approved by the Audit Committee in compliance with the Sarbanes-Oxley Act of 2002.

During the year, circumstances may arise when it may become necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit Committee requires specific pre-approval before engaging the independent registered public accounting firm. The Audit Committee has delegated pre-approval authority to the Chair of the Audit Committee for those instances when pre-approval is needed prior to a scheduled Audit Committee meeting. The Chair of the Audit Committee must report on such approvals at the next scheduled Audit Committee meeting.

All fees and services described in the table above were pre-approved pursuant to this policy.

Table of Contents

PROPOSAL NO. 2—ADVISORY VOTE ON THE COMPENSATION OF

OUR NAMED EXECUTIVE OFFICERS

As required by federal securities laws, we are seeking a vote on an advisory (non-binding) basis to approve the compensation of the NEOs as disclosed in this Proxy Statement. This proposal, commonly known as a “say-on-pay” proposal, gives Shareholders the opportunity to endorse or not endorse the Company’s executive compensation program and policies. At the Annual Meeting, Shareholders will be asked to consider, and if thought advisable, to approve, on an advisory (non-binding) basis, with or without variation, the following resolution:

“RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, compensation tables and related narrative discussion contained in the proxy statement, dated April 27, 2021, is hereby approved on an advisory basis.”

As described under “Compensation Discussion and Analysis” above, we believe that our executive compensation program and policies are designed to support the Company’s success by achieving the following objectives:

•positioning the Company competitively among companies against which we compete for talent;

•aligning the interests of our executives with those of our Shareholders by tying significant portions of pay to performance, paying a substantial portion of compensation in equity and subjecting equity compensation to multi-year vesting periods and, beginning in March 2021, requiring share ownership; and

•tying executive compensation to performance and achievement of the Company’s short- and long-term business goals and ensure that compensation varies based on business performance and achievement of individual objectives.

We urge Shareholders to read the section entitled “Compensation Discussion and Analysis” and the related narrative and tabular compensation disclosure included in this Proxy Statement. The section entitled “Compensation Discussion and Analysis” provides detailed information regarding our executive compensation program and policies, as well as the compensation of the NEOs.

Required Vote

With regard to the advisory (non-binding) resolution approving the compensation of the NEOs as disclosed in this Proxy Statement, you may select “For”, “Against” or “Abstain”. Approval of the resolution requires the affirmative vote of a majority of the votes cast at the Annual Meeting. Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting on this proposal.

While this advisory vote on the compensation of the NEOs officers is not binding on us, our Board or the Compensation Committee, we value the opinions of our Shareholders. Accordingly, our Board and the Compensation Committee will consider the outcome of this advisory vote when making future compensation decisions for our NEOs.

Table of Contents

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE ADVISORY (NON-BINDING) RESOLUTION APPROVING THE COMPENSATION OF THE NEOs AS DISCLOSED IN THIS PROXY STATEMENT.

Table of Contents

PROPOSAL NO. 3—APPOINTMENT OF KPMG LLP

The Audit Committee has recommended to the Board that KPMG be nominated for appointment by the Shareholders to serve as the Company’s independent auditors and to audit the consolidated financial statements of the Company as of and for the fiscal year ending December 31, 2021. KPMG was first appointed to serve as the Company’s independent auditors effective May 18, 2018 and has audited the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2020 and December 31, 2019.

All audit and non-audit services provided by KPMG to the Company and its subsidiaries in fiscal years 2019 and 2020 are described above under “Principal Accountant Fees”. All fees and services described under “Principal Accountant Fees” were pre-approved pursuant to the Audit Committee’s pre-approval policy. In addition, the Audit Committee is responsible for audit fee negotiations with KPMG. KPMG has advised the Audit Committee that it is “independent” of the Company within the meaning of the SEC’s rules and regulations, and those of the Public Company Accounting Oversight Board. Representatives of KPMG will be present at the Annual Meeting and will have the opportunity to make a statement if they desire to do so and to respond to appropriate questions from Shareholders.

The Company is asking Shareholders to appoint KPMG to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 and to authorize the Board to fix KPMG’s remuneration. If the Shareholders do not appoint KPMG, KPMG will continue to act as the Company’s independent auditors until a successor auditor is appointed.

Required Vote

With regard to the appointment of KPMG to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 and the authorization of the Board to fix KPMG’s remuneration, you may select “For” or “Withhold”. The affirmative vote of a majority of votes cast at the Annual Meeting is necessary to appoint KPMG to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 and authorize the Board to fix KPMG’s remuneration. U.S. (but not Canadian) brokers may exercise discretion and vote on this matter and these will be counted as votes cast. Broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting on this proposal.

THE BOARD AND AUDIT COMMITTEE UNANIMOUSLY RECOMMEND THAT YOU VOTE “FOR” THE APPOINTMENT OF KPMG AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2021 AND TO AUTHORIZE THE BOARD TO FIX KPMG’S REMUNERATION.

Table of Contents

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), requires the Company’s directors and executive officers and persons who beneficially own more than ten percent of a registered class of the Company’s equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of equity securities of the Company. Directors, officers and greater-than-ten-percent beneficial owners are required by SEC regulations to furnish the Company with copies of all Section 16(a) forms filed by them. To the Company’s knowledge, based solely on a review of the copies of such filings on file with the Company and written representations from the Company’s directors and executive officers, all Section 16(a) filing requirements applicable to the Company’s directors, executive officers and greater-than-ten-percent beneficial owners were complied with on a timely basis for fiscal year 2020, except that (i) a Form 3 for Summer Frein was filed on August 4, 2020, three business days after the deadline, due in part to a disruption of logistical support as a result of the impact of COVID-19; (ii) a Form 4 for Jeffrey Jacobson was filed on August 14, 2020 in order to report the transfer of 2,500 Shares to an immediate family member that were previously misreported as being beneficially owned by Mr. Jacobson on his Form 3 filed on December 31, 2019; (iii) a Form 4 filed on November 10, 2020 for Mr. Gorenstein corrected the number of Shares beneficially owned by Mr. Gorenstein, which was misreported on his Form 3 filed on December 31, 2019; and (iv) a Form 3/A for Jason Adler was filed on November 11, 2020 to correct the number of Shares beneficially owned by Mr. Adler.

OTHER BUSINESS

If any matters other than those referred to in the Notice of Annual Meeting properly come before the Annual Meeting, the individuals named in the accompanying proxy card or voting instruction form will vote the proxies held by them in accordance with their best judgment. As of the date of this Proxy Statement, Cronos is not aware of any business other than the items referred to in the Notice of Annual Meeting that will be considered at the Annual Meeting.

SHAREHOLDER PROPOSALS FOR THE 2022 ANNUAL MEETING

Cronos is subject to both the rules of the SEC under the Exchange Act and the provisions of the BCBCA with respect to Shareholder proposals. As clearly indicated under the BCBCA and the rules of the SEC under the Exchange Act, simply submitting a Shareholder proposal does not guarantee its inclusion in the proxy materials.

Shareholders who, in accordance with the SEC’s Rule 14a-8, wish to present proposals for inclusion in the proxy materials to be distributed by us in connection with our 2022 annual meeting of Shareholders must submit their proposals to the Corporate Secretary of the Company on or before January 14, 2021 (which is 120 calendar days before the anniversary of the date this Proxy Statement was first sent to Shareholders), to be eligible for inclusion in our proxy statement and proxy card or voting instruction form relating to that meeting. In the event that we hold our 2022 annual meeting of Shareholders more than 30 days before or after the one-year anniversary date of the Annual Meeting, we will disclose the new deadline by which Shareholders’ proposals must be received by any means reasonably calculated to inform Shareholders.

Shareholders who, in accordance with the BCBCA, wish to present proposals for inclusion in the proxy materials to be distributed by us in connection with our 2022 annual meeting of Shareholders must submit their proposals on or before March 25, 2022 (which is three months before the anniversary of the Annual Meeting).

Table of Contents

A Shareholder may also nominate a person for election as a director of Cronos at an annual meeting of Shareholders, other than pursuant to a Shareholder proposal under the rules of the SEC under the Exchange Act and the provisions of the BCBCA by complying with the procedures set forth in the Company’s Advance Notice Requirements.

HOUSEHOLDING OF ANNUAL MEETING MATERIALS

Intermediaries and other holders of record may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of our proxy materials may have been sent to multiple Shareholders in your household. If you want to receive separate copies of our proxy materials in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your Intermediary or other holder of record, or you may contact the Corporate Secretary of the Company. However, please note that if you received a Notice of Internet Availability and want to receive a paper proxy or voting instruction form or other proxy materials with respect to the Annual Meeting, you should follow the instructions to request such materials included in the Notice of Internet Availability of Proxy Materials that was sent to you.

DISTRIBUTION OF CERTAIN DOCUMENTS

This Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 are available at https://thecronosgroup.com.

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 is being made available with this Proxy Statement to our Shareholders. Shareholders are referred to our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, including the Company’s audited consolidated financial statements for the fiscal year ended December 31, 2020 and related management’s discussion and analysis contained therein, for financial and other information about us. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 is not part of this Proxy Statement.

We are required to file annual, quarterly and current reports, proxy statements and other reports with the SEC. Copies of these filings are available through our website at https://thecronosgroup.com, on the SEC’s website at www.sec.gov and on the Company’s profile on SEDAR at www.sedar.com. We will furnish copies of our filings (without exhibits), including this Proxy Statement and the Annual Report on Form 10-K for the fiscal year ended December 31, 2020, without charge to any Shareholder upon request to Investor Relations at 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1, or by e-mail request to investor.relations@thecronosgroup.com.


			By order of the Board of Directors,

			Michael Gorenstein Executive Chairman

APPENDIX A—BOARD MANDATE

CRONOS GROUP INC.

BOARD MANDATE

This Mandate was approved by the Board of Directors of Cronos Group Inc. as of March 25, 2021.

1.Purpose

The Board of Directors (the “Board”) has the duty to supervise the management of the business and affairs of Cronos Group Inc. (the “Corporation”). The Board, directly and through its committees and the chair of the Board (the “Chair”) or, if applicable, the independent director appointed as “Lead Director” (as discussed herein), shall provide direction to senior management, generally through the President and Chief Executive Officer, to pursue the best interests of the Corporation.

2.Composition

General

The composition and organization of the Board, including the number, qualifications and remuneration of directors, the number of Board meetings, quorum requirements, meeting procedures and notices of meetings are governed by the Business Corporations Act (British Columbia), applicable Canadian securities laws, applicable stock exchange rules and policies and the articles of the Corporation, in each case as they may be amended and/or replaced from time to time, subject to any exemptions or relief that may be granted from such requirements.

Each director should seek to have an understanding of the Corporation’s principal operational and financial objectives, plans and strategies, and financial position and performance. Directors should seek to have sufficient time to carry out their duties and not assume responsibilities that would materially interfere with, or be incompatible with, Board membership. Directors who experience a significant change in their personal circumstances, including a change in their principal occupation, are expected to advise the Chair.

Independence

A majority of the Board must be independent. “Independent” shall have the meaning, as the context requires, given to it under applicable NASDAQ listing standards , as the same may be amended and/or replaced from time to time. From time to time the Board shall establish independence standards for the Board in accordance with the binding requirements of any stock exchanges on which the Corporation’s securities are listed and all other applicable laws, and, at least annually, shall determine the independence of each director in accordance with these standards and review the Board’s and the Board’s committees’ ability to act independently from management in fulfilling their responsibilities.

Chair of the Board

The Chair shall act as the effective leader of the Board and ensure that the Board’s agenda will enable it to successfully carry out its duties. If the Chair of the Board is not independent, then the independent directors may select from among their number a director who will act as Lead Director and who will assume responsibility for providing leadership to the Board complementary to that of the Chair to, among other things, enhance the effectiveness and independence of the Board.

3.Duties and Responsibilities

The Board shall have the specific duties and responsibilities outlined below.

A-1

Strategic Planning

(a)Strategic, Business and Capital Plans

The Board shall adopt a strategic plan for the Corporation. At least annually, the Board shall review and, if advisable, approve the Corporation’s strategic planning process and annual strategic, business and capital plans, as well as policies and processes generated by management relating to the authorization of major investments and significant allocations of capital. In discharging this responsibility, the Board shall review the plan in light of management’s assessment of emerging trends, the competitive environment, the opportunities for the business of the Corporation, risk issues, and significant business practices and products.

(b)Monitoring

At least annually, the Board shall review management’s implementation of the Corporation’s strategic, business and capital plans. The Board shall review and, if advisable, approve any material amendments to, or variances from, these plans.

Risk Management

(a)General

The Board shall periodically review reports provided by management of principal risks associated with the Corporation’s business and operations, review the implementation by management of appropriate systems to manage these risks, and review reports by management relating to the operation of, and any material deficiencies in, these systems.

(b)Compliance with Laws

The Board shall periodically review legal and regulatory compliance matters that may have a material impact on the Corporation, the effectiveness of the Corporation’s compliance policies, and any material communications from regulators, as well as management’s plans to remediate any deficiencies identified.

Human Resource Management

(a)Succession Review

The Board shall periodically review the succession plans of the Corporation for the Chair, the Lead Director, the Chief Executive Officer and other executive officers, including the appointment, training and monitoring of such persons.

(b)Integrity of Senior Management

The Board shall review the integrity of the Chief Executive Officer and other executive officers of the Corporation and encourage the Chief Executive Officer and other senior officers strive to create a culture of integrity throughout the Corporation.

Corporate Governance

(a)Director Independence

At least annually, the Board shall review the director independence standards established by the Board and the Board’s ability to act independently from management in fulfilling its duties.

A-2

(b)Ethics Reporting

The Board has adopted a written Code of Business Conduct and Ethics (the “Code”) applicable to directors, officers and employees of the Corporation. At least annually, the Board shall review the Code. Any material change to the Code must be approved by the Board.

(c)Board of Directors Mandate Review

At least annually, the Board shall review and assess the adequacy of this Mandate to ensure compliance with any rules or regulations promulgated by any regulatory body and approve any material modifications to this Mandate as considered advisable.

Financial Information

(a)General

The Board shall, in conjunction with the Audit Committee, review the effectiveness of the Corporation’s internal control over financial reporting and disclosure controls and procedures.

(b)Financial Statements

The Board shall review the recommendation of the Audit Committee with respect to the annual and interim financial statements. After completing its review, if advisable, the Board shall approve the filing of such financial statements with regulatory authorities.

Communications

(a)General

The Board has adopted a Disclosure Policy for the Corporation. The Board shall periodically review the Corporation’s overall Disclosure Policy, including measures for receiving feedback from the Corporation’s stakeholders and management’s compliance with such policy. The Board shall, if advisable, approve material changes to the Corporation’s Disclosure Policy.

(b)Shareholders

The Corporation endeavors to keep its shareholders informed of its progress through an annual report, quarterly interim reports and periodic press releases. In addition, the Corporation shall maintain a website that is regularly updated and provides investors with relevant information on the Corporation and an opportunity to communicate with the Corporation.

4.Committees of the Board

The Board has established the following committees: the Compensation Committee and the Audit Committee. Subject to applicable law and regulations, the Board may establish other Board committees or merge or dispose of any such Board committee.

Committee Charters

The Board has approved charters for each Board committee and shall approve charters for each new Board committee. The Board shall periodically review each committee charter and approve any changes it considers appropriate.

A-3

Delegation to Committees

The Board has delegated to the applicable committee those duties and responsibilities set out in each Board committee’s charter.

Consideration of Committee Recommendations

As required by applicable law, by the applicable committee charter or as the Board may consider advisable, the Board shall consider for approval the specific matters delegated for review to Board committees.

Board/Committee Communication

To facilitate communication between the Board and each Board committee, each committee chair shall provide a report to the Board on material matters considered by the committee at the first Board meeting after the committee’s meeting.

5.Meetings

The Board will meet at least once in each quarter, with additional meetings held as deemed advisable. The Chair (in conjunction with the Lead Director, as applicable) is primarily responsible for the agenda and for supervising the conduct of the meeting. Any director may propose the inclusion of items on the agenda.

Meetings of the Board shall be conducted in accordance with the Corporation’s constating documents.

Secretary and Minutes

The Corporation’s Secretary, his or her designee or any other person the Board requests shall act as secretary of Board meetings. Minutes of Board meetings shall be recorded and maintained by the Secretary or his or her designee and subsequently presented to the Board for approval.

Meetings Without Management

The independent members of the Board shall hold regularly scheduled meetings, or portions of regularly scheduled meetings, at which non-independent directors and members of management are not present.

Access to Management and Outside Advisors

In discharging the forgoing duties and responsibilities, the Board shall have unrestricted access to management and employees of the Corporation and to the relevant books, records and systems of the Corporation as considered appropriate. The Board shall have the authority to retain legal counsel, consultants or other advisors to assist it in fulfilling its responsibilities. The Corporation shall provide appropriate funding, as determined by the Board, for the services of these advisors.

Service on Other Boards and Audit Committees

Directors may serve on the boards of other public companies so long as these commitments do not materially interfere and are compatible with their ability to fulfill their duties as a member of the Board. Directors must advise the Chair in advance of accepting an invitation to serve on the board of another public corporation.

6.Responsibilities of Individual Directors

Responsibilities Set out in the Mandate

A-4

A director shall review and participate in the work of the Board necessary in order for the Board to discharge the duties and responsibilities set out in accordance with this mandate and under applicable law.

Meeting Preparation and Attendance

In connection with each meeting of the Board and each meeting of a committee of the Board of which the director is a member, it is expected each director will review the material provided to the director in connection with the meeting, provided that such review is practicable in the view of the time at which such material was delivered to the director.

Other Responsibilities

A director shall perform such other functions as may be delegated to that director by the Board or any committee of the Board from time to time.

7.Management

Position Descriptions for Directors

The Board has approved position descriptions for the Chair and the chair of each Board committee. The Board shall periodically review such position descriptions.

Position Descriptions for CEO

The Board has approved a position description for the Chief Executive Officer, which includes delineating management’s responsibilities. The Board shall periodically review such position description.

8.Director development and evaluation

Each new director shall participate in the Corporation’s initial orientation program and each director shall participate in any of the Corporation’s continuing director development programs. The Board shall periodically review the Corporation’s initial orientation program and continuing director development programs.

The Board will conduct an annual self-assessment to assess the effectiveness of the Board as a whole, its committees and the contribution of individual directors. The ability of individual directors to contribute to the Board shall be considered in connection with the re-nomination process.

9.No Rights Created

This Mandate is a statement of broad policies and is intended as a component of the flexible governance framework within which the Board, assisted by its committees, directs the affairs of the Corporation. While it should be interpreted in the context of all applicable laws, regulations and listing requirements, as well as in the context of the Corporation’s articles, it is not intended to establish any legally binding obligations, create any rights of shareholders or others to enforce this Mandate or create any other third-party beneficiary rights.

A-5

Table of Contents